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patients: the evidence.
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Introduction
The genus Mycobacterium consists of over 150 species, of which Mycobacterium tuberculosis 
complex, Mycobacterium ulcerans and Mycobacterium leprae are best known, as they are 
the causative agents of tuberculosis, Buruli ulcer disease and leprosy in humans. The other 
Mycobacterium species are collectively labeled nontuberculous mycobacteria (NTM). These 
NTM are increasingly recognized as causative agents of mostly opportunistic infections of 
humans.1,2 The epidemiology of these infections has a strong local character because the NTM 
species distribution differs by geographical region,3 the respective species differ in their clinical 
relevance,4 the prevalence of predisposing conditions differs per setting and, though this awaits 
experimental confirmation, strains of a single species isolated in different regions may differ in 
their virulence.1 Pulmonary disease caused by NTM (NTM-PD) is the most frequent disease 
manifestation. Although many NTM species can cause NTM-PD, its most frequent causative 
agents are the slow growing mycobacteria (SGM) of the Mycobacterium avium complex 
(MAC), Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium malmoense and the 
rapid growing mycobacterium (RGM) Mycobacterium abscessus. The exact composition of 
this top five differs by region.1,3
NTM-PD has two main radiological manifestations. The first is a fibro-cavitary disease (Figure 
1A) similar to pulmonary tuberculosis, which typically affects patients with underlying lung 
diseases such as chronic obstructive pulmonary disease (COPD);4,6 the second is nodular-
bronchiectatic disease (Figure 1B) which commonly affects an elderly population of mostly 
female patients without a significant history of pre-existing pulmonary disease.7 Rarely, NTM-
PD presents as a solitary pulmonary lesion mimicking malignancy. NTM incidentally cause 
hypersensitivity pneumonitis.8
NTM can also cause a wide variety of other -extrapulmonary- diseases, which fall into three 
main categories. The first is lymphadenitis, typically of cervical or submandibular lymph 
nodes in otherwise healthy and presumably immunocompetent children. This relatively benign 
disease affects children under the age of 6 years, is caused mainly by M. avium, M. malmoense, 
M. haemophilum and M. kansasii and is usually treated by surgical resection of the affected 
lymph node.9,10 The second extrapulmonary NTM disease entity are the inoculation infections; 
these are infections of skin, soft tissues or bones in a single site, after penetrating trauma 
and secondary infection by NTM. The best known example is the skin disease caused by M. 
marinum. This so-called fish tank granuloma is acquired when damaged skin is exposed to the 
fish pathogen M. marinum, for example during aquarium cleaning. The result is a nodular or 
ulcerative skin lesion on the hand, which may spread along lymphatic vessels, similar to the 
Sporothrix fungus, hence called sporothrichoid spread, to more proximal on the arm.11 Other 
examples are catheter-related infections like peritonitis in patients using peritoneal dialysis and 
catheter-related bloodstream infections.12 The third category of extrapulmonary NTM diseases 
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are the disseminated infections in the severely immunocompromised.13 Two distinct entities 
are recognized in clinical practice. The first is a disseminated skin disease, with ulcers and 
nodules of the skin, most prominent on the distal extremities.13 These infections are mostly 
seen in patients who use immunosuppressive drugs, for example after solid organ transplant. 
The most frequent causative agents are rapid growers like M. chelonae, M. abscessus and M. 
fortuitum and the slow growing M. haemophilum. The second manifestation of disseminated 
disease became notorious in HIV/AIDS patients and is clinically characterized by fever, night 
sweats, weight loss and generalized lymphadenopathy. This disease is mostly caused by M. 
avium, M. simiae and M. genavense.12,13
Treatment of NTM-PD
The fibro-cavitary and nodular-bronchiectatic NTM-PD types often require drug treatment, 
with adjunctive surgical resection of affected lobes in selected patients.1 Despite their current 
status as ‘emerging pathogens’, treatment of NTM-PD has a very limited evidence base. Very 
few trials have been performed and for many species, only small case series of patients treated 
with widely varying regimens of a very different duration are available. As a result, treatment of 
NTM-PD leans heavily on expert opinion expressed in the current treatment recommendations 
issued by the American Thoracic Society (ATS) and Infectious Diseases Society of America 
(IDSA).1
Within this chapter, we first focus on treatment and outcome as reported in clinical trials and 
case series available in the PubMed database (National Center for Biotechnology Information 
[NCBI]), to reconstruct a more evidence-based overview of possible drug treatment regimens 
of MAC-PD and M. abscessus-PD and their outcomes, as these species are clinically most 
important. Second, we describe the main non-clinical models that have been used, to provide 
information on the treatment of NTM-PD. At the end of the chapter, we present this thesis´ aims 
and objectives.
Figure 1. Main radiological manifestations of pulmonary nontuberculous mycobacterial disease. 
A: Fibro-cavitary disease by M. avium. B: Nodular-bronchiectatic disease by M. intracellulare
A B
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Clinical studies in humans
M. avium complex
Treatment of pulmonary disease caused by M. avium complex (MAC-PD) has received most 
attention and has been subject of a small number of clinical trials. In historical perspective, 
three phases in the treatment of these infections can be observed. First, in the 1960s and 1970s, 
drug treatment often consisted of combinations of para-aminosalicylic acid (PAS), isoniazid 
(H) and streptomycin, identical to tuberculosis treatment. Despite the multi-drug treatment, 
failure and relapse were common and prolonged culture conversion could only be achieved in 
30% of patients affected.14,15 Since the late 1970’s, rifampicin (R), ethambutol (E), ethionamide 
and streptomycin were increasingly used in the treatment of NTM pulmonary disease (PD), 
especially MAC-PD; these regimens could yield long-term culture conversion in up to 50% of 
patients.16 The third phase in NTM disease treatment started when the HIV epidemic spurred 
a new search for active drugs and the macrolides arose as an important new drug class to 
combat MAC-PD. In the 1990s, several case series revealed that macrolide monotherapy 
quickly led to resistance and failure.17,18 Addition of other drugs, including rifampicin (R), 
ethambutol (E), clofazimine and aminoglycosides could prevent macrolide resistance and these 
combination regimens proved highly efficacious, especially on the short term (Table 1).15-32 
After the influential case series by Wallace 19 and Tanaka,20 the rifamycin-ethambutol-macrolide 
regimens became standard treatment regimens. Across the heterogeneous trials and case series, 
this regimen cured 453 of the 770 (59%) patients enrolled (Table 1).
Parallel to the inclusion of the new macrolides in RE-based MAC-PD treatment regimens, two 
groups have studied inclusion of macrolides in clofazimine-based regimens. Both a clofazimine-
ethambutol-clarithromycin and a clofazimine-minocycline-clarithromycin regimen have 
been studied in retrospective non-comparative cohort studies. With culture conversion rates 
reaching 67% and 64%, these regimens do not seem inferior to rifamycin-ethambutol macrolide 
regimens (Table 1).21,25 Both these studies, however, offer limited information on their patient 
cohorts, thus the role of clofazimine-based regimens is now generally considered to be second-
line, restricted to patients who cannot be treated with rifamycins.1
One of the subjects of ongoing debate is the role of the aminoglycoside amikacin or streptomycin 
as adjuncts to rifampicin ethambutol- macrolide regimens. Many of the case series describing 
outcomes of the macrolide-based regimens included patients who used adjunctive amikacin or 
streptomycin thrice weekly for the first 2–6 (mean: 3) months of treatment (Table 1).19,20,26,28,32 
Yet, only a single randomized trial has assessed the efficacy of adding streptomycin. This trial, 
with 73 patients in each arm, revealed that sputum culture conversion rates were higher in the 
group that received adjunctive streptomycin and culture conversion was faster; nonetheless, 
relapse rates and symptom and radiological scores did not differ between the two arms.27 The 
only impact thus seems to be the improvement of short-term microbiological outcomes.
16
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Based upon the above two aspects, most experts currently recommend using a regimen that 
includes rifampicin, ethambutol and a macrolide, with adjunctive streptomycin or amikacin 
during the first 2–3 months for severe disease (Table 2).1,33
Another subject of debate is the use of intermittent -i.e. thrice weekly- therapy, which can be 
used successfully in mild nodular-bronchiectatic disease. 34,35
M. abscessus
Among the RGM, most clinical attention has been given to M. abscessus pulmonary disease 
in recent years as it is most frequent and extremely difficult to treat. This disease appears to be 
emerging in several settings, especially in cystic fibrosis (CF) patients.1,43 Because M. abscessus 
is highly resistant to most classes of antibiotics, treatment regimens are usually built on the 
basis of findings from in vitro drug susceptibility testing. Yet, the evidence for the relationship 
between in vitro susceptibility and in vivo outcome of treatment is scant.1,44
Table 1. Outcome of treatment regimens for MAC lung disease in HIV-negative patients
* Cure is defined as culture conversion without relapse during study. H, isoniazid; P, para-aminosalicylic 
acid (PAS); S, streptomycin; K, kanamycin; R, rifampicin/rifabutin; E, ethambutol; Cla, clarithromycin; 
Azm, azithromycin; Clo, clofazimine; Cip, ciprofloxacin; Mox, moxifloxacin; FQ, various fluoroquinolones. 
ND, no data provided.
Regimen Cure rate * Cavitary disease 
(%)
Mean follow-up
(months)
Ref.
HPS 32% (92/285) ND ND 15
24RE 27% (10/37) 21/37 (57%) 60 23
24HRE 34% (13/38) 25/38 (66%) 60 23
Cla +/- H/R/E/Clo/FQ 71% (32/45) 26/45 (58%) 0 17
>12RECla (+/-S) 82% (32/39) 35/50 (70%) 19 19
>12RECla (+2-6K; +FQ) 84% (26/31) 18/46 (39%) 32 20
>12RECla (low-dose+3S) 58% (41/71) 39/71 (55%) ND 26
>12RECla +3S
>12RECla
52% (38/73)
33% (24/73)
81/146 (55%) 16 27
>12RECla (+3S) 75% (45/60) 18/60 (30%) ND 28
>12RECla 50% (7/14) 0 33 30
>12RECla/Azm 86% (154/180) 4/180 (2%) 44 22
24RECla 24% (20/83) 57/83 (69%) 60 24
24RECla 100% (14/14) 14/14 (100%) 6 29
RECla 3/wk 44% (40/91) 49/91 (54) 0 31
CloECla 67% (20/30) ND 18 21
15CloMinCla 64% (14/22) 13/29 (45%) 24 25
24RECip 23% (20/87) 57/87 (66%) 60 24
REClaMox (+S) 29% (12/41) 19/41 (46%) ND 32
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In recent years, several retrospective series have been published. A recent series described 69 
patients treated in the USA (seven patients with CF) and revealed a culture conversion rate 
of just 48% for 3–5 drug regimens based on in vitro drug susceptibility test results. Patients 
who underwent adjunctive surgical resection of affected lung tissue more frequently achieved 
prolonged culture conversion (57 vs. 28%).45 Two smaller case series have assessed the outcomes 
of treatment with regimens based on in vitro drug susceptibility testing. In the first, 22 patients 
received treatment for M. abscessus pulmonary disease; after 12 months of treatment, 6 (27%) 
had already experienced treatment failure.46 In the second, 41 patients were retrospectively 
studied; 17 received a susceptibility testing. At the end of treatment 80.5% (33/41) of the patients 
had converted to negative cultures and treatment was considered successful. This percentage 
did not differ between patients treated with one or two parenteral drugs. During an average 
of 15 months of follow-up after treatment, four patients relapsed, thus 29 of 41 (70%) had 
prolonged (i.e., >6 months) conversion to negative cultures.47 Interestingly, similar results were 
obtained in a case series in South Korea, in which 65 non-CF patients with M. abscessus lung 
disease received a fixed regimen of clarithromycin, ciprofloxacin and doxycycline, combined 
with intravenous (iv.) amikacin and cefoxitin for the first 4 weeks. In this case series, prolonged 
(>12 months) culture conversion was achieved in 38 patients (58%).48 Thus, the use of drugs 
to which in vitro resistance is the rule (doxycycline, ciprofloxacin) can still lead to favorable 
clinical outcomes. All the above mentioned case series have applied a biphasic approach to 
treatment. The first, intensive phase is composed of multiple iv. drugs combined with oral drugs 
(mostly macrolides), generally selected on basis of in vitro susceptibility. This phase typically 
lasts 1–4 months (i.e., at least until culture conversion or clear failure) and is followed by a 
continuation phase of daily oral drugs or, rarely, intermittent iv. drugs or combinations thereof. 
1,45–48 While most series have used drug susceptibility test results to help design continuation 
phase regimens,45,46 some have used drugs to which resistance in vitro is common place (e.g., 
ciprofloxacin and doxycycline).48 All series have used macrolides as the cornerstone for both 
phases of treatment;45–48 in the continuation phase, the role of the companion drugs is either to 
be active by themselves or prevent the emergence of macrolide resistance.1,45
In later case series, molecular tools were applied to distinguish M. abscessus subspecies 
abscessus from M. abscessus subspecies bolletii (particularly ‘M. massiliense’), because the 
former shows inducible resistance to macrolides. Across these series, it was obvious that 
treatment outcomes of macrolide-based regimens were better in ‘M. massiliense’ disease than 
in M. abscessus subspecies abscessus disease, suggesting a clear in vitro-in vivo correlation.48–50 
The fixed regimen of clarithromycin, ciprofloxacin and doxycycline, combined with iv. amikacin 
and cefoxitin for the first 4 weeks given to 56 patients led to prolonged culture conversion 
in 25% (M. abscessus subspecies abscessus) and 88% (‘M. massiliense’) of patients.49 In 
another series from Japan, which analyzed treatment outcomes of 62 patients (42: M. abscessus 
subspecies abscessus; 20: ‘M. massiliense’), culture conversion rates were lowest for M. 
abscessus subspecies abscessus, 31% vs. 50% for ‘M. massiliense’. Moreover, relapse rates 
18
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after initial culture conversion were higher in patients with M. abscessus subspecies abscessus 
disease.50 The inducible macrolide resistance is a likely cause of differences in treatment 
outcome between patients diseased by the two subspecies. Since these publications, separate 
intensive phase regimens are advised for these two subspecies of M. abscessus (Table 2).33
The taxonomy of the M. abscessus group is still subject of debate. Although ‘M. massiliense’ 
(partial erm gene deletion, macrolide susceptible) and ‘M. bolletii’ (erm gene intact, inducible 
macrolide resistance) have been described as separate species, they have most recently been 
lumped into a single subspecies, M. abscessus subspecies bolletii.51 This status is unfortunate, 
because it includes both macrolide susceptible strains and strains with inducible macrolide 
resistance that is likely clinically significant.49,50 Hence, measuring inducible macrolide 
resistance needs to become a standard laboratory test, based on either erm gene sequence 
analysis or phenotypic testing with prolonged incubation.49,51,52
Perspective
The currently available literature offers a very limited evidence base on which to select or advise 
treatment regimens that lead to a likely clinical cure for patients with NTM-PD. Furthermore, 
most currently recommended treatment regimens have grown historically by accumulation of 
knowledge on drug activity. These regimens were thus not rationally designed. An interesting 
example is the concomitant use of rifampicin and macrolides for MAC-PD despite well-
known pharmacokinetic interactions leading to suboptimal macrolide concentrations.53 Much 
can probably be gained by designing new regimens on basis of synergistic activities, smart 
Table 2. Currently recommended treatment regimens for NTM-PD, per species
AS: Amikacin or streptomycin; Clo: Clofazimine; CN: Negative cultures; E: Ethambutol; H: Isoniazid; MAC: 
Mycobacterium avium complex; NTM-PD: Nontuberculous mycobacterial pulmonary disease; R: Rifampicin.
Species Recommended regimen Alternative
MAC 1,34,35 RE-macrolide (+/- AS) 
Duration: >12 months CN
CloE-macrolide
M. kansasii 1-36-39 
(rifampicin susceptible)
HRE (+/- AS) 
Duration: 12 months
RE-macrolide 
Duration: >12 months CN
M. malmoense 1,24,40 RE-macrolide 
Duration: >12 months CN
RE-quinolone 
Duration: >12 months CN
M. xenopi 1,24,41 RE-macrolide (+/- quinolone) 
Duration: >12 months CN
RE-quinolone 
Duration: >12 months CN
M. abscessus subsp. abscessus
or M. abscessus subsp. bolletii
(former ‘Mycobacterium bolletii’)42
Inducible macrolide resistance
3 or 4 of: amikacin, cefoxitin, 
imipenem, tigecycline, linezolid 
Duration: >12 months CN
M. abscessus subsp. bolletii
(former ‘Mycobacterium massiliense’)42
No inducible macrolide resistance
Macrolide, plus 2 of: amikacin, 
cefoxitin, imipenem, tigecycline, 
linezolid 
Duration: >12 months CN
Amikacin, cefoxitin, 
macrolide, ciprofloxacin, 
doxycycline 
Duration: >12 months CN
Introduction
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combinations of rapidly killing and slower sterilizing drugs and optimal dosing to achieve active 
concentrations. Another area for investigation may be the host-directed therapies. For many 
patients with NTM-PD, the predisposing condition is not evident. Subtle immunodeficiencies 
have recently been recorded in many patients with nodular-bronchiectatic NTM-PD.54,55 These, 
as well as the well-known predisposing conditions including COPD and CF may be improved 
by host-directed therapies and thereby influence the course of NTM-PD.
Preclinical models
The limitations in clinical information on NTM-PD treatment extends to the fundamental level; 
little is known on the dose-response relationships, pharmacokinetic and pharmacodynamic 
characteristics of common antibiotics used to treat NTM-PD. Pharmacokinetics describes the 
time course of antibiotic after the administration of a dosage regimen; providing information 
on the absorption, distribution, metabolism and excretion of the antibiotic in the body. Only 
two large studies and one small case series have investigated the pharmacokinetics of the key 
drugs used in NTM-PD treatment, 53,56,57 however, there is still lack of knowledge on some key 
antibiotics. Pharmacodynamics, on the other hand, describes the magnitude of the antibiotic 
effect in relation to its concentration.58 Crucial pharmacodynamic information has been gathered 
for Mycobacterium tuberculosis;5,60 however, that is not the case for NTM. There is still a 
need to know the activity, the potential to selectively amplify resistant subpopulations, and the 
pharmacokinetic/pharmacodynamic (PK/PD) relationships for antibiotics used in the treatment 
of NTM-PD.60 The determination of pharmacodynamic properties, and the establishment of 
PK/PD ratios may be difficult to get in humans, therefore in vitro and in vivo preclinical models 
have been proposed as surrogates. Diverse preclinical models can be used for this purpose 
as well as to guide in the selection and optimization of treatment regimens. We will shortly 
introduce the main models and the most important findings related to NTM-PD.
In vitro models
Different classifications of in vitro pharmacodynamic models have been the matter of 
reviews,58,61 however, from a simple point of view we will use here the classification of static or 
dynamic models. In static models, there is a constant exposure of the bacteria to the antibiotic, 
which means that the antibiotic concentration remains static throughout the whole experiment. 
Dynamic models, in contrast, are meant to mimic the different exposures that usually are 
achieved in human fluids when treated with an antibiotic, that means that the antibiotic 
concentration changes during the experiment.61 In the following paragraphs we will show the 
main pre-clinical models that have been described for the study of NTM-PD. MIC determination 
and time-kill assays are the most commonly used static models, while the hollow-fiber model is 
the main dynamic model described so far for NTM. 
20
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Minimum inhibitory concentration determination
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) are 
perhaps the major pharmacodynamic parameters used to establish the in vitro activity of an 
antibiotic against an infectious pathogen,58 in our case NTM. According to the Clinical and 
Laboratory Standards Institute (CLSI) the determination of MIC by the broth microdilution 
method is the standard drug susceptibility procedure for NTM.62 For such determination 
commercially available systems (Sensititre™) or in-house assays can be used; for both, 96-
well plates (with antibiotic in two-fold dilutions) are inoculated with a standardized inoculum 
of approximately 5×105 colony forming units (cfu) from a pure culture of NTM. The growth 
observed after the incubation time with the different antibiotics is compared with the growth 
in a drug-free control well in order to determine MICs.63 MICs for NTM are usually high for 
several antibiotics used in treatment regimens, compared to MICs for common Gram positive or 
Gram negative bacteria. The correlation between in vitro MIC and in vivo outcome of treatment 
remains to be determined for most antibiotics against most NTM species. What is clear so far 
is the relationship between clarithromycin in vitro activity and in vivo efficacy, demonstrated 
in patients with pulmonary MAC disease.20 To a lesser extent, this is also true for amikacin. 
64 MICs of rifampicin or ethambutol are less relevant, as these antibiotics are only used as 
companion drugs to avoid the emergence of macrolide resistance.65
To determine the MBC, samples obtained from MICs are diluted and subcultured on antibiotic-
free medium for an additional time. The lowest concentration of an antibacterial agent that 
results in a ≥99.9% decrease in the initial inoculum is considered the MBC. Bacteriostatic 
activity has been defined as a ratio of MBC/MIC >4, while bactericidal activity, on the other 
hand, has been defined as a ratio <4, but these definitions although very used are subject of 
debate. The in vitro microbiological determination of the bactericidal or bacteriostatic nature of 
an antibiotic may be influenced by growth conditions, bacterial density, test duration, etc, thus 
should be tested for each particular organism.66
Time-kill kinetic assays
Although MIC and MBC are considered excellent predictors of the potency of an antibiotic 
and measure the interaction of an antibiotic with a pathogen, they do not provide information 
on the time course of the antimicrobial activity.62 Time-kill assays allow the study of the 
pharmacodynamics, examining the rate at which different concentrations of an antibiotic 
kill bacteria, whether it’s killing is concentration-dependent or time-dependent. The effect of 
the main antibiotics against M. tuberculosis has been evaluated by time-kill assays,67,68 but 
only few published works are available for NTM, and even fewer are particularly related to 
NTM-PD.
For M. avium strain 101, Bakker-Woudenberg in 2005,69 described the time-kill kinetics of five 
antimycobacterial agents: clarithromycin, ethambutol, rifampicin, amikacin and moxifloxacin. 
All antibiotics inhibited mycobacterial growth, but their bactericidal activity was different; 
amikacin showed the fastest killing activity and moxifloxacin the highest killing activity in the 
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experiment over 21 days. Clarithromycin showed extremely low killing rate. No studies were 
found for other SGM species. 
For RGM, the single and combined effect of isoniazid and the natural quinone, β-lapachone, 
were evaluated by time-kill curves for M. fortuitum and M. smegmatis confirming that both 
microorganisms are resistant to isoniazid, but the two antibiotics in combination had bactericidal 
effect.70 No information on M. abscessus was available. 
Dynamic PK/PD models
The periodic administration of an antibiotic (or antibiotic combinations) to a patient, as is the 
case in patient treatment, implies that the concentrations of those antibiotics in human tissues 
will be variable or dynamic and therefore it will have a different effect on the mycobacteria. 
To overcome the need of a dynamic evaluation in large patient cohorts, several in vitro PK/PD 
models have been developed.58,61 The in vivo conditions of varying antibiotic concentrations 
over time, as in humans, are mimicked to allow the study of time-kill curves following the 
microbial kill and growth that take place under therapy. This is clearly superior to traditional 
approaches such as susceptibility testing or time-kill experiments performed in tubes.58 Dynamic 
models can adapt a variety of conditions to evaluate different microorganisms, environmental 
conditions, dosing schemes, single or combination therapies, etc. Although evidence suggests 
that there is a good correlation between certain dynamic models and in vivo findings,59,60,71 there 
are still limitations to be overcome; this is a field of constant evolution.
Early descriptions of the dynamic aspects of the relationship between antibiotics and NTM 
included the use of an in vitro dialysis model (cellophane dialyzing tube) and the membrane 
filtration technique applied to MAC.72-74 Clofazimine, rifabutin and amikacin were evaluated, 
showing a potential bactericidal action at concentrations attainable in humans; however, these 
investigations and the model itself were preliminary.72-74 Then the hollow-fiber system model, 
a robust in vitro PK/PD dynamic model was described for NTM.75,76 Hollow-fiber systems 
represent a two-compartment diffusion model, where the central compartment is composed of 
the central reservoir, the inner lumina of the hollow fiber capillaries, and connecting tubing. 
The other compartment, the peripheral, is the space outside the hollow-fiber capillaries that is 
enclosed by an impermeable plastic cartridge.78 Bacteria, in this case mycobacteria, can grow in 
the peripheral compartment but since the pore size of the membrane is smaller than bacteria, it 
selectively allows transfer of nutrients, drugs and bacterial metabolites and restrict the bacteria 
to the peripheral compartment. Special pumps are used to provide antibiotic(s) via a dosing port, 
and fresh culture medium is pumped into the central compartment while antibiotic-containing 
media is removed at rates programmed to simulate the drug half-life encountered in humans. By 
repetitive sampling of the bacterial culture exposed to the antibiotic(s) under study, the number 
of cfu of mycobacteria surviving the exposure can be measured by quantitative culture.78 While 
such models have been used more intensively to study M. tuberculosis,59,60,79 there are only 
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two published studies performed for NTM, specifically modeling disseminated disease by M. 
avium.75,76 Yet, these studies have yielded interesting insights. The first study focused on the 
activity of ethambutol against MAC and concluded that in the currently recommended doses, 
ethambutol has little activity. The efficacy of ethambutol would be far better if doses >50 mg/kg 
were used, which, to avoid toxicity, should be given intermittently, for example, twice or thrice 
weekly.75 The second study focused on the potential role of moxifloxacin to treat MAC disease. 
In short, this study, too, revealed that moxifloxacin in its current dose should be considered 
inactive against most MAC strains, since these generally have MICs that can’t be overcome 
by the standard dose of moxifloxacin (400 mg/day). Moxifloxacin is only likely to have some 
activity if the dose would be 2–3 times higher.76 For both antibiotics, the tolerability, safety 
and efficacy of such dosing regimens should be subject of future clinical studies. No studies 
reporting the use of hollow-fiber with RGM were found.
In vivo models
Soon after NTM were associated with human diseases, their study in laboratory animals 
started.80,81 Many of the initial descriptions particularly focused on pathogenicity, virulence, 
the type of disease or the type of immunological response associated with members of MAC, 
with preferential attention to the disseminated disease.82-84 Several mouse strains and routes of 
infection, as well as bacterial loads were tested until acute disease was produced in different 
organs of Beige mice, by intravenous infection of 107 viable cfu.82 Later, chronic disease was 
obtained with the administration of agents that promote macrophage activation, enhancing 
resistance to infection by M. intracellulare.84 Then the evaluation of therapy started; a landmark 
study investigated rifabutin alone and in combination with clofazimine. When used alone, 
rifabutin showed limited activity against acute or chronic M. intracellulare infection; however, 
complete sterilization in lungs and spleens was produced with the combination of rifabutin 
(10 mg/kg) and clofazimine (20 mg/kg), but only when the treatment initiated immediately 
after the challenge. When treatment initiated when the infection was already established, the 
combination was considerable less effective;85 these findings early highlighted the importance 
of combined therapy and that the stage of the infection is crucial for the treatment of NTM. 
Amikacin was also tested alone showing a remarkable activity in the treatment of early and 
established MAC infections The addition of clofazimine increased the activity of amikacin, 
but a third drug, rifabutin, did not. It was concluded then that amikacin-containing regimens 
are worthy of consideration for the treatment of MAC infections, as is a role for clofazimine.86 
The evaluation of liposomal encapsulation of aminoglycosides in the model opened a new 
window to improve therapy for MAC infection; liposome-mediated delivery of amikacin and 
streptomycin to MAC-infected tissues in vivo enhanced the efficacy of the drugs, thus it may 
improve the therapy of this disease.87,88 Additional testing in C57BL/6 mice confirmed previous 
findings, clarithromycin and combinations with clarithromycin showed activity against 
M. avium infection, both in the spleen and in lungs, ethambutol was also found to be active.89,90 
Some other drugs like sparfloxacin and thioacetazone, which had high in vitro activity, failed to 
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show in vivo activity.83 A recent characterization of different mouse models for MAC infections 
included the comparison of BALB/c, C57BL/6, nude and beige mice. Nude mice resulted more 
susceptible to the infection, but the impact of treatment was clearer in BALB/c mice than in 
the other strains.91 Regarding treatment, the most effective combination was clarithromycin-
ethambutol-rifampicin, confirming that clarithromycin-containing regimens are key in MAC 
treatment.91
For M. abscessus, few studies have been performed.92,93 Murine models for M. abscessus were 
initially used to characterize the smooth (Mab-S) and rough (Mab-R) morphotypes, finding 
that a mutation in the Mab-S altered the ability of this mycobacteria to persist and multiply in 
macrophages.92 For the evaluation of drug activity, some studies have assessed multiple mouse 
models. Initially, in C57BL/6 mice, antagonism was observed between moxifloxacin and 
macrolides for most of the M. abscessus clinical strains used, whilst indifference or synergy was 
observed for M. massiliense.93 In GKO and SCID mice models, the combination of clofazimine-
bedaquiline was found effective in decreasing the bacterial burden in organs.94,95 Recently, Nude 
and GKO mice strains demonstrated to perform better for M. abscessus infections. Nude mice 
were chosen to evaluate the activity of single antibiotics and the combined standard treatment 
of amikacin, clarithromycin and cefoxitin. Cefoxitin was the most active single antibiotic, 
although tigecycline displayed bactericidal activity; clarithromycin and amikacin prevented 
death but their impact on bacillary loads was limited. The standard treatment was not more 
active than cefoxitin alone.96
Although animal models can provide similar growing conditions for bacteria imitating 
characteristics of a human infection, there is no consensus yet on the extent of this extrapolation 
from animals to humans, neither on which one is the best model to evaluate therapy against 
each NTM. Due to the growing interest in developing alternative hosts to better represent 
aspects of bacterial–host interactions, new models for NTM disease have been recently 
developed. Free living ameba (Dictyostelium discoideum), goldfish (Carassius auratus), 
zebrafish (Danio rerio) and fruit fly (Drosophila melanogaster) have been used to reproduce 
and describe the characteristics of NTM infection, some have been used for preliminary in vivo 
efficacy studies.97-100 However, no single model necessarily mirrors the complexity of chronic 
pulmonary disease seen in patients. There still a real need for a model or perhaps a combination 
of in vivo and in vitro models that can be used in the pre-clinical evaluation of individual and 
combined regimens against NTM-PD. 
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Aims and outline of this thesis
There is a serious lack of evidence to support NTM-PD treatment. At the clinical level more 
support is needed and ideally well-designed clinical trials should be conducted to improve our 
knowledge on the NTM-PD therapy and patient´s clinical outcome. First, in preparation for 
such clinical trials, questions at the more fundamental level need to be addressed to design a 
more rational antibiotic treatment regimen. 
Within this PhD study, we aimed to assess the pharmacodynamics of commonly used drugs 
to treat NTM disease by means of the time-kill kinetic assays and the development of a 
pharmacodynamic model on basis of the in vitro hollow-fiber system. We first studied the 
pharmacodynamics of antibiotics commonly used against the RGM M. abscessus and M. 
fortuitum, by means of time-kill kinetic assays (Chapter 2). Subsequently, we applied this same 
strategy to study the basic pharmacodynamics for key antibiotics used to treat M. avium and M. 
xenopi pulmonary disease (Chapter 3). As a next step in regimen design, we applied the time-kill 
kinetic assay to obtain information on the killing activity of the combinations of clofazimine/
amikacin, and clofazimine/clarithromycin against the two key NTM species, M. avium and M. 
abscessus. To assess the extent of possible synergy, we applied two pharmacodynamic drug 
interaction models: the response surface model of Bliss independence and isobolographic 
analysis of Loewe additivity (Chapter 4). From Chapter 5 onwards, we shifted focus to M. 
abscessus. For this extremely drug-resistant species, we have developed a tractable model 
to further perform PK/PD studies and to identify the different antibiotic exposures and doses 
associated with optimal microbial killing and suppression of acquired drug resistance. In chapter 
5 we introduce the model to study the activity -or lack thereof- of amikacin, one of the standard 
drugs in currently recommended regimens. In Chapter 6, we show that the commonly used 
fluoroquinolone, moxifloxacin, shows no activity against M. abscessus at clinically achievable 
doses. In Chapter 7 we describe the first antimicrobial drug that do has appreciable activity 
against M. abscessus in our model, tigecycline. In Chapter 8, we move away from monotherapy 
studies and have assessed the activity of the currently recommended combination regimen of 
cefoxitin, amikacin and clarithromycin against M. abscessus. This can be used as a baseline to 
assess activities of new combination regimens. Lastly, principal findings are summarized and 
discussed according to their current scientific context in the general discussion presented in 
Chapter 9.
These efforts should provide a basis for more rational regimen design and, in turn, clinical trials. 
The poor treatment outcomes in NTM-PD are unacceptable and need to be shortly improved by 
systematic and innovative research.
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Summary
Objectives: This study was conducted to generate basic pharmacodynamic information on the 
relationship between antibiotic concentrations and the growth of rapidly growing mycobacteria 
(RGM), and thereby contribute to a better understanding of current and future drug regimens 
for diseases caused by RGM. 
Methods: Type strains of Mycobacterium abscessus and Mycobacterium fortuitum were used; 
the MICs of cefoxitin, amikacin, moxifloxacin, linezolid and clarithromycin were determined 
by broth microdilution. Time-kill assays were performed, exposing the bacteria to 2-fold 
concentrations from 0.25 to 32 times the MIC at 30 °C for 120 h. The sigmoid maximum effect 
(Emax) model was fitted to the time-kill curves data. 
Results: The highest killing of M. abscessus was observed between 24 and 72 h; amikacin had 
the highest Emax (0.0427 h-1), followed by clarithromycin (0.0231 h-1) and cefoxitin (0.0142 h-1). 
For M. fortuitum, between 3 and 24 h, amikacin also showed the highest Emax (0.1933 h-1). There 
were no significant differences between the Hill’s slopes determined for all the antibiotics tested 
against M. abscessus or M. fortuitum (P=0.2213 and P=0.2696, respectively). 
Conclusions: The total effect observed for all antibiotics was low and primarily determined 
by the Emax and not by the Hill’s slope. The limited activity detected fits well with the poor 
outcome of antibiotic treatment for disease caused by RGM, particularly for M. abscessus. An 
evaluation of drug combinations will be the next step in understanding and improving current 
treatment standards.
Time-kill kinetics of rapidly growing mycobacteria
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Introduction
Infections caused by non-tuberculous mycobacteria (NTM) are emerging in many settings, 
particularly those where the incidence of tuberculosis is in decline.1 NTM are environmental 
organisms, able to produce chronic disease in patients with a local or systemic immune 
impairment. Pulmonary NTM disease is the most frequent manifestation, involving both 
slowly growing mycobacteria and rapidly growing mycobacteria (RGM), with a variation in 
the epidemiology by geographical region.2 
The treatment of such diseases is complicated, as NTM are naturally resistant to most 
commonly used antibiotics and the outcome is often poor. In RGM disease, Mycobacterium 
abscessus disease is the most frequent but also the most difficult to treat. Currently 
recommended treatment regimens for M. abscessus depend on the infecting subspecies. For 
M. abscessus subspecies abscessus and M. abscessus subspecies bolletii strains that show 
inducible macrolide resistance, a combination of three or four drugs is used that includes 
amikacin, cefoxitin, imipenem, tigecycline or linezolid, while for M. abscessus subspecies 
bolletii strains that lack inducible macrolide resistance (former Mycobacterium massiliense), 
the recommended regimens include a macrolide in combination with two drugs from amikacin, 
cefoxitin, imipenem and linezolid. The choice of drugs is based on in vitro drug susceptibility 
testing. The treatment should continue for more than 12 months after cultures have converted to 
negative.3 For Mycobacterium fortuitum, the second most frequent RGM, a combination of two 
or three drugs is recommended and should include a fluoroquinolone, co-trimoxazole, amikacin, 
linezolid, imipenem or tetracycline, again based on in vitro susceptibility. However, there is 
limited clinical evidence to support these treatment regimens.4 Even at the more fundamental 
level, little is known about the pharmacodynamics of commonly used antibiotics against RGM. 
Time-kill assays allow the study of the pharmacodynamics of antibiotics, examining the rate 
at which different concentrations of an antibiotic kill bacteria; the concentration-dependent 
and time-dependent bactericidal activities of antimicrobial agents such as aminoglycosides, 
fluoroquinolones or β-lactams and macrolides can be studied using this methodology. The 
purpose of this study was to assess the pharmacodynamics of commonly used drugs to treat 
RGM disease by means of the time-kill assay and subsequent modeling of the results to assist 
in a more rational design of treatment regimens.
Materials and Methods
Bacterial strains 
We used M. abscessus subspecies abscessus CIP 104536 (Collection of Institute Pasteur, Paris, 
France) and M. fortuitum ATCC 6841 (ATCC, Rockville, MD, USA) for the experiments. Stock 
vials of each mycobacterium were preserved at -80 °C in trypticase soy broth with 40% glycerol 
and were thawed for each assay.
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Antibiotics
Moxifloxacin, cefoxitin, amikacin and clarithromycin were obtained from Sigma-Aldrich 
(Zwijndrecht, the Netherlands) and linezolid was obtained from Pfizer BV (Capelle aan den 
Ijssel, the Netherlands) as the 2 mg/ml infusion. Water was the solvent for preparing stock 
solutions, except for clarithromycin, which was dissolved in methanol. Stock solutions were 
stored at -80 °C; prior to each experiment, one aliquot was thawed to prepare the different 
concentrations to be tested.
Susceptibility testing 
The MIC of each of the tested antibiotics was determined by broth microdilution in cation-
adjusted Mueller –Hinton broth (CAMHB; BD Bioscience, Erembodegem, Belgium) at 30 °C,
according to CLSI guidelines.5 For the initial evaluation, commercial panels were used 
(RAPMYCO Sensititre®, Trek Diagnostics/ThermoFisher, Landsmeer, the Netherlands) 
following the manufacturer’s recommendations. If the MIC fell outside the concentration 
range tested in the commercial assay, we performed manual broth microdilution with wider 
concentration ranges.
Time-kill assays
The mycobacterial inoculum was prepared freshly for each experiment by growing over 24 
h in CAMHB with oleic acid/bovine albumin/dextrose/catalase (OADC) growth supplement 
(BD Bioscience, Erembodegem, Belgium) and 0.05% Tween 80 (Sigma-Aldrich), to obtain 
bacteria in the early logarithmic phase of growth. Individual bottles of 20 ml of CAMHB 
plus OADC and 0.05% Tween 80 containing eight 2-fold increasing concentrations of each 
antibiotic (from 0.25 to 32 times the MIC, except for M. abscessus and cefoxitin, for which 
two lower concentrations were included) were cultured with the inoculum (density 105–106 
cfu/ml) at 30 °C, under shaking conditions (100 rpm); ventilation through a bacterial filter 
(FP 30/0.2 Ca/S, Whatman GmbH, Germany) was incorporated. A growth control bottle, with 
inoculum but without antibiotic, as well as a sterility control (medium only) were included. 
At defined time intervals (3, 6, 12, 24, 36, 48, 72, 96 and 120 h), the size of the bacterial 
population was quantified to characterize the effect of the different antibiotics. Samples of 1 
ml were taken from each bottle and serial 10-fold dilutions in 0.85% sterile saline solution 
were prepared. Volumes of 10 µl from undiluted samples and from each dilution were plated 
in triplicate on Middlebrook 7H11 (BD Bioscience, Erembodegem, Belgium) for further cfu 
counting after 3 –5 days of incubation at 30 °C. The theoretical detection limit was 33.3 cfu per 
plate, corresponding to 1.52 log10 cfu/ml.
Curve fitting and analysis
The experimental data derived from time-kill assays were analyzed using GraphPad Prism 5.03 
(GraphPad Inc., San Diego, CA, USA). Log cfu values were plotted against time for each 
antibiotic. The kill rate was determined at different time intervals (3 –24, 3 –36, 24 –72, 24 
Time-kill kinetics of rapidly growing mycobacteria
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–96 and 24 –120 h), undertaking a linear regression to find the slope for each concentration; 
the logarithmic transformed concentration was then plotted against each slope and a non-linear 
regression analysis (dose – response) was run. The sigmoid maximum effect (Emax) model (four-
parameters Hill’s equation)6,7 was fitted to the kill rate data, analyzing each assay to determine 
the pharmacodynamic relationship between the antibiotic concentration and bacterial growth 
or death. Emax, 50% effective concentration (EC50), Hill’s slope (ɣ) and R2 were calculated for 
each assay.
Results 
Susceptibility
The MICs determined for each antibiotic are shown in Table 1. All the MICs were higher for M. 
abscessus than for M. fortuitum.
Time-kill assays 
Figures 1 and 2 show the pattern of growth and kill by antibiotics of M. abscessus and M. 
fortuitum, respectively, at different concentrations of each of the tested antibiotics. The growth 
curves differ for each species. M. abscessus showed a lag phase of 3–12 h and its maximum 
growth was higher than the growth for M. fortuitum in all the experiments. The lag phase for 
M. fortuitum was around 3 h. In general, time-kill curves for M. abscessus showed smaller 
decreases in bacterial population size than those observed for M. fortuitum when exposed to 
antibiotics. 
For M. abscessus, the cefoxitin time-kill curve was different from those of amikacin and 
clarithromycin. After a short lag phase, a slow decline was observed at almost all concentrations, 
reaching the lowest cfu counts only after 96 –120 h of incubation. In contrast, during amikacin 
and clarithromycin exposure, killing was observed after only 24 h and for some concentrations, 
in particular with clarithromycin, there appeared to be significant growth even before killing was 
observed. Only after 24 h did concentrations higher than 2× MIC started to effectively decrease 
the bacterial density, with its maximum decrease at 120 h at the two highest concentrations. 
Regrowth was, however, observed with 2, 4 and 8× MIC.
Table 1. Susceptibility data for M. abscessus and M. fortuitum type strains tested by broth microdilution in 
CAMHB, reading at 72 h.5
MIC (mg/l)
Strain Cefoxitin Amikacin Moxifloxacin Linezolid Clarithromycin
M. abscessus CIP104536 64 32 8 32 4
M. fortuitum ATCC6841 32 1 0.062 8 2
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Figure 1. Time-kill curves of (A) cefoxitin, (B) 
amikacin and (C) clarithromycin against M. 
abscessus CIP 104536. Antibiotic concentrations 
are indicated by different symbols.
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Interestingly, after 48 h, part of the colonies exposed to amikacin concentrations of 2× MIC 
and higher converted to a rough morphology, which was observed after plating the samples for 
cfu counting.
Significant differences in the killing characteristics of the antibiotics were observed for M. 
fortuitum. Linezolid showed only slight but prolonged killing without apparent concentration 
dependent effects. The curves for cefoxitin, amikacin and moxifloxacin shared some 
characteristics and exhibited an important reduction in growth during the first 24–36 h (Figure 
2); however, regrowth occurred after the initial killing and was noticeable for amikacin 
in particular, with the phenomenon also observed for M. abscessus. Amikacin also showed 
the highest kill rate and concentration-dependent activity; the main fall in cfu was observed 
at concentrations 4× MIC or higher. The same phenomenon of morphology changes noted 
previously for M. abscessus was observed for M. fortuitum colonies exposed to 2× MIC or 
higher of amikacin.
Time-kill modeling 
After a lag phase, the maximum kill rate was present over the period 24–72 h for M. abscessus 
and 3–24 h for M. fortuitum. Figure 3 shows the relationship between the kill rate and 
concentration for the two RGM species. Pharmacodynamic parameter estimates were obtained 
with the Emax model with a variable slope (Table 2).
The Emax model fitted well and confirmed that the kill rate for M. abscessus was relatively low. 
The highest killing rate was observed for amikacin, 0.0427 h-1, between 24 and 72 h. There 
was no significant difference in Hill’s slope estimated for the antibiotics tested (P=0.2213), 
indicating that the differences in effect modality are primarily determined by the maximum 
kill rate of each antibiotic. For M. fortuitum, the maximum kill rate was observed much earlier, 
A           cefoxitin
C           clarithromycin
B          amikacin
Time-kill kinetics of rapidly growing mycobacteria
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between 3 and 24 h of exposure, and again amikacin showed the highest Emax, 0.1933 h-1. As 
with M. abscessus, no significant differences were found between the Hill’s slope calculated 
for each of the antibiotics tested (P=0.2696), indicating that the effect is primarily determined 
by the maximum effect.
Discussion
This study provides fundamental new information on the pharmacodynamic relationship 
between antibiotic concentrations and mycobacterial population dynamics for RGM.
Amikacin, cefoxitin and clarithromycin did not show a high killing effect on M. abscessus, 
although killing proceeded with time. For M. fortuitum, amikacin, cefoxitin and moxifloxacin 
showed highest killing rates. The higher growth level consistently reached by M. abscessus 
could, at least in part, explain the lesser effect observed for the antibiotics on this species. 
 
The individual analysis of each antibiotic indicated that amikacin had the highest effect on 
both RGM. For M. abscessus, amikacin inhibited the growth during the first 24 h, but the 
killing activity started after that time. For M. fortuitum, killing from amikacin started earlier. 
We observed morphological changes after exposure to amikacin concentrations of 2× MIC or 
higher. This phenomenon has been previously observed for Pseudomonas aeruginosa after 6 h 
of incubation in time-kill assays.8 Whether the changes we observed are related to the appearance 
of resistant mutants or are the result of an adaptation response should be addressed in the future. 
Figure 2. Time-kill curves of (A) cefoxitin, (B) amikacin, (C) moxifloxacin and (D) linezolid against M. 
fortuitum ATCC 6841. Antibiotic concentrations are indicated by different symbols.
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Recently published work with clinical strains of M. abscessus exposed to amikacin, as well as 
to linezolid, tigecycline and moxifloxacin, states a lack of antimicrobial bactericidal activity of 
these antibiotics.9 However, the assays were conducted only until 24 h, a difference from the 
present study, which describes the activity over 120 h assays; the observed lack of activity by 
the authors may therefore be largely explained by the lag phase we have also observed. Our 
results clearly indicate that the effects of antimicrobials on M. abscessus should be studied over 
at least 72 h to provide useful information. 
Although it involved a different NTM, previous work on Mycobacterium avium complex 
(MAC) showed that amikacin appeared highly and rapidly bactericidal in the early logarithmic 
phase of growth.10 Moreover, with Mycobacterium tuberculosis, the time-kill kinetics of 
amikacin displayed a high and extremely rapid killing activity that was not time dependent 
and could eliminate all mycobacteria.11 Against M. abscessus and M. fortuitum, we observed 
a significantly weaker effect. Nonetheless, amikacin still can play an important role in the 
treatment of disease caused by RGM.
The effect of cefoxitin was different in the two RGM species evaluated. For M. abscessus, 
cefoxitin behaved like other β-lactams and the bacterial density gradually declined during 
exposure to it. This is in contrast to the effect observed in M. fortuitum, where cefoxitin 
showed a concentration-dependent effect and the second highest Emax. Differences in the effect 
of cefoxitin have previously been reported in MRSA. Combining cefoxitin with a variety of 
β-lactams enhanced their in vitro activity against community-acquired MRSA strains but not 
against hospital-acquired MRSA; this may result from the differential binding of cefoxitin to the 
target (penicillin binding protein 4, PBP4), which plays an important role only in the β-lactam 
resistance of community-acquired strains.12 Cefoxitin targets or mechanisms of action may not 
be the same in M. abscessus and M. fortuitum; this could explain the differences observed and 
will be an interesting subject for further evaluation.  
Figure 3. The best-fit sigmoid curves obtained from the Emax model of (A) M. abscessus CIP 104536 exposed 
to cefoxitin, amikacin and clarithromycin, between 24 and 72 h, and (B) M. fortuitum ATCC 6841 exposed 
to cefoxitin, amikacin, moxifloxacin and linezolid, between 3 and 24 h. A different y-axis scale is used for 
(A) and (B).
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Clarithromycin, long considered a cornerstone of M. abscessus treatment,1,3 showed killing 
capacity only at concentrations greater than 4× MIC. Similarly, previous studies of MAC 
observed a maximum bactericidal effect at a relatively high concentration (256 mg/l).10 
Linezolid and moxifloxacin were only tested for M. fortuitum as these drugs were considered 
inactive against the M. abscessus type strain (Table 1); however, their killing capacity was not 
high for M. fortuitum. Few comparative data are available for those antibiotics.
According to the Emax model fitted to our data, Hill’s slopes were not significantly different 
between the antibiotics tested for each species. In this regard, the total effect observed was 
primarily determined by the Emax, representing the extent of kill as a function of concentration, 
and not by the Hill’s slope. This is different from the effect of antibiotics in other bacterial species, 
where a clear difference is observed for time-dependent antimicrobials such as β-lactams (lower 
Emax, higher Hill´s slope) and concentration-dependent drugs such as aminoglycosides (higher 
Emax, lower Hill´s slope).
7 
Our data for M. abscessus contrast with the recent findings from the nude mice model, in which 
cefoxitin was superior in efficacy to amikacin and clarithromycin. Only cefoxitin improved 
survival and reduced bacillary loads in the spleen; amikacin and clarithromycin prevented death 
but had little impact on bacillary loads. Interestingly, in this model the amikacin/clarithromycin/ 
cefoxitin combination was as active as cefoxitin alone.13 
Strain Antibiotic Time 
(h)
Emax 
(h-1)
95 % CI EC50 
(mg/l)
95 % CI Hill’s slope 
(ɣ)*
95 % 
CI
R2
M. abscessus  
CIP104536
Cefoxitin 24-72 0.0142 0.008719-
0.01976
6.24 4.450-
8.735
3.534 1.804-
5.263
0.97
Cefoxitin 24-72 0.0427 0.03456-
0.05083
51.74 41.18-
65.01
0.97
Clarithromycin 24-72 0.0231 0.01430-
0.03185
9.63 7.163-
12.96
0.92
M. fortuitum  
ATCC6841
Cefoxitin 3-24 0.1247 0.1041-
0.1454
18.24 12.78-
26.02
1.416 1.021-
1.811
0.93
Amikacin 3-24 0.1933 0.1689-
0.2177
0.910 0.6848-
1.209
0.99
Moxifloxacin 3-24 0.0677 0.04939-
0.08590
0.021 0.01295-
0.03445
0.93
Linezolid 3-24 0.0338 0.01518-
0.05234
3.203 1.784-
5.750
0.97
Table 2. Parameter estimates, with 95% CI, derived from inhibitory Emax.
* Pooled value for all antibiotics by species.
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Extrapolating these data to the treatment setting, the limited activity detected for amikacin, 
cefoxitin and clarithromycin against M. abscessus fits well with the clinical observations that 
treatment with regimens containing these drugs leads to poor outcomes.3 The amikacin peak 
serum concentration in patients with NTM pulmonary disease averages 55 mg/l,14,15 i.e. around 
the MIC measured for the M. abscessus type strain. Given that the activity of amikacin was 
best at the highest concentrations, the current dosing may not yield concentrations at the site 
of infection that can exhibit significant killing activity. This may in part explain the limited 
efficacy of amikacin against M. abscessus in the nude mice model.13 Local administration, e.g. 
inhaled amikacin for pulmonary disease caused by M. abscessus, may be more efficacious. 
The M. abscessus type strain had an MIC of clarithromycin of 4 mg/l, and the maximum effect 
was attained at concentrations > 2× MIC. These concentrations are above the concentration 
attainable in the serum of patients (which average 4 mg/l),4,14,15 but the macrolides are known 
to accumulate in lung tissue, epithelial lining fluid and macrophages at concentrations 2-200 
times higher than serum concentrations,16 although it is not clear whether these concentrations 
are active.17 Hence, the high concentrations needed to achieve a significant effect in our time-
kill assay may be attainable at the site of infection in M. abscessus lung disease. Unfortunately, 
no pharmacokinetic data are available for cefoxitin in this patient category, which needs to 
be investigated if cefoxitin is to continue to be included in the treatment regimens for RGM 
disease. 
The time-kill assays performed in this study provide basic information on the individual effect 
of static concentrations of each antibiotic on M. abscessus and M. fortuitum. However, this 
setting is very different from the in vivo situation where multidrug therapy, the daily intake of 
drugs and their pharmacokinetics, and the localization of the causative mycobacteria create 
a very different scenario. Thus, the next step should be to continue these studies in dynamic 
pharmacokinetic/pharmacodynamic models for the evaluation of combined regimens (which 
are, and should be, the norm) in RGM disease. These models, despite their abstractions, will 
provide data that are much closer to the in vivo situation and may aid in the design of more 
active treatment regimens. 
In conclusion, time-kill kinetic assays revealed that amikacin was more active than clarithromycin 
and cefoxitin against M. abscessus and that amikacin, followed by cefoxitin, moxifloxacin and 
linezolid, was also most active against M. fortuitum. However, we demonstrate that the activity 
of all the drugs tested was relatively low and the concentrations effective in vitro can hardly be 
reached in vivo, reminiscent of the poor outcomes of antibiotic treatment for RGM diseases.
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Summary
Objectives: This study aimed to provide basic pharmacodynamic information for key antibiotics 
used to treat Mycobacterium avium and Mycobacterium xenopi pulmonary disease.
Methods: M. avium subspecies hominissuis IWGMT49 and M. xenopi ATCC 19250 type strains 
were used; the MICs of clarithromycin, amikacin and moxifloxacin were determined by broth 
microdilution. Time-kill assays were performed, exposing bacteria to 2-fold concentrations 
from 0.062× to 32× the MIC at 37 °C for 240 h for M. avium or 42 days for M. xenopi. The 
sigmoid maximum effect (Emax) model was fitted to the time-kill curve data. 
Results: Maximum killing of M. avium by amikacin was obtained between 24 and 120 h 
(0.0180 h-1) and was faster and higher than with clarithromycin (0.0109 h-1); however, regrowth 
and amikacin-resistant mutants were observed. Killing rates for M. xenopi were higher, 0.1533 
h-1 for clarithromycin and 0.1385 h-1 for moxifloxacin, yet required 42 days. There were no 
significant differences between the Hill´s slopes determined for all the antibiotics tested against 
M. avium or M. xenopi (P= 0.9663 and P= 0.0844, respectively).
Conclusions: The killing effect of amikacin and clarithromycin on M. avium subspecies 
hominissuis was low, although amikacin activity was higher than that of clarithromycin, 
supporting its role in a combined therapy. Clarithromycin and moxifloxacin may have similar 
activity within treatment regimens for M. xenopi disease. Future studies of in vitro and in vivo 
pharmacokinetic/pharmacodynamic interactions are needed to improve the current regimens to 
treat these two important slowly growing mycobacteria in pulmonary disease.
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Introduction
Pulmonary disease is the most common clinical manifestation of non-tuberculous mycobacteria 
(NTM) infection.1 Several NTM can cause such disease, although their geographical 
distribution varies from region to region.2 Mycobacterium avium complex (MAC) is the most 
frequently isolated slowly growing mycobacteria (SGM) involved in pulmonary disease,2,3 but 
Mycobacterium xenopi has also been frequently isolated in Northern Europe as an important 
infectious species.2,3 Treatment of pulmonary disease caused by M. avium and M. xenopi is a 
challenge and the outcome is uncertain. Only macrolides, like azithromycin or clarithromycin, 
are active both in vitro and in vivo against M. avium, 1,4 hence treatment regimens include 
macrolides, but rifampicin and ethambutol are added in order to prevent acquired macrolide 
resistance. Amikacin is also used, during the first 2–3 months of therapy, despite clinical 
evidence; only the in vitro MIC supports its role.1,4 Likewise the recommended regimen for M. 
xenopi includes isoniazid, rifampicin, ethambutol and clarithromycin, with aminoglycosides 
added during the first months. Moxifloxacin has also been suggested to play a role in the treatment 
of such mycobacterial disease.1,4 However, there is little information on the effectiveness of 
those antibiotics against M. avium and M. xenopi pulmonary disease and cure rates are low.4,5 
Moreover, patient cohorts of M. xenopi pulmonary disease stand out for their high mortality 
rates.3 The limited information on the activity of the antibiotics currently used in these regimens 
emphasizes the need to better understand the fundamentals of SGM treatment, in particular the 
potency and activity of the antimicrobials that currently play a major role. In the present study 
we aimed to study the basic pharmacodynamics for key antibiotics used to treat M. avium and 
M. xenopi pulmonary disease by performing in vitro time-kill kinetics. Because of the slow 
growth of SGM and the long duration of treatment, some experiments were conducted over up 
to 42 days of exposure.
Materials and Methods
Bacterial strains and antibiotics
We used M. avium subspecies hominissuis IWGMT49 (International Working Group on 
Mycobacterial Taxonomy) and M. xenopi ATCC 19250 (ATCC, Manassas, VA, USA) as 
test strains. Stock vials of each mycobacteria in the early logarithmic phase of growth were 
preserved at -80 °C in trypticase soy broth with 40% glycerol and were thawed for each assay. 
Moxifloxacin, amikacin and clarithromycin were obtained from Sigma-Aldrich (Zwijndrecht, 
The Netherlands) and dissolved in water, except for clarithromycin, which was dissolved in 
methanol, following CLSI recommendations.6 Stock solutions, stored at -80 °C, were thawed 
for each experiment to prepare the different concentrations to be tested. 
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Susceptibility testing 
The MIC of each of the tested antibiotics was determined by broth microdilution in CAMHB (BD 
Bioscience, Erembodegem, Belgium) at 37 °C, according to CLSI guidelines,7 using commercial 
panels (SLOWMYCO Sensititre®, Trek Diagnostics/ThermoFisher-Landsmeer, The Netherlands).
Time-kill assays
Individual bottles of 20 ml of Middlebrook 7H9 (BD Bioscience, Erembodegem, Belgium) plus 
OADC growth supplement (BD Bioscience) and 0.05% Tween 80 (Sigma-Aldrich), containing 
ten 2-fold increasing concentrations of each antibiotic (from 0.062× to 32× the MIC) were 
cultured with the inoculum (density 105–106 cfu/ml) at 37 °C. All bottles were shaken (100 rpm) 
and ventilated with air through a bacterial filter (FP 30/0.2 Ca/S, Whatman GmbH, Germany). 
In order to perform cfu counting of the bacterial population, samples of 200 ml were taken 
from each bottle and serial 10-fold dilutions in 0.85% sterile saline solution were plated on 
Middlebrook 7H11 (BD Bioscience) plates, at different time intervals (12, 24, 48, 72, 96, 120, 
144, 168 and 240 h for M. avium and 3, 6, 9, 12, 15 18, 21, 28 and 42 days for M. xenopi).
Mutation frequency 
Mutants were counted at time 0 and after 240 h for M. avium exposed to both amikacin and 
clarithromycin, by plating the bacterial suspension and 10-fold dilutions on Middlebrook 7H11 
plates containing 4× the MIC of each antibiotic. Owing to the higher mutation rate expected for 
amikacin, mutation frequency was determined throughout the experiment for bottles containing 
1×, 4×, 8×, 16× and 32× MIC. No mutation frequency was determined for M. xenopi, since no 
resistant mutants were expected.
Curve fitting and analysis
Log cfu values were plotted against time for each antibiotic and analyzed using Graphpad Prism 
5.03 (Graphpad Inc., San Diego, CA, USA). The sigmoid maximum effect (Emax) model (four-
parameter Hill’s equation)8 was fitted to the kill rate data, analyzing each assay to determine the 
pharmacodynamic relationship between antibiotic concentration and bacterial growth or death. 
Emax, 50% effective concentration (EC50), Hill’s slope (ɣ) with 95% CI and R
2 were calculated 
for each assay.
Amikacin concentrations cfu/ml Mutation frequency One mutant in cfu/ml
Growth Control 4.00 × 109
1× MIC (8 mg/l) 2.80 × 107 7.00 × 10-3 143
4× MIC (32 mg/l) 0 - -
8× MIC (64 mg/l) 3.23 × 107 8.03 × 10-3 124
16× MIC (128 mg/l) 5.33 × 107 1.33 × 10-2 75
32× MIC (256 mg/l) 3.33 × 106 8.33 × 10-4 1200
Table 1. Mutation frequency of M. avium IWGMT49 exposed to amikacin after 240 h.
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Results 
Susceptibility
Clarithromycin and amikacin MICs for M. avium were 4 and 8 mg/l. Clarithromycin and 
moxifloxacin MICs for M. xenopi were both 0.25 mg/l.
Time-kill assays 
M. avium
Kill curves of M. avium exposed to clarithromycin and amikacin are shown in Figure 1. In the 
experiments with clarithromycin we observed a lag phase of 24 h; thereafter a slow decline 
in bacterial cfu/ml was noted for each concentration, except for the lowest of 0.062× MIC, 
which only produced inhibition of growth. Killing appeared to be maximized at relatively low 
multiples of the MIC and was hardly concentration dependent. Regrowth was observed after 
168 h for concentrations in the lower range - 0.062×, 0.25×, 0.5× and 2× MIC. In contrast, 
amikacin killing was faster and higher for concentrations above 2× MIC. However, regrowth 
was observed earlier than with clarithromycin, after 96–120 h, except for 4× MIC.
M. xenopi
Kill curves of M. xenopi exposed to clarithromycin and moxifloxacin are shown in Figure 2. 
When clarithromycin was used, the lag phase involved 3 days and thereafter a slow decline in 
cfu/ml was observed at almost all concentrations; killing was maximum after 42 days. Low 
clarithromycin concentrations showed killing, but similar to M. avium, regrowth was observed 
at the lower concentrations of 0.062×, 0.125×, 0.25× and 0.5× MIC. Concentrations of 1× 
MIC and higher produced constant killing with no regrowth; only concentrations 4× MIC and 
higher resulted in undetectable cfu/ml after 42 days of exposition. When moxifloxacin was 
tested, a lag phase of 3 days was also observed, but only for concentrations of 0.062 to 1× 
MIC; concentrations 2× MIC and higher already showed a killing effect by that time. After 3 
days, low concentrations of 0.062× to 0.25× MIC initially showed some killing, but regrowth 
appeared after 9-12 days, depending on the concentration.
Figure 1. Time-kill curves of M. avium IWGMT49 with (A) clarithromycin and (B) amikacin. Antibiotic 
concentrations are indicated by different symbols.
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Constant killing with no regrowth was observed with concentrations 0.5× MIC and higher, 
but only concentrations 1× MIC and higher resulted in undetectable cfu/ml after 42 days of 
exposition.
High mutation frequency in amikacin-exposed M. avium
No amikacin-resistant or clarithromycin-resistant mutants were detected at time 0 for the M. 
avium inoculum used in the experiments. After 240 h of incubation of the growth control, 
we observed a mutation frequency of 3.24×10-7 for amikacin and a mutation frequency of 
4.05×10-8 for clarithromycin. In amikacin-exposed cultures, the first M. avium resistant 
mutants appeared after 72-96 h of incubation. Mutation frequency after 240 h of exposure was 
on average 7.3×10-3, excluding 4× MIC where no mutants appeared (Table 1).
Emax model 
The Emax model fitted well; the highest kill rate for M. avium was observed after 24-120 h of 
exposure to amikacin, 0.0180 h-1 . There was no significant difference in Hill’s slope estimated 
for amikacin and clarithromycin (P=0.9663), indicating that the differences in effect modality are 
primarily determined by the maximum kill rate of each antibiotic. For M. xenopi, the maximum 
kill rate was observed in a different time interval, 3-42 days of exposure. The Emax values were 
higher than for M. avium but very similar between clarithromycin and moxifloxacin. Again, no 
significant differences were found between the Hill’s slope calculated for the two antibiotics 
tested (P=0.0844). Table 2 shows the parameter estimates obtained with the Emax model for each 
experiment and Figure 3 shows the best fitted sigmoid curves for the kill rate and concentration 
for the two SGM.
Discussion
This study presents basic pharmacodynamic information for antibiotics used to treat pulmonary 
disease caused by M. avium and M. xenopi. Amikacin showed a higher killing effect on M. 
avium than clarithromycin, although the killing was relatively low. For M. xenopi, the killing 
obtained with clarithromycin or moxifloxacin was similar and very slow for both agents. 
The amikacin killing rate was higher than that of clarithromycin for M. avium. Its effect was 
faster, especially at concentrations over 2× MIC; therefore, its role as a support antibiotic in 
combined regimens holds promise. Strong and rapid in vitro killing by amikacin has been noted 
for Mycobacterium tuberculosis;9 however, no early bactericidal activity was detected in a 
group of patients with untreated, smear-positive, pulmonary TB in South Africa.10
Superior activity of amikacin over clarithromycin was also observed in vitro against M. avium 
subspecies avium11 and M. abscessus.12 Only the higher concentrations of amikacin, 2× MIC 
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and above ( ≥16 mg/l), were effective against M. avium in this study, some of which can be 
close to the achievable levels in serum.13 Whether clinically achievable levels are good enough 
to attain the maximum kill is a question that should be answered in the future. The use of inhaled 
amikacin, currently in trials (ClinicalTrials.gov identifier NCT01315236), may overcome this 
pharmacodynamic barrier since higher concentrations can be obtained in lungs with potentially 
less nephrotoxicity and ototoxicity.14,15
Regrowth of M. avium was observed soon after the initial drop in cfu obtained with 
amikacin. A high mutation frequency was determined in this study after in vitro exposure 
of M. avium subspecies hominissuis to amikacin concentrations of 1×, 8×, 16× and 32× 
MIC (8, 64, 128 and 256 mg/l). The emergence of resistant mutants has been previously 
observed in M. tuberculosis, when exposure to an amikacin concentration window between 
8 and 256 mg/l resulted in the selection of resistant bacteria, which harbored the A1401G 
mutation in the rrs gene.9 Previous work done with M. avium subspecies avium did not 
show the early and high mutation rate that we observed in this study.11
Macrolides are considered the cornerstone for the treatment of MAC disease, particularly 
because of the established in vitro–in vivo correlation of their activity.4,16 In this study, 
clarithromycin showed a slow killing for M. avium subspecies hominissuis, basically at 
all concentrations, which was maximum after 240 h; however, the regrowth observed after 
168 h underlines that macrolide monotherapy should not be used. In addition, if there is 
unknown resistance to all of the companion antibiotics, clarithromycin monotherapy will 
favor the emergence of resistance.
When clarithromycin was tested against M. avium subspecies avium, it resulted in both 
concentration-dependent and time dependent effects.11 However, concentration was not 
the most important factor for clarithromycin effect in our study, which may be evidence of 
the intrinsic differences in the interaction of the same antibiotic with different M. avium 
subspecies.
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Figure 2. Time-kill curves of M. xenopi ATCC 19250 with (A) clarithromycin and (B) moxifloxacin. 
Antibiotic concentrations are indicated by different symbols.
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In the set of experiments with M. xenopi, killing took a lot of time; it was maximal after 42 
days, but we found no significant difference among the effect obtained with clarithromycin 
or moxifloxacin. Our observation is concordant with the characterization of the activity of 
anti-mycobacterial drugs against M. xenopi in the mouse model performed by Andréjak 
et al,5 who found no differences between clarithromycin- and moxifloxacin containing 
regimens. Rifampicin/ethambutol synergy in vitro is absent in M. xenopi isolates,17 which 
points out the role of clarithromycin during therapy. That, along with the underlying 
diseases in M. xenopi patients, may explain the poor results with treatment.18 The absence 
of correlation between the in vitro activity of clarithromycin and moxifloxacin and the 
in vivo outcomes of treatment with regimens based on these antimicrobials, as a result of 
these underlying diseases, could be hampering our understanding of M. xenopi and how 
to deal with it.
Hill’s slopes were not significantly different for amikacin and clarithromycin against M. avium, 
but the values of Emax were different. This is a confirmation of a previous observation made in 
a set of experiments that we conducted with rapidly growing mycobacteria,12 where the total 
effect observed was mainly determined by the Emax and not by the Hill’s slope. Hill’s slopes were 
also not significantly different for clarithromycin and moxifloxacin against M. xenopi, although 
neither were their Emax values. The Hill’s slope helps to infer the concentration dependency 
of an antibiotic. In this study both antibiotics showed similar steeper slope values for both 
Mycobacterium species; therefore the difference in concentration between the maximum and 
minimal effect was small. The overall effect is thus more of a time-dependent nature than 
concentration dependent. 
We acknowledge several limitations of this study. Although 42 °C is the optimal growing 
temperature for M. xenopi, we performed our experiments at 37 °C. We preferred the 
physiological temperature of the human host; however, we do not know how this could have 
affected the results. There is a discrepancy between the in vitro MIC and the concentration 
Table 2. Parameter estimates, with 95% CI, derived from inhibitory Emax
* Pooled value for the two antibiotics evaluated by species.
Strain Antibiotic Time Emax 
(h-1)
95 % CI EC50 
(mg/l)
95 % CI Hill’s slope 
(ɣ)*
95 % CI R2
M. avium 
IWGMT49
Clarithromycin 24-120 
hours
0.0109 0.0089-
0.0130
0.149 0.010-
0.222
1.838 1.265-
2.410
0.98
Amikacin 0.0180 0.0154-
0.0205
1.427 1.160-
1.755
0.99
M. xenopi 
ATCC19250
Clarithromycin 3-42 
days
0.1533 0.1356-
0.1711
0.191 0.149-
0.245
2.543 1.484-
3.602
0.98
Moxifloxacin 0.1385 0.1232-
0.1539
0.076 0.059-
0.099
0.96
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that leads to 2 log kill in the time-kill curves (99% kill) at the time for MIC readout. These 
discrepancies result in part from technical aspects, including the fact that MICs were determined 
in CAMHB, while time-kill assays were conducted in Middlebrook 7H9, which has a lower 
pH that affects clarithromycin activity.7 Bottles used in the time-kill experiments are shaken 
constantly and they have a big head space and filtered vents, which allows a stable oxygen 
supply. 
Our experiments were designed to evaluate the role of each individual antibiotic in the therapy; 
however, it is necessary to evaluate combined regimens as they are used in clinical practice. 
Dynamic models for pharmacokinetic and pharmacodynamic determinations can provide more 
representative data for the in vivo situation; the next step is to continue with the evaluation of 
current regimens with those models to help in the design of new and hopefully more effective 
therapies. 
In conclusion, the killing effect of amikacin and clarithromycin on M. avium subspecies 
hominissuis is low, although amikacin activity was higher than that of clarithromycin, supporting 
its role in a combined therapy. Time-kill assays with M. xenopi showed no differences between 
clarithromycin and moxifloxacin, which did have high killing rates yet required a lot of time. 
Clarithromycin and moxifloxacin may have identical activity within treatment regimens for 
M. xenopi disease. Future studies of in vitro and in vivo pharmacokinetic/pharmacodynamic 
interactions are needed to be able to improve the current regimens against these two important 
SGM in pulmonary disease.
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Summary
Multidrug therapy is a standard practice when treating infections by nontuberculous mycobacteria 
(NTM), but few treatment options exist. We conducted this study to define the drug-drug 
interaction between clofazimine and both amikacin and clarithromycin and its contribution to 
NTM treatment. Mycobacterium abscessus and Mycobacterium avium type strains were used. 
Time-kill assays for clofazimine alone and combined with amikacin or clarithromycin were 
performed at concentrations of 0.25× to 2× MIC. Pharmacodynamic interactions were assessed 
by response surface model of Bliss independence (RSBI) and isobolographic analysis of Loewe 
additivity (ISLA), calculating the percentage of statistically significant Bliss interactions and 
interaction indices (I), respectively. Monte Carlo simulations with predicted human lung 
concentrations were used to calculate target attainment rates for combination and monotherapy 
regimens. Clofazimine alone was bacteriostatic for both NTM. Clofazimine-amikacin was 
synergistic against M. abscessus (I = 0.41; 95% confidence interval [CI], 0.29 to 0.55) and M. 
avium (I = 0.027; 95% CI, 0.007 to 0.048). Based on RSBI analysis, synergistic interactions 
of 28.4 to 29.0% and 23.2 to 56.7% were observed at 1× to 2× MIC and 0.25× to 2× MIC 
for M. abscessus and M. avium, respectively. Clofazimine-clarithromycin was also synergistic 
against M. abscessus (I = 0.53; 95% CI, 0.35 to 0.72) and M. avium (I = 0.16; 95% CI, 0.04 to 
0.35), RSBI analysis showed 23.5% and 23.3 to 53.3% at 2× MIC and 0.25× to 0.5× MIC for 
M. abscessus and M. avium, respectively. Clofazimine prevented the regrowth observed with 
amikacin or clarithromycin alone. Target attainment rates of combination regimens were >60% 
higher than those of monotherapy regimens for M. abscessus and M. avium. The combination of 
clofazimine with amikacin or clarithromycin was synergistic in vitro. This suggests a potential 
role for clofazimine in treatment regimens that warrants further evaluation.
Clofazimine prevents regrowth and resistance
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Introduction
The treatment of diseases caused by nontuberculous mycobacteria (NTM) is a challenge, partly 
due to the natural resistance of NTM to most antibiotics. Treatment outcomes are generally 
poor, and current treatment recommendations have a very limited evidence base, since very few 
clinical trials have been performed.1,2
Multidrug therapy is a standard practice when treating mycobacterial infections. However, 
the pharmacodynamic (PD) interactions among the combined drugs are largely unknown. 
Understanding these interactions will help to identify synergistic combinations with increased 
antibacterial killing, which ultimately can result in a better treatment outcome.
One of the promising combinations is amikacin and clofazimine, given the key role of amikacin 
in the treatment of NTM infections2,3 and the unique characteristics of clofazimine, like its 
prolonged half-life, its preferential accumulation inside macrophages,4 and the recently found 
bactericidal activity only after 2 weeks of treatment in the mouse model of tuberculosis.5 
Clarithromycin, on the other hand, has substantial in vitro and clinical activity against 
Mycobacterium avium complex (MAC), and it has been long considered the cornerstone for 
Mycobacterium abscessus treatment.3 Hence, the examination of its interaction with clofazimine 
is interesting. 
Previous studies showed in vitro synergy between clofazimine and amikacin against both 
rapidly and slowly growing NTM.1,6 The combination clarithromycin-clofazimine also showed 
synergy against MAC strains in checkerboard evaluation.7 These checkerboard titrations offer 
no information on the mechanism of synergistic activity, the exact killing activity of these 
combinations, or its concentration dependence. We therefore investigated the pharmacodynamic 
interactions between clofazimine and amikacin, and clofazimine and clarithromycin, against two 
key NTM species, using time-kill assays analyzed with two pharmacodynamic drug interaction 
models: the response surface model of Bliss independence (RSBI) and isobolographic analysis 
of Loewe additivity (ISLA).8,9
Materials and Methods
Bacterial strains, media, and antibiotics
Mycobacterium abscessus subsp. abscessus CIP 104536 (Collection of Institute Pasteur) 
and Mycobacterium avium subsp. hominissuis IWGMT49 (International Working Group on 
Mycobacterial Taxonomy) type strains were used. Stocks of each strain were preserved at -80 °C
in Trypticase soy broth with 40% glycerol and were thawed for each assay. Pure powders of 
amikacin, clarithromycin, and clofazimine obtained from Sigma-Aldrich were dissolved in 
water, methanol, and dimethyl sulfoxide (DMSO), respectively.
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Susceptibility testing 
MICs were determined at the beginning and at the end of the experiments, following 
CLSI recommendations,10 by broth microdilution in cation-adjusted Mueller-Hinton broth 
(CAMHB); commercially available panels were used for amikacin and clarithromycin 
(RAPMYCO Sensititre, SLOWMYCO Sensititre; Trek Diagnostics/ Thermo Fisher), while 
for clofazimine, manual broth microdilution was performed in Middlebrook 7H9 broth (BD 
Biosciences). The unexposed M. abscessus type strain was used as a quality control during all 
MIC determinations.
Mutation analysis
Mutation analysis of rrs and rrl was performed to detect mutations associated with amikacin 
and clarithromycin resistance, respectively, in mycobacteria exposed to the two antibiotics in 
the drug-drug interaction experiments. Briefly, mycobacterial suspensions were heat inactivated 
at 95 °C for 30 min, and then DNA was extracted using MagNA Pure LC (Roche Life Science). 
Relevant fragments of rrs and rrl were amplified using previously described primers and PCR 
conditions.11,12 Sequence analyses were performed to detect mutations at codon 1408 in rrs and 
codons 2058 and 2059 in rrl.
Time-kill assays for single drugs
The inoculum consisted of mycobacteria in the early logarithmic phase of growth. Individual 
bottles of 20 ml of Middlebrook 7H9 with oleic acid-bovine albumin-dextrose-catalase growth 
supplement (BD Biosciences) and 0.05% Tween 80, containing increasing concentrations (from 
0.062× to 8× MIC for M. abscessus and 0.062× to 32× MIC for M. avium) of clofazimine, were 
cultured with the inoculum (~105 to 106 cfu/ml) at 30 °C for M. abscessus and 37 °C for M. 
avium, under shaking conditions at 100 rpm (GFL); ventilation through a bacterial filter (FP 
30/0.2 Ca/S; Whatman GmbH) was incorporated. A drug-free and inoculum-free bottle with 
medium served as the growth and sterility controls, respectively. At defined time points (3, 6, 
12, 24, 36, 48, 72, 96, and 120 h for M. abscessus and 12, 24, 36, 48, 72, 96, 120, 144, 168, 
and 240 h for M. avium), 10 µl from undiluted samples and samples serially diluted 10-fold 
in normal saline were plated in triplicate on Middlebrook 7H11 agar plates (BD Biosciences). 
Plates were incubated for 3 to 5 days at 30 °C for M. abscessus, or 7 to 9 days at 37 °C for M. 
avium, and the cfu per milliliter were calculated (lower limit of detection, 33.3 cfu/ml).
Time-kill assays for drug-drug interaction
Following the same protocol as described above, time-kill assays for M. abscessus and M. 
avium were performed with four concentrations (from 0.25× to 2× MIC) of each antibiotic 
alone and in paired combination with clofazimine. MICs for amikacin, clarithromycin, 
and clofazimine were checked by duplicate at the final sampling time, when colonies were 
present.
Clofazimine prevents regrowth and resistance
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Pharmacodynamic drug interaction analysis
In order to assess the nature and the magnitude of the in vitro interactions between clofazimine 
and amikacin or clarithromycin against NTM, the data obtained with time-kill assays 
were analyzed using the response surface analysis of Bliss independence (RSBI) and the 
isobolographic analysis of Loewe additivity (ISLA) as described previously.8,9 The RSBI was 
used to describe the kinetics of pharmacodynamic interactions at different time points, whereas 
the ISLA was used to describe the full concentration-effect relationships of the drugs alone 
and in combination at the end of the experiment. For that purpose, the percentage of bacterial 
load at each drug concentration and combination was calculated by dividing the log10 cfu per 
milliliter with the log10 cfu per milliliter of growth control at each sampling time throughout 
the experiment. Bliss synergy and antagonism was concluded if the observed bacterial load was 
statistically significantly (P< 0.05) lower or higher than the expected bacterial load derived 
from Bliss independence; otherwise, Bliss independence was deemed.8,9
In order to assess the pharmacodynamic interactions at the entire range of drug concentrations 
with the ISLA, concentration-effect curves were constructed using the reduction in log10 cfu per 
milliliter compared to growth control at the end of each experiment and analyzed with sigmoidal 
maximum-effect (Emax) model after nonlinear regression analysis with global fitting, i.e., shared 
Emax and minimum effect (Emin) (Graphpad Prism 5.03; Graphpad Inc.). The interaction index 
(I) was calculated for the stasis effect, i.e., 0-log10 cfu/ml reduction compared to the initial 
inoculum, as the ratio ECmix/ECadd, where ECmix is the effective concentration of the mixture 
and ECadd is the effective concentration of a theoretical additive combination, as described 
previously.8,9 All analyses were made using multiples of the MIC. Synergy or antagonism was 
concluded when the I was statistically significantly (P< 0.05) lower or higher than 1; otherwise, 
additivity was claimed.
Monte Carlo analysis
In order to bridge the findings to concentrations in humans, Monte Carlo analysis was 
performed to predict how many patients treated with standard dosing regimens will attain free 
lung concentrations (Cmax) associated with stasis for strains of both mycobacterial species with 
MICs usually observed for these species, i.e., 4 to 128 mg/l for amikacin, 0.125 to 4 mg/l for 
clarithromycin, and 0.03 to 4 mg/l for clofazimine. The mean ± SD target serum Cmax values 
were 55.3 ± 16.88 mg/l for amikacin, 2.31 ± 1.89 mg/l for clarithromycin, and 0.43 ± 0.19 mg/l 
for clofazimine.13 In order to determine the free lung concentrations, the epithelial lining fluid/
serum concentration ratios of 0.5 for amikacin14 and 8 for clarithromycin15 were used, whereas 
for clofazimine, the total lung/serum concentration ratio of 30 (found in mice) was used after 
taking into account the 85% protein binding.5 Monte Carlo simulation analysis was performed 
using the normal random number generator function of Excel spreadsheet (MS Office 2007) for 
10,000 patients.
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Results 
Susceptibility
MICs for clofazimine, clarithromycin, and amikacin were 0.5, 4, and 32 mg/l for M. abscessus 
CIP 104536 and 0.06, 4, and 8 mg/l for M. avium IWGMT49.
Time-kill assays for single-drug exposure
Growth and killing curves of M. abscessus and M. avium exposed to different concentrations 
of clofazimine are shown in Figure 1. For M. abscessus (Figure 1A), the effect of clofazimine 
mainly consisted of inhibition of growth that was concentration dependent. Regrowth appeared 
after the initial inhibition. Because of solubility issues of clofazimine, concentrations higher 
than 8× MIC could not be evaluated for M. abscessus. 
For M. avium (Figure 1B), the clofazimine effect was in general stronger than that observed 
for M. abscessus. Again, the effect was a concentration-dependent inhibition of growth. The 
highest concentration, 32× MIC, did show some killing effect, particularly from 96 to 240 
h. Single exposures of amikacin and clarithromycin were previously described for both M. 
abscessus16 and M. avium.17
Time-kill assays for combinations
M. abscessus
The time-kill curves of the drug combinations clofazimine-amikacin and clofazimine-
clarithromycin at the different concentrations are shown in Figure 2 and 3. The effect of 
clofazimine was consistent with that in the single-drug assay at all concentrations (Figure 1). 
Amikacin inhibited growth at concentrations 0.25× and 0.5× MIC and showed discrete 
killing at 1× and 2× MIC, although regrowth appeared after 96 h at both concentrations. 
The combination of clofazimine-amikacin showed an inhibitory effect at 0.25× and 0.5× 
MIC and discrete killing at 1× and 2× MIC but did not reveal the regrowth observed with 
amikacin alone (Figure 2A to D). The MICs of the two antibiotics for the colonies exposed 
Figure 1. Time-kill curves of M. abscessus CIP 104536 (A) and M. avium IWGMT49 (B) exposed to 
different concentrations of clofazimine. Antibiotic concentrations are indicated by different symbols. Error 
bars represent SDs from the replicates.
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to clofazimine, amikacin, and the combination, for 120 h, were identical to those measured 
prior experiment. No mutations in rrs were detected in M. abscessus colonies exposed to 
amikacin alone or clofazimine-amikacin at the end of the experiment. Clarithromycin inhibited 
growth, particularly at 2× MIC (Figure 2E), but regrowth readily appeared after 48 h. For 
the combination of clofazimine-clarithromycin, the greatest effect was observed at the paired 
concentrations of 2× MIC, which prevented the regrowth observed with clarithromycin alone. 
Again, the MICs of both antibiotics for the colonies exposed to clofazimine-clarithromycin 
and the combination, for 120 h, were identical to those measured prior to the experiment; no 
mutations in rrl were detected in M. abscessus exposed to clarithromycin or the clofazimine-
clarithromycin combination.
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Figure 2. Time-kill curves of M. abscessus CIP 104536 exposed to clofazimine and amikacin (A to D) 
and clofazimine and clarithromycin (E to H), alone and combined at 2× MIC, 1× MIC, 0.5× MIC, and 
0.25× MIC of each drug. No killing was observed in most combinations, except in the paired combination 
consisting of 2× MIC amikacin and clofazimine. Error bars represent SDs from the replicates.
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M. avium
When M. avium IWGMT49 was exposed to clofazimine and amikacin, alone and in combination, 
in the same experiment (Figure 3A to D) the killing effect was greater than that observed for 
M. abscessus. Clofazimine only inhibited the growth; amikacin effect was stronger and faster, 
especially at 0.5×, 1×, and 2× MIC, but regrowth appeared after 96 to 120 h. The combination 
of clofazimine-amikacin, at all concentrations, prevented regrowth, and its effect was maximal 
at the end of the experiment. The MIC for the mycobacteria exposed to clofazimine after 
240 h remained the same, whereas amikacin-exposed bacteria showed MICs higher than the 
initial MICs (>64 mg/l, versus 8 mg/l). This increase in MIC was not observed for bacteria 
exposed to the combination clofazimine-amikacin, in which the amikacin MIC did not change. 
Colonies exposed to amikacin alone, at any concentration, showed the A1408G mutation in 
the rrs product, but this mutation was not found in colonies exposed to any of the clofazimine-
amikacin combinations.
For the set of experiments with the combination of clofazimine- clarithromycin (Figure 3E 
to H), clarithromycin killing effect was observed for all concentrations; however, after 144 h, 
regrowth was observed, especially at 0.25× and 0.5× MIC. The combination of clofazimine-
clarithromycin showed sustained killing at all concentrations, and no regrowth was observed 
until 240 h. The MIC of clofazimine for the mycobacteria exposed to this antibiotic for 240 h 
remain identical to those measured prior to the experiment, but the clarithromycin MIC was 
higher (>64 mg/l, versus 4 mg/l) in bacteria exposed to clarithromycin alone. Again, this increase 
was not observed in colonies exposed to the combination of clofazimine-clarithromycin. The 
A2058G mutation in the rrl product was found only in colonies exposed to 0.25× and 0.5× 
MIC clarithromycin alone, not in colonies exposed to any of the clofazimine-clarithromycin 
combinations.
Interaction analysis
The RSBI analysis of the combination of clofazimine-amikacin against M. abscessus showed 
independent interactions within the first 12 h which converted to antagonistic interactions at 
24 to 48 h and ultimately to synergistic interaction of 29.0% and 28.4% at the end of the 
experiment for 2× and 1× MIC, respectively (Figure 4A).
Isobolographic analysis of the full concentration-effect relationship of the same combination 
showed synergy at the end of the experiment at concentrations of ≥ 1× MIC with an I of 0.41 
and a 95% CI of 0.29 to 0.55 (Figure 5A); stasis was achieved at 4× and 8× MIC of amikacin 
and clofazimine alone; for the combination, stasis was found at 1× MIC of both drugs. 
The RSBI analysis of the combination clofazimine-clarithromycin against M. abscessus also 
showed independence in the first 12 h which converted to antagonistic interactions at high 
concentrations, but ultimately synergistic interactions of 23.5% were observed only at 2× MIC 
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(Figure 4B). Similarly, ISLA of the same combination showed synergistic interaction reaching 
stasis at 2× MIC when the drugs were combined. For each drug alone, the endpoint was reached 
at 8× MIC (I = 0.53; 95% CI, 0.35 to 0.72) (Figure 5B).
 
For the combination clofazimine-amikacin against M. avium, the RSBI analysis showed 
independence up to 48 h, then antagonism up to 120 h, and synergy at the end of the 
experiment, of 23.2 to 56.7% at all concentrations (Figure 4C). Strong synergy was found 
with the ISLA (I = 0.027; 95% CI, 0.007 to 0.048) since stasis was found at 0.5× MIC 
of the drugs in combination; the same endpoint was reached at 8× MIC and 32× MIC for 
clofazimine and amikacin alone (Figure 5C). The same profile of interactions was found 
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Figure 3. Time-kill curves of M. avium IWGMT49 exposed to clofazimine and amikacin (A to D) and 
clofazimine and clarithromycin (E to H), alone and combined at 2× MIC, 1× MIC, 0.5× MIC, and 0.25× 
MIC of each drug. Modest killing was observed with most combinations, except with the paired combination 
consisting of 2× MIC of amikacin and clofazimine. Error bars represent SDs from the replicates.
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for the combination clofazimine-clarithromycin; with RSBI analysis, independence was 
observed up to 48 h, then antagonism up to 120 h, and ultimately synergy. However, the 
synergistic interactions were found at concentrations of 0.25× and 0.5× MIC (53.3% and 
23.3%, respectively) (Figure 4D). This was also confirmed with the ISLA (I = 0.16; 95% CI, 
0.04 to 0.35), with stasis observed at combinations with < 0.25× MIC of each drug, whereas 
the same endpoint was reached at 0.5× MIC of clarithromycin and 8× MIC of clofazimine 
alone (Figure 5D). Interestingly, at combinations with > 1× MIC of each drug, the effect was 
similar to the effect of clarithromycin alone, indicating no interaction as the RSBI analysis 
showed at the end of the experiment.
Monte Carlo simulations
The percentages of patients that will attain lung concentrations associated with stasis of 
both M. abscessus and M. avium are shown in Figure 6. For M. abscessus, target attainment 
rates with clofazimine-amikacin and clofazimine-clarithromycin combinations were higher 
than with monotherapy regimens, particularly for isolates with amikacin/clofazimine MICs 
of 16/0.25 mg/l and clarithromycin/clofazimine MICs of 2/0.25 mg/l, respectively (>60% 
difference between combination and monotherapy regimens). For M. avium, a >60% difference 
was found for the clofazimine-amikacin combination for isolates with amikacin/clofazimine 
MICs 32 to 128/0.25 to 1 mg/l and for the clofazimine-clarithromycin combination for isolates 
M. abscessus CLO+AMK
0 12 24 36 48 60 72 84 96 108 120
-30
-20
-10
0
10
20
30
40
50
60
2 x MIC
1 x MIC
0.5 x MIC
0.25 x MIC
Synergy
Antagonism
Time (hours)
B
li
ss
 in
te
ra
ct
io
ns
M. abscessus CLO+CLA
0 12 24 36 48 60 72 84 96 108 120
-30
-20
-10
0
10
20
30
40
50
60
2 x MIC
1 x MIC
0.5 x MIC
0.25 x MIC
Synergy
Antagonism
Time (hours)
B
li
ss
 in
te
ra
ct
io
ns
M. avium  CLO+AMK
0 24 48 72 96 120 144 168 192 216 240
-30
-20
-10
0
10
20
30
40
50
60
2 x MIC
1 x MIC
0.5 x MIC
0.25 x MIC
Synergy
Antagonism
Time (hours)
B
li
ss
 in
te
ra
ct
io
ns
M. avium  CLO+CLA
0 24 48 72 96 120 144 168 192 216 240
-30
-20
-10
0
10
20
30
40
50
60
2 x MIC
1 x MIC
0.5 x MIC
0.25 x MIC
Synergy
Antagonism
Time (hours)
B
li
ss
 in
te
ra
ct
io
ns
a.
b.
c.
d.
Figure 4. Time course of Bliss interactions of clofazimine and amikacin (CLO+AMK) and clofazimine 
and clarithromycin (CLO+CLA) combinations at 2×, 1×, 0.5×, and 0.25× the respective MICs against M. 
abscessus (A and B) and M. avium (C and D). Dotted lines represent the significance level for synergistic 
(+10%) and antagonistic (-10%) interactions. Note the antagonistic interaction at earlier time points 
followed by the synergistic interaction at later time points.
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with clarithromycin/clofazimine MICs of 32 to 124/0.5 to 2 mg/l. High (>95%) and low (<5%) 
target attainment rates were found for all monotherapy and combination regimens for M. 
abscessus isolates with amikacin/clofazimine/clarithromycin MICs of ≤4/0.06/0.5 mg/l and 
≥64/1/8 mg/l and for M. avium isolates with amikacin/clofazimine/clarithromycin MICs of 
≤8/0.06/8 mg/l and ≥128/1/256 mg/l, respectively (except amikacin monotherapy against M. 
avium, for which target was not attained even for isolates with very low MICs).
Discussion
This study evaluated the activity of clofazimine and the drug-drug interaction in the 
combinations clofazimine-amikacin and clofazimine-clarithromycin against M. abscessus and 
M. avium. Although the effect of clofazimine alone was poor, we found synergy, at specific 
concentrations, for both combinations against both species. The combined therapy prevented 
the regrowth observed when amikacin or clarithromycin was used alone. 
Clofazimine is the prototype riminophenazine antibiotic with in vitro activity against most 
mycobacteria.1,4 Its main clinical use so far is in the multidrug treatment of leprosy and 
multidrug-resistant tuberculosis.18 For the treatment of MAC pulmonary disease, a clofazimine-
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Figure 5. Concentration-effect curves of clofazimine and amikacin (left graphs) and clofazimine and 
clarithromycin (right graphs) combinations against M. abscessus CIP 104536 after 120 h (A and B) and M. 
avium IWGMT49 after 240 h (C and D). I, interaction index.
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ethambutol-macrolide regimen was suggested to be as effective as a rifampin-ethambutol-
macrolide regimen.2,19 Our in vitro results support the role of clofazimine for the treatment 
of M. avium disease, as we found synergistic effects between clofazimine and amikacin or 
clarithromycin. Its role still needs to be determined but may be to replace rifamycins in patients 
who do not tolerate those drugs, or as an add-on in the early phase of treatment of severe fibro-
cavitary MAC pulmonary disease, when amikacin is also added to the rifampin-ethambutol-
macrolide regimen.2,3 The regrowth observed in experiments with M. avium exposed to amikacin 
and clarithromycin was associated with an increase in MIC and the appearance of mutations 
in rrs (A1408G) and rrl (A2058G).11,12 Clofazimine prevented this mutational resistance from 
emerging.
For the treatment of M. abscessus, clofazimine is used, but there is less supportive clinical 
evidence of its efficacy.20 Amikacin and clarithromycin are cornerstones of treatment, but 
outcomes remain poor.2,3 The evaluation of new multidrug regimens is urgently needed, and the 
inclusion of clofazimine should be considered. In contrast to M. avium, M. abscessus showed 
regrowth when exposed to amikacin and clarithromycin alone, but without increases in MICs 
for these compounds; no mutation was found in the target genes and codons evaluated. This 
suggests the presence of other mechanisms to decrease susceptibility; adaptive resistance 
through the expression of efflux pumps has been hypothesized to be linked to reversible low 
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Figure 6. Percentages of patients achieving serum concentrations associated with stasis for M. abscessus 
and M. avium isolates with increasing MICs for mean daily doses of 15.05 ± 3.62 mg/kg of amikacin 
(AMK), 14.33 ± 5.09 mg/kg of clarithromycin (CLA), and 1.62 ± 0.28 mg of clofazimine (CLO) alone 
and in combination corresponding to Cmax of 55.30 ± 16.88 mg/l, 2.31± 1.89 mg/l, and 0.43 ± 0.19 mg/l, 
respectively).13
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levels of resistance in other mycobacteria.21,22 Clofazimine may prevent the activation of these 
mechanisms. 
The current 100-mg-once-daily dose of clofazimine19,20 has a very limited evidence base. In 
MAC-infected patients, it yields a peak plasma drug concentration of 0.43 mg/l,13 close to the 
MIC we found in this study for M. abscessus CIP 104536 and 8× MIC of M. avium IWGMT49. 
Clofazimine levels are much higher in tissues than in blood, and the drug accumulates 
particularly in macrophages, similar to the macrolides.18 Whether the current 100-mg-once-
daily dose leads to active concentrations at the site of infection in patients with M. abscessus 
or M. avium pulmonary disease is not known. A pharmacokinetic-pharmacodynamic (PK-PD) 
study of clofazimine in the mouse model suggested that lower doses could be effectively used 
for treatment of tuberculosis,5 but this should be investigated for NTM. 
Monte Carlo analysis showed that the number of patients attaining concentrations associated 
with stasis in vitro was higher in combination than in monotherapy regimens for a wide range of 
MICs for both mycobacterial species, particularly for M. avium because of the stronger synergy 
found for this species. The lowest target attainment rates were found for amikacin, which 
may be explained by the lower amikacin concentrations in tissue than in serum. The currently 
evaluated inhaled liposomal amikacin could overcome this by delivering larger amounts of the 
antibiotic directly to the lung.23 
The use of Bliss independence and Loewe additivity analyses8,9 allowed us to describe the 
kinetics of pharmacodynamic interactions and the full concentration-effect relationship. The 
use of a global response surface model to describe the entire time concentration-response 
surface is challenging,24 because of the complexity of pharmacodynamic interactions ranging 
from antagonistic to synergistic interactions at different time points. We found that after a short 
period of independent interactions, first antagonism was observed and later synergy. The initial 
antagonistic interaction, where the effect of combination is similar to the effect of the most 
active drug without the effect of the least active drug, might be explained by slow intracellular 
accumulation of the least active drug or a differential effect on mycobacterial subpopulations. 
Antagonism has been found previously for amikacin combinations against mycobacterial 
species as well as other antimycobacterial drugs targeting both RNA and DNA synthesis against 
M. avium.25,26 The exact mechanisms of these interactions need further investigation. 
Our study had some limitations. First, only combinations at fixed-ratio concentrations of 
1×:1× MIC were analyzed, prohibiting the investigation of complex concentration-dependent 
pharmacodynamic interactions. Second, for comparative purposes, all analyses were 
intentionally performed using multiples of the MICs determined with broth microdilution 
formats that most labs are using as reference standards. Because MICs may be different in 
different test systems and media, extrapolation of the present findings should be done using 
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MICs determined as in the present study, i.e., RAPMYCO Sensititre panels in CAMHB for 
amikacin and clarithromycin and broth microdilution method in Middlebrook 7H9 broth for 
clofazimine. Third, although time kill assays allow a more dynamic evaluation than MIC, they 
do not provide actual dynamic concentrations of the antibiotics, as it occurs during the course of 
therapy in humans. Nevertheless, we found synergistic combinations that can be further tested 
in dynamic PK-PD models. Fourth, the emergence of resistance was investigated partially 
by detecting MIC increases after exposure and resistance-associated mutations in selected 
colonies. An alternative approach could have been plating of samples on plates containing 
several magnitudes of the MIC of the drugs under study. 
In conclusion, clofazimine is not very active itself but prevents regrowth of M. avium and M. 
abscessus exposed to amikacin and clarithromycin. This synergistic activity supports a role for 
clofazimine as part of a combined therapy with amikacin or clarithromycin for M. avium and, to 
some extent, for M. abscessus. Its role should be further evaluated with dynamic PK-PD models 
and hopefully later in clinical trials.
Clofazimine prevents regrowth and resistance
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Summary
The treatment of pulmonary Mycobacterium abscessus disease is associated with very high 
failure rates and easily acquired drug resistance. Amikacin is the key drug in treatment 
regimens, but the optimal doses are unknown. No good preclinical model exists to perform 
formal pharmacokinetics/pharmacodynamics experiments to determine these optimal doses. We 
developed a hollow-fiber system model of M. abscessus disease and studied amikacin exposure 
effects and dose scheduling. We mimicked amikacin human pulmonary pharmacokinetics. Both 
amikacin microbial kill and acquired drug resistance were linked to the peak concentration-to-
MIC ratios; the peak/MIC ratio associated with 80% of maximal kill (EC80) was 3.20. However, 
on the day of the most extensive microbial kill, the bacillary burden did not fall below the 
starting inoculum. We performed Monte Carlo simulations of 10,000 patients with pulmonary 
M. abscessus infection and examined the probability that patients treated with one of 6 doses 
from 750 mg to 4,000 mg would achieve or exceed the EC80. We also examined these doses for 
the ability to achieve a cumulative area under the concentration-time curve of 82,232 mg·h/l × 
days, which is associated with ototoxicity. The standard amikacin doses of 750 to 1,500 mg a 
day achieved the EC80 in <21% of the patients, while a dose of 4 g/day achieved this in 70% of 
the patients but at the cost of high rates of ototoxicity within a month or two. The susceptibility 
breakpoint was an MIC of 8 to 16 mg/l. Thus, amikacin, as currently dosed, has limited efficacy 
against M. abscessus. It is urgent that different antibiotics be tested using our preclinical model 
and new regimens developed.
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Introduction
Mycobacterium abscessus is a rapidly growing mycobacterium (RGM) responsible for 
about 80% of all pulmonary infections caused by RGM.1 It is one of the most drug-resistant 
microorganisms encountered in the clinic, far worse than extensively and totally drug-
resistant Mycobacterium tuberculosis; this is a reason why it is considered the “new antibiotic 
nightmare”.2 The current treatment for M. abscessus diseases varies according to the infecting 
subspecies;3 in general, it involves a backbone of amikacin in combination with clarithromycin 
and either cefoxitin or imipenem early during therapy, followed by subsequent use of oral 
antibiotics, which is analogous to the initial and continuation phases of tuberculosis treatment.1 
Unfortunately, at least half of the patients either fail this therapy, relapse, or die; there is no 
reliable antibiotic regimen that cures M. abscessus lung disease.1,4 Several other regimens 
have been tried and found wanting. In such regimens and the standard regimen, the doses 
were chosen based on what has worked well in mundane Gram negative bacilli. No formal 
antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) analyses have been performed with 
M. abscessus. 
Our time-kill assays in the past demonstrated that amikacin was the most active antibiotic 
compared to cefoxitin and clarithromycin.5 Here, we performed formal PK/PD studies of 
amikacin, which is considered the most active parenteral antibiotic against M. abscessus, 
according to treatment guidelines.1 Recent attempts to evaluate antibiotics and regimens in 
preclinical M. abscessus disease models have included the use of Drosophila melanogaster and 
zebra fish.6,7 However, a tractable model in which PK/PD experiments can be performed still 
needs to be developed. 
Here, we adapted the hollow-fiber system models (HFS) of slower-growing mycobacteria8-11 and 
developed a novel PK/PD system for M. abscessus pulmonary disease in order to identify the 
amikacin exposures and dose schedules associated with optimal microbial kill and suppression 
of acquired drug resistance (ADR).
Materials and Methods
Bacterial and drugs
M. abscessus ATCC 19977 (American Type Culture Collection) was used as the test strain. 
Stock cultures of the mycobacteria were preserved at -80 °C in Middlebrook 7H9 broth 
supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) and 15% glycerol. For 
each assay, one vial was thawed and incubated for 24 to 48 h at 30 °C to achieve logarithmic-
growth phase. Amikacin sulfate powder for intravenous administration was purchased from the 
Baylor University Medical Center pharmacy (Dallas, TX) and then diluted in sterile water to 
desired concentrations for the assays. Apramycin was purchased from Sigma.
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MIC and mutation frequency
Broth macrodilution in Middlebrook 7H9 broth (here termed “broth”) was used to identify 
the MIC).12 In addition to the turbidity test, the cfu per milliliter were enumerated for each 
concentration evaluated in the broth macrodilution test, and the MIC was defined as the 
lowest concentration associated with ≥99% inhibition of growth. The Etest (bioMérieux) on 
Middlebrook 7H10 agar (here termed “agar”) was also used as a screening test when an MIC 
evaluation was needed for HFS liquid cultures. Mutation frequency was determined for the 
inoculum by culturing 0.2 ml each on 20 agar plates supplemented with 3 times the amikacin 
MIC. This concentration was chosen since 3 times the MIC is the lowest fold change associated 
with efflux pump-related resistance in other mycobacteria.13
Concentration-effect studies in test tubes
M. abscessus was grown in broth in log phase to the equivalent of a 0.5 McFarland standard 
turbidity based on optical density measurements at 600 nm, and it was then back diluted to 
reach a bacterial density of approximately 106 log10 cfu/ml. M. abscessus was exposed to 
amikacin concentrations of 0, 1/8, 1/4, 1/2,1, 2, 4, and 8 times the MIC at 30 °C in test tubes. 
After 72 h of incubation, the contents of each tube were washed with saline and then serially 
diluted and cultured on agar at 30 °C in order to enumerate the cfu per milliliter. The inhibitory 
sigmoid maximum effect (Emax) model was used to identify the relationship between amikacin 
concentration and M. abscessus cfu per milliliter.
Hollow-fiber model for M. abscessus
The HFS model has two physical compartments: the central compartment, in which drug 
circulates, and the peripheral compartment, which houses the mycobacteria.8 The peripheral 
compartment is separated from the central compartment by the semi permeable hollow fibers 
with a pore size of 42 Da, through which fresh medium (broth with 10% dextrose) circulates. 
Thus, the concentrations of chemicals in the peripheral compartment are in equilibrium with the 
central compartment. Twenty milliliters of 106 log10 cfu/ml log phase M. abscessus cells were 
inoculated into the peripheral compartment of each cellulosic hollow-fiber cartridge (FiberCell 
Systems). M. abscessus cells are much larger than the pores and thus stay confined to the 
peripheral compartment, where they are continuously bathed by dynamic concentrations of 
chemicals and drugs. All systems were permanently kept in a 30 °C incubator.
Pharmacokinetic/pharmacodynamic study
Twelve HFS were inoculated with M. abscessus, as described above. For the dose-effect 
experiments, amikacin doses that mimic the serum area under the concentration-time curve 
from 0 to 24 h (AUC
0–24
) and peak concentrations (Cmax) achieved in humans exposed to human-
equivalent doses of 66.7, 125, 250, 500, 1,000, 2,000, 4,000, and 6,400 mg were administered 
once daily to the central compartment via computerized syringe pumps. Dose-scheduling 
studies were simultaneously performed; we tested human-like doses of 500, 2,000, and 4,000 
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mg, chosen based on the pilot concentration-effect study in test tubes, to be administered thrice 
daily in order to match some of the Cmax/MIC and percent time the concentration remains 
above the MIC (%T MIC) in the once-a-day regimens. The dilution rates were set to achieve an 
amikacin half-life of 3 h, as encountered in serum and bronchial secretions.14,15 The amikacin 
concentrations achieved in all the HFS were validated by sampling each central compartment 
during the last 2 days at 0, 0.5, 2.7, 5.4, 18.7, 23.5, 24.5, 26.7, 29.4, 42.7, and 47.5 h after the 
drug administration; the sampling times were chosen based on optimal sampling theory for 
the pharmacokinetics of amikacin.16-18 In order to quantify the M. abscessus cfu per milliliter, 
1 ml of the peripheral compartment contents was removed from each system on days 0, 1, 2, 
3, 5, 7, 10, and 14. The samples were washed with saline to avoid antibiotic carryover, after 
which samples were serially diluted and cultured on agar. To quantify the amikacin-resistant M. 
abscessus cfu per milliliter, the same samples were also inoculated on agar supplemented with 
3 times the amikacin MIC.
Drug assays
Apramycin was used as the internal standard. Calibrator, controls, and apramycin were included 
in each analytical run for quantitation. Stock solutions of amikacin and apramycin were prepared 
in 80:20 methanol-water at a concentration of 1 mg/ml and stored at -20 °C. An eight-point 
calibration curve was prepared by diluting the amikacin stock solution in drug-free broth (1, 2, 
10, 20, 50, 100, 200, and 400 µg/ml). Quality control samples were prepared by spiking media 
with stock standards for two levels of controls. Samples were prepared in 96-well microtiter 
plates, 10 µl of calibrator, quality controls, or sample was added to 190 µl of 0.1% formic acid 
in water containing 10 µg/ml apramycin, and the samples were vortexed. Chromatographic 
separation was achieved on an Acquity ultrahigh-performance liquid chromatography (UPLC) 
high strength silica (HSS) T3, 1.8 µm, 50 by 2.1-mm analytical column (Waters) maintained 
at 30 °C at a flow rate of 0.2 ml/min, with a binary gradient and a total run time of 6 min. The 
observed ion (m/z) values of the fragment ions were amikacin (m/z 586 →425) and apramycin 
(m/z 540→378). Sample injection and separation were performed using an Acquity UPLC 
interfaced with a XevoTQ mass spectrometer (Waters). All data were collected using MassLynx 
version 4.1 SCN810. The limit of quantitation for this assay was 0.5 µg/ml.
Pharmacokinetic and PK/PD modeling
The drug concentrations from each HFS were comodeled as a one-compartment 
pharmacokinetic model, a two-compartment model, and a three-compartment model using the 
ADAPT 5 program.19 The best model was chosen using the Akaike information criterion (AIC) 
and parsimony.20,21 The pharmacokinetic parameter estimates were then used to calculate the 
observed AUC
0–24
, the AUC
0–24
/MIC ratio, and %TMIC. The observed Cmax in each HFS was 
used to calculate the Cmax/MIC. Dose response was modeled using the inhibitory sigmoid Emax 
model with the total bacterial burden used as the response parameter, while drug exposure 
was expressed as either the AUC
0–24
/MIC ratio, %TMIC, or Cmax/MIC ratio. However, the 
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development of drug resistance is not in accordance with the inhibitory sigmoid Emax model but 
rather an integrated quadratic model, which was used to identify the relationship between drug 
exposure and the amikacin-resistant subpopulation.22-25
Translation from the hollow-fiber model to clinical doses
In order to translate from the HFS to the bedside, we performed computer aided clinical trial 
simulations based on Monte Carlo experiments, according to the steps outlined in the recent 
recommendations for academia and industry.24 
The population pharmacokinetic parameter estimates we used and the covariance were from 
a study by Delattre et al.18 of 88 Belgian patients. This study was chosen because of the 
rigorous use of optimal sampling theory, which minimizes bias and inaccuracies in identifying 
pharmacokinetic parameter estimates. The pharmacokinetic parameters used as the domain of 
input in subroutine PRIOR of ADAPT are shown in Table S1 in the supplemental material. 
First, Monte Carlo simulations were performed to identify the Cmax, AUC0–24, and concentration-
time profiles achieved by doses of 750, 1,000, 1,500, 2,000, 3,000, and 4,000 mg in 10,000 
patients. Since at steady state with once-a-day dosing in patients with pneumonia, peak 
concentrations in bronchial secretion are only 40.5% of those in serum, and the AUC
0–24
 is only 
81% of those in serum, these penetration ratios into the lung were taken into account.15 Next, 
we introduced the effect of MIC variability, based on the MICs identified in 44 patients seen by 
one of us (J.v.I.) with M. abscessus pulmonary disease at Radboud University Medical Center, 
Nijmegen, the Netherlands. The probability of achieving the EC80 exposure Cmax/MIC ratio, or 
target attainment probability, at each MIC was then calculated. The results were then used to 
calculate the cumulative fraction of response. Exposure associated with toxicity in patients was 
also calculated for different doses, based on exposures we have identified as causing ototoxicity 
in amikacin-treated patients who had multidrug-resistant tuberculosis, in which a cumulative 
AUC
0–24 
of 82,232 mg·h/l × days predicts amikacin ototoxicity.17
Figure 1. Amikacin concentration-effect 
response in test tubes. The graph shows 
impressive microbial kill after 3 days of 
incubation in test tubes. Surprisingly, the 
pattern of microbial kill, characterized by 
maxing out at 2 to 4 times the MIC, would 
be more consistent with time-dependent 
killing instead of concentration-dependent 
killing.
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Results
The amikacin MIC for the M. abscessus laboratory strain was 32 mg/l by all methods, on 
repeat analysis. The minimum bactericidal concentration (MBC), which is the concentration 
associated with ≥99.9% kill, was 64 mg/l, so that the MBC/MIC ratio was 2, making amikacin 
a bactericidal agent by standard definitions.26 The mutation frequency to 3 times the amikacin 
MIC was 2.73 ± 0.31 × 10-6 in repeat experiments. 
The relationship between amikacin concentration as a multiple of the MIC and microbial burden 
after 3 days of incubation in test tubes is shown in Figure 1. This experimental design, which 
uses static concentrations of amikacin, was associated with a maximum effect (Emax) of 2.65 
log10 cfu/ml (95% confidence interval [95% CI], 2.26 to 3.04 log10 cfu/ml), a Hill´s slope (H) of 
3.88 (95% CI, 1.13 to 6.63), and a 50% effective concentration (EC50) of 0.57 times the MIC 
(95% CI, 0.46 to 0.69 times the MIC) (r2 =0.93). Figure 1 shows that the bacterial burden at 
the Emax was 5.12 log10 cfu/ml, which is >1.0 log10 cfu/ml less than the bacterial burden of 6.13 
log10 cfu/ml at the beginning of incubation, with just 3 days of incubation with static amikacin 
concentrations. This magnitude of microbial kill is consistent with the notion that amikacin is 
very active against M. abscessus. 
Next, we performed HFS studies that used dynamic concentrations of amikacin, and we co-
modeled the 121 amikacin concentrations that were measured in all the HFS. The concentrations 
were best described by a two-compartment pharmacokinetic model, which was characterized 
by a total clearance of 1.5 l/h, volume of central compartment of 7.98 l, intercompartmental 
clearance of 22.3 l/h, and a peripheral volume of 0.04 l, which are virtually similar to those 
parameters in patients treated with amikacin.17
The day 0 bacterial burden in the HFS (i.e., just prior to start of therapy) was 6.69 log10 cfu/
ml. The changes in total bacterial burden and the amikacin-resistant subpopulation for each 
drug exposure are shown in Figure 2. The figure shows that the amikacin efficacy (i.e., Emax) 
was minimal. By day 3, the bacterial burden at the Emax was only 0.50-log10 cfu/ml lower than 
starting bacterial burden, which is considerably lower than that with static concentrations. 
Figure 2 also shows that amikacin microbial kill was effectively terminated by day 5, and 
starting on day 7, the overall bacterial burden had begun to reflect the replacement of the total 
population by the amikacin-resistant subpopulation. 
We performed an Etest at the beginning and end of the experiments, and as shown in Figure 
2C and D, there was a change in the MIC in the two highest concentration treatments, from 
32 to >256 mg/l on both the once-a-day and three-times-a-day treatment schedules. Inhibitory 
sigmoid Emax models for microbial kill up to 7 days, using either observed Cmax/MIC, AUC/
MIC, or %TMIC, revealed the Akaike information criterion (AIC) scores shown in Table 1. 
The lowest AIC score was for Cmax/MIC for all days up to day 5. If one simply used the r2 for 
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model fit, the r2 values were highest for Cmax/MIC up to day 5. It should be noted that while the 
day 7 results seemed to indicate the lowest AIC score for %TMIC, the result was judged to be 
spurious, since the EC50 exceeded the possible extrema of the %TMIC function; in this case, 
the maximum possible %TMIC of 100% was exceeded by the EC50. Taken together, amikacin 
efficacy was primarily driven by Cmax/MIC ratios, which had the lowest AIC scores for up to 5 
days, beyond which the total population was replaced by drug-resistant subpopulation in some 
systems. 
The relationship between the Cmax/ MIC ratio and bacterial burden on day 5 is shown in Figure 
3. The relationship was characterized by Emax of 2.40 ± 0.22 log10 cfu/ml, a Hill´s slope of 3.79 
± 2.44, and an EC50 that was a Cmax/MIC of 2.22 ± 0.44 (r2=0.97). Thus, the EC50 is considerably 
higher than that in the static amikacin concentration experiments (Figure 1), while the H is 
virtually identical. The EC80, which is considered the optimal exposure, was a Cmax/MIC ratio 
of 3.20. Table 2 shows the AIC for Cmax/MIC, %TMIC, and AUC/MIC versus the amikacin-
resistant subpopulation modeled on the quadratic function for drug resistance. While the 
quadratic function for resistance emergence 22-25 is integrated over time, we utilized piecewise 
functions for each day of sampling, since we have found that PK/PD indices “wobble” with the 
Figure 2. Changes in bacterial burden and amikacin-resistant subpopulation with time. (A to D) The total 
M. abscessus population (solid lines) and amikacin resistant subpopulation (dashed lines) over the course 
of 14 days of exposure to different Cmax/MIC exposures are shown. There was a higher amikacin-resistant 
subpopulation of M. abscessus as the Cmax/MIC increased, so that at higher Cmax/MIC ratios (C and D), the 
total population had been completely replaced by the amikacin-resistant subpopulation by day 14.
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duration of therapy.27 Table 2 shows the same wobble phenomenon, and that the PK/PD index 
associated with the size of the amikacin-resistant subpopulation during the first 3 days was 
%TMIC; by day 14, this had changed to Cmax/MIC. Figure 4 shows a system of inverted “U” 
curves during the first 2 days, with a switch to a straight line on day 3, followed by “U” curves 
from day 3 onwards. The day 14 relationship between Cmax/MIC and the amikacin-resistant 
subpopulation was described by log10 cfu/ml = 4.333 + 0.364 × (Cmax/MIC) + 0.006 × (Cmax/
MIC)2; r2=0.906. This means that by day 14, there was no amikacin concentration that could 
reduce the size of the drug-resistant subpopulation to the 3.8 log10 cfu/ml encountered in non 
treated controls. 
To translate our HFS findings to the clinic, we performed Monte Carlo simulations to identify 
the probability that different amikacin doses could achieve or exceed the EC80 exposure Cmax/
MIC ratio of 3.2. The MIC distribution in 44 clinical isolates used in the simulations is shown 
in Figure 5; the median MIC was 16 mg/l (range, 4 to 128 mg/l). Figure 5A and B show 
the proportions of patients treated with doses of 750, 1,000, and 1,500 mg who achieved this 
target exposure, which give cumulative response percentages of 3.94%, 8.41%, and 20.77% 
of patients, respectively. Figure 5B and C also show target attainment by the higher doses of 
2,000, 3,000, and 4,000 mg, for which the cumulative response fractions were 39.21%, 61.43%, 
and 70.05%, respectively. This means that none of the doses tested would achieve or exceed 
the EC80 in >90% of the patients, which is considered an adequate proportion of patients in 
other mycobacterial infections. Figure 5A and B also illustrate the MIC below which there is 
Table 1. Akaike information criteria scores for pharmacokinetic/pharmacodynamic (PK/PD) indices linked 
to microbial kill.
PK/PD parameter Day 2 Day 3 Day 5 Day 7
% time above MIC 3.272 No convergence -0.7837 -4.925
AUC/MIC -5.173 -1.303 3.955 -0.9094
Cmax/MIC -5.173 -2.244 -14.56 -3.525
Figure 3. Amikacin exposure effect in 
the hollow-fiber system. The results are 
shown up to day 7, at which point the 
drug-resistant subpopulation had begun 
to replace the total population in some 
systems. This is reflected by the increase 
in Emax each day until day 5, after which 
it began to decline. At the maximal 
microbial kill, the bacterial burden barely 
fell below the stasis line, suggesting that 
in fact amikacin is not bactericidal in the 
hollow-fiber system.
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reduced microbial kill in at least 10% of patients with the standard dose, which is 8 mg/l, while 
Figure 5B and C show that with higher doses of ≥2,000 mg, this is 16 mg/l. Thus, the resistance 
breakpoint drug concentration in Middlebrook broth would be set at 16 mg/l at the most, and 
it should be considered that beyond this MIC, patients will not have good responses unless 
the dose is increased. However, such dose increases would increase the chances of toxicity. 
As an example, the duration of therapy and a cumulative AUC
0–24
 of 82,232 mg·h/l × days 
predict amikacin ototoxicity, and Figure 5D shows the probability of achieving that threshold 
concentration associated with an increased risk of ototoxicity for the six different daily doses. 
There is a rapid increase in odds of deafness at doses of 3,000 to 4,000 mg a day.
Discussion
Amikacin has long been considered the most active parenteral antibiotic against M. abscessus.1 
We found that while models of static concentrations suggested that it is a bactericidal drug 
with time-driven efficacy, they overestimated amikacin efficacy compared to that in the HFS 
model. The HFS model’s poor amikacin efficacy correlates better with clinical observations of 
Table 2. Akaike information criteria scores for pharmacokinetic/pharmacodynamic (PK/PD) indices linked 
to acquired resistance.
PK/PD parameter Day 1 Day 2 Day 3 Day 5 Day 7 Day 10 Day 14
% time above MIC -8.984 -19.28 -0.7686 11.37 10.44 19.89 11.27
 AUC/MIC -6.262 -16.93 0.5867 5.903 1.006 1.087 7.316
Cmax/MIC -7.126 -18.72 0.1416 9.673 6.695 7.812 0.2809
Figure 4. Amikacin-resistant 
subpopulation evolution with 
duration of treatment. The curves 
for each day are piecewise for the 
U-shaped relationship between 
exposure versus size of the drug-
resistant subpopulation. With 
increasing time, the baseline 
amikacin-resistant subpopulation 
in the absence of drug exposure 
grows so that curves start at a 
different y intercept on each day. 
For days 1 and 2, the curve shape 
is an inverted U curve; at day 
3, it is a straight line, and then 
it switches to an upright “U.” 
However, by day 14, the right side 
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of the curve has straightened out, which means that there was no amikacin Cmax/MIC ratio high enough to 
reduce the size of the drug-resistant subpopulation, and the curve is no longer a “U.”
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amikacin containing regimens in the antibiotic treatment of pulmonary M. abscessus, which 
entail high failure rates, “the talking M. abscessus blues”.28,29 We found that both optimal 
amikacin microbial kill and ADR were associated with the Cmax/MIC ratio; for ADR, however, 
the PK/PD response parameter was %TMIC in the first 3 days but changed to Cmax/MIC beyond 
day 3. The optimal Cmax/MIC ratio for microbial kill was 3.2, which is considerably lower than 
the Cmax/MIC of 8 to 12 identified for mundane bacteria.30,31 However, we show that even for 
that relatively lower Cmax/MIC ratio, the standard amikacin doses failed to achieve the target 
in more than three-quarters of patients, and much higher intravenous doses would need to be 
administered to even achieve the target in >70% of patients. In any case, this EC80 target would 
merely hold bacterial burden constant at best, which is just “cuddling” the bacteria, while with 
the higher doses, the patients would pay with a high risk of deafness. Alternative delivery 
methods, such as the use of inhaled liposomal amikacin, could overcome this: the efficacy, 
safety, and tolerability of daily dosing of 590 mg of liposomal amikacin for inhalation versus 
placebo in patients with recalcitrant nontuberculous mycobacterial lung disease are currently 
Figure 5. Probability target attainment of different amikacin doses in 10,000 patients. (A) At doses of 750 
mg and 1,000 mg, which are standard doses, there was very poor target attainment at the most commonly 
encountered MICs. The target attainment fell below 90% at the 8 mg/l MIC. (B) At doses of 1,500 mg to 
2,000 mg, 90% of the patients achieved the target Cmax/MIC after the MIC of 8 mg/l. At a dose of 15 mg/
kg of body weight, patients weighing up 100 kg would have 1,500 mg as normal dose, while the 2,000-mg 
dose is higher than currently administered. (C) Doses of 3,000 mg and 4,000 mg would better attain target 
concentrations, but even at these high doses, target attainment falls below 90% at an MIC of 32 mg/l. 
(D) Probability of ototoxicity in 10,000 patients exposed to different amikacin concentrations for different 
durations of therapy, indicating a rapid increase in the odds of attaining toxic cumulative AUCs (cAUC) 
with just 2 months of therapy for doses of ≥2,000 mg.
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being assessed (ClinicalTrials.gov identifier NCT01315236). However, by definition, even 
such delivery methods would not have a higher Emax, so that effect would still be compromised. 
Regardless, our findings mean that the role of intravenous amikacin in the current regimens 
used for pulmonary M. abscessus should be revisited and perhaps be replaced by more active 
antibiotics. 
Current M. abscessus regimens are partly guided by in vitro results, but the clinical correlation is 
lacking. The existing susceptibility breakpoint for amikacin, tested in cation-adjusted Mueller-
Hinton medium, is ≥64 mg/l.12 However, this breakpoint has failed to discriminate patients who 
would respond to therapy. Based on HFS findings and Monte Carlo simulations, we propose 
a breakpoint of 16 mg/l in Middlebrook broth. The poor correlation observed between in vitro 
tests and patient outcomes might be explained by this discrepancy, since most isolates would 
be considered resistant based on this proposed breakpoint. While these are merely simulations 
of a single agent used in combination therapy in real life, experience with antituberculosis 
drugs has demonstrated that such HFS- and Monte Carlo simulation- derived breakpoints for 
monotherapy are highly accurate in predicting the breakpoints above which therapy fails that 
are actually observed in the clinic in combination therapy studies.32-36 Thus, our results will 
likely be borne out in the clinic setting in the future.
Finally, our new HFS model of M. abscessus disease is a tractable model that can be used 
to study the roles of other antibiotics, both as monotherapy and as combination therapy. The 
model allows repetitive sequential sampling in the same system of bacterial cultures and drug 
concentrations, which let us follow the evolution of the bacteria when exposed to different 
treatment regimens. This approach, which is not possible with animal models, for which 
harvesting of lungs is a terminal procedure, or with fruit flies, permits more powerful statistical 
computations, such as time-to-event analyses, repeated-measures analyses, and construction of 
systems equations for phenomena, such as resistance emergence.
Our study has some limitations. First, we examined only the effect of amikacin alone. Amikacin 
is used in combination with other antibiotics in patients. However, for optimal combination 
regimen design, it was necessary to start with the optimization of each component of the 
regimen as monotherapy for those combinations in which the drugs are additive. In the case of a 
synergistic combination, it may be possible to achieve more microbial kill without optimization 
of the combination. Second, we show the results of an HFS model for extracellular infection. 
However, M. abscessus, like all mycobacteria, is both an extracellular and intracellular 
pathogen. Nevertheless, amikacin does not kill intracellular bacteria due to only 5% penetration 
into macrophages,37 so amikacin efficacy might be worse than what we observed. We have 
intracellular HFS models of M. abscessus, which we will use to study those agents that are 
active intracellularly. Third, we report results with one M. abscessus strain. A larger number 
of isolates would give a more robust EC80 target;38 this, however, is limited by costs associated 
with performing each HFS study.
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In summary, we developed a preclinical model for M. abscessus disease in which we identified 
the low efficacy of intravenous amikacin. The model will be useful for understanding the 
efficacy and ADR during the treatment of M. abscessus infection, dose-ranging and dose-
scheduling studies, and the design of new and more effective combination regimens.
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Summary
Current regimens used to treat pulmonary Mycobacterium abscessus disease have limited 
efficacy. There is an urgent need for new drugs and optimized combinations and doses. We 
performed hollow fiber system studies in which M. abscessus was exposed to moxifloxacin lung 
concentration-time profiles similar to human doses between 0 and 800 mg/day. The minimum 
bactericidal concentration and MIC were 8 and 2 mg/l in our M. abscessus strain, suggesting 
bactericidal activity. Measurement of moxifloxacin concentrations in each hollow fiber system 
revealed an elimination rate (kel) of 0.11 ± 0.05 h-1 (half-life of 9.8 h). Inhibitory sigmoid 
maximal effect (Emax) modeling revealed that the highest Emax was 3.15 ± 1.84 log10 cfu/ml on 
day 3, and the exposure mediating 50% of Emax (EC50) was a 0-24 h area under the concentration 
time curve (AUC0-24) to MIC ratio of 41.99 ± 31.78 (r2=0.99). The EC80 was an AUC0-24/MIC 
of 102.11. However no moxifloxacin concentration killed the bacteria to burdens below the 
starting inoculum. There was re-growth beyond day 3 in all doses, with replacement by resistant 
subpopulation that had an MIC >32 mg/l by the end of experiment. A quadratic function best 
described the relationship between AUC0-24/MIC and moxifloxacin-resistant subpopulation. 
Monte Carlo simulations of 10,000 patients revealed that the 400-800 mg/day doses would 
achieve or exceed the EC80 in ≤12.5% of patients. The moxifloxacin susceptibility breakpoint 
was 0.25 mg/l, which means almost all M. abscessus clinical strains were moxifloxacin-
resistant by these criteria. While moxifloxacin´s efficacy against M. abscessus was poor, formal 
combination therapy studies with moxifloxacin are still recommended.
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Introduction
Mycobacterium abscessus is a rapidly growing mycobacterium that is notorious because of 
resistance to most antibiotics.1 Pulmonary disease due to M. abscessus infection is chronic and 
relentless. Current regimens used to treat M. abscessus consist of a combination of amikacin, a 
macrolide, and either cefoxitin or imipenem; however the regimens fail in most patients.2 Based 
on static in vitro models, amikacin is considered the key antibiotic in the treatment regimens.3-6 
We recently demonstrated that the efficacy of amikacin based on concentration-time profiles 
achievable in human lungs as recapitulated in the hollow-fiber system model of M. abscessus 
(HFS-Mab) was poor, and failed to kill the bacteria below stasis.7 This, as well as clinical 
experience of high failure rates of amikacin-based regimens, means that there is an urgent 
need to find new antibiotics and optimize their doses. Here we approached this by conducting 
recommended formal pharmacokinetic/pharmacodynamic (PK/PD) evaluation of alternative 
antibiotics with potential bactericidal activity.8
The 8-methoxy fluoroquinolone, moxifloxacin, has been shown to have excellent efficacy against 
M. tuberculosis, M. avium and M. kansasii.9-12 In addition, continuation regimens currently used 
to treat pulmonary M. abscessus include moxifloxacin in the combination, starting from the 
second month of therapy. Given these prior successes of moxifloxacin, as well as its current 
role in the treatment of M. abscessus, we also tested it against this species. We performed 
formal moxifloxacin PK/PD work in the hollow fiber system model of pulmonary M. abscessus. 
We exposed M. abscessus to moxifloxacin concentration-time profiles as encountered in lungs 
of patients with pneumonia.13 Repetitive day-to-day sampling of hollow fiber systems is a 
major advantage in identifying the evolution of bacteria in response to the periodic fluctuation 
of antibiotic concentrations, vital given M. abscessus’ propensity to develop acquired drug 
resistance.8,14-17
Materials and Methods
Bacteria, antibiotic and growth conditions
Stock cultures of M. abscessus ATCC 19977 (American Type Culture Collection, Manassas, 
VA) were stored at -80 °C in Middlebrook 7H9 broth supplemented with 10% OADC (Remel, 
Lenexa, KS) and 15% glycerol, were used for all the experiments. One vial was thawed before 
each assay and incubated for 24-48 h at 30 °C to achieve logarithmic growth phase (log-phase). 
Moxifloxacin hydrochloride was purchased from Baylor University Medical Center pharmacy. 
On the day of use, the moxifloxacin was diluted in sterile water to desired concentrations for 
the assays.
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Antimicrobial susceptibility testing and mutation frequency
The MIC was identified using broth macrodilution in Middlebrook 7H9 broth (here termed 
“broth”) as well as by use of the E-test (BioMerieux, Durham, NC). In addition to the turbidity 
test, colony-forming units (cfu) per ml were enumerated for each concentration evaluated in the 
broth macrodilution test. In this test, the MIC was defined as the lowest concentration associated 
with ≥99% decrease in cfu/ml compared to untreated control and MBC as the concentration 
corresponding to >99.9% of kill. Mutation frequency was determined for the inoculum by 
culturing 0.2 ml on Middlebrook 7H10 agar plates (here termed “agar”) supplemented with 3 
times the moxifloxacin MIC. Cultures were incubated for 5 days. 
Exposure-response studies in the Hollow-fiber system
The hollow fiber system model of pulmonary M. abscessus (HFS-Mab) has been previously used 
to perform PK/PD evaluation of amikacin.7 Twenty milliliters of 6 log10 cfu/ml M. abscessus 
in log-phase were inoculated into the peripheral compartment of each of seven hollow fiber 
cartridges (FiberCell Systems, Frederick, MD). Doses that mimicked the non-protein bound 
plasma 0-24h area under the concentration time curve (AUC0-24), peak concentrations, and 
time to maximum concentration, achieved in humans treated with moxifloxacin doses of 0, 
25, 50, 100, 200, 400 and 800 mg were administered to the central compartment once daily via 
computerized syringe pumps.18
These exposures were chosen because they represent the range of clinically tolerated doses 
of moxifloxacin. Treatment was for 21 days of daily therapy. A plasma-to-lung epithelial 
lining fluid penetration ratio of 1 was assumed, based on the literature.13,19,20 As an example, 
the standard 400 mg a day dose was expected to achieve a peak concentration of 4.2 mg/l, 
and a half-life of 12 h, translating to an AUC0-24/MIC ratio of 28.3. Actual moxifloxacin 
concentrations achieved in all the systems were validated by repetitive sampling of 1 ml from 
the central compartment of each HFS-Mab during the first three days at 0, 1, 6, 9, 12, 18, 23.5, 
25, 30, 33, 36, 42, and 47.5 h post dose. In order to quantify the M. abscessus burden, 1 ml 
of the peripheral compartment culture contents was removed from each system on days 0, 1, 
2, 3, 5, 7, 10,14 and 21. The samples were washed with saline to avoid antibiotic carryover, 
after which samples were serially diluted and cultured on agar. To quantify the moxifloxacin-
resistant M. abscessus cfu/ml, the same samples were also inoculated on agar supplemented 
with 3 times the moxifloxacin MIC.
Drug assay
Moxifloxacin concentrations in the samples collected from the central compartment of HFS-
Mab were analyzed by LC/MS/MS. Moxifloxacin and moxifloxacin-13Cd3 (internal standard) 
were purchased from SIGMA (St. Louis, MO) and Santa Cruz Biotech (Santa Cruz, CA), 
respectively. Calibrator, controls and internal standard were included in each analytical run 
for quantitation. Stock solutions of moxifloxacin and internal standard were prepared in 80:20 
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methanol:water at a concentration of 1mg/ml and stored at -20 ºC. A 7-point calibration curve 
was prepared by diluting moxifloxacin stock solution in drug-free media (0.1, 0.2, 1, 2, 5, 10, 
20 mg/l). Quality control samples were prepared by spiking media with stock standards for 
two levels of controls. Samples were prepared in 96-well microtiter plates by the addition of 
10 µl of calibrator, quality controls or sample to 190 µl 0.1% formic acid in water containing 
10 mg/l internal standard followed by vortex. Chromatographic separation was achieved on an 
Acquity UPLC HSS T3 1.8 μm 50 x 2.1 mm analytical column (Waters) maintained at 30 °C 
at a flow of 0.2 ml/min with a binary gradient with a total run time of 6 min. The observed ions 
(m/z) values of the fragment ions were moxifloxacin (m/z 402.2→384.2) and internal standard, 
Moxifloxacin-13CD (m/z 406.2→388.3). Sample injection and separation was performed by an 
Acquity UPLC interfaced with a Xevo TQ mass spectrometer (Waters). All data were collected 
using MassLynx version 4.1 SCN810. The limit of quantitation for this assay was 0.1 mg/l. The 
inter- and intra-day variation was 1.5% and 9.4%, respectively.
Pharmacokinetic and pharmacodynamic modeling
All drug concentrations from each of the HFS-Mab units at all time points were co-modeled 
using the ADAPT 5 software (Biomedical Simulations Resource, University of Southern 
California, CA). Steps used in the pharmacokinetic parameter analysis were as described in 
detail in prior studies.10,21 The pharmacokinetic parameter estimates identified were used to 
calculate the observed AUC0-24 and AUC0-24/MIC ratios. Exposure-response was modeled using 
the inhibitory sigmoid Emax model, a standard model recommended for examination of effect 
of antibiotics whether they are static or cidal, and can be seen in both clinical and laboratory 
data.22-24 Total bacterial burden was used as the response parameter, while drug exposure was 
expressed as AUC0-24/MIC ratio. For moxifloxacin-resistance emergence, we used the quadratic 
model we have identified in the past, with drug exposure examined versus size of moxifloxacin-
resistant sub-population each sampling day.8,25
Monte Carlo simulations
In order to put our findings into clinical context, we performed a 10,000 patient Monte 
Carlo simulation to identify two important clinical aspects. First, we wanted to identify the 
clinical dose best able to achieve or exceed the EC80, which is the exposure mediating 80% 
of maximal kill (Emax). This exposure is considered “optimal” since Emax is on an asymptote, 
and is independent of whether a drug is cidal or static. Second, we wanted to identify the 
susceptibility breakpoint, which we considered as the MIC below which >10% of patients 
achieve the EC80 with standard dosing or with the highest dose that can be administered. 
Steps in the Monte Carlo simulations were as detailed in recommendations and in our prior 
work.8,26 We examined moxifloxacin doses of 400 mg a day, 600 mg a day, and 800 mg a day. 
We entered the two compartment model pharmacokinetic parameter estimates and covariance 
identified by Kees et al. into subroutine PRIOR of ADAPT 5, as shown in Table 1.27 We 
assumed a 1:1 AUC0-24 ratio in the lung versus plasma.13An MIC distribution from Korea 28 
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was used; as comparators data on MIC distribution from Nijmegen, the Netherlands and the 
Dallas-Fort Worth metroplex, USA was included for comparison of the impact of the new 
susceptibility breakpoint.
Results 
In this study the moxifloxacin MIC for the M. abscessus laboratory strain was 2 mg/l. In 
addition, the concentration associated with >99.9% of kill, or MBC, was 8 mg/l. Thus the MBC/
MIC ratio was 4, which means that moxifloxacin would be considered bactericidal according 
to standard convention.29 The mutation frequency to 3 times the moxifloxacin MIC was 2.11 ± 
0.16 x 10-5 in repeat experiments.
In the HFS-Mab dose-effect studies, the measured moxifloxacin concentrations in each HFS-
Mab unit revealed an elimination rate constant (kel) of 0.11 ± 0.05 h-1, which translates to a 
half-life of 9.8 h, consistent with moxifloxacin pharmacokinetics in a recent 241 patient clinical 
study.18 As an example, the r2 for intended drug concentrations, exposures and half-life of 
the 400 mg standard dose versus observed concentrations was 0.98, which means intended 
pharmacokinetics were recapitulated well. Figure 1 shows the time-kill curves for each of 
the moxifloxacin exposures in the HFS-Mab. None of the evaluated exposures achieved a 
considerable killing effect of the M. abscessus. 
The relationship between the AUC0-24/MIC and M. abscessus burden in the HFS-Mab is shown 
in Figure 2; the highest Emax was encountered on day 3. The day 3 parameters were an Emax 
of 3.15 ± 1.84 log10 cfu/ml, a Hill´s slope of 1.56 ± 0.63, and an EC50 that was an AUC0-24/
MIC ratio of 41.99 ± 31.78 (r2=0.987). Based on the inhibitory sigmoid Emax relationship for 
day 3, the EC80 was calculated as an AUC0-24/MIC ratio of non-protein bound moxifloxacin of 
102.11. The Emax appears high mainly because in non-treated controls the M. abscessus grew 
Pharmacokinetic parameter Observed in patients 
(entered into subroutine PRIOR)
Simulated in 10,000 patients
Parameter 
estimate
IIV as % CV Parameter 
estimate
IIV as % CV
Total clearance (l/h) 11.3 23.7 11.3 14.58
Intercompartmental clearance (l/h) 47.7 * 47.7 19.19
Absorption rate constant (h-1) 1.09 135 1.09 143
Central volume (l) 55.6 * 55.6 18.40
Peripheral volume (l) 59.6 15.3 59.6 14.99
Table 1. Pharmacokinetic parameter estimates utilized in Monte Carlo simulations.
* Fixed in the pharmacokinetic model by Kees et al.27
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to large bacterial burdens of about 10 log10 cfu/ml, starting from 6.0 log10 cfu/ml at the start of 
the experiment. Indeed, Figure 2 shows that even on day 3, moxifloxacin never reduced the 
bacterial burden below the starting inoculum (stasis).
Figure 3 shows that acquired drug resistance emerged after 10 days of exposure. The figure 
further shows that the moxifloxacin resistant sub-population had replaced the total population 
in the systems exposed to the 3 highest doses by day 21.The relationship between size of 
resistant subpopulation and moxifloxacin exposure was described by a system of changing 
“U” shaped curves, in effect a quadratic function. However, even at the highest AUC0-24/MIC 
ratios tested, moxifloxacin was not able to suppress acquired drug resistance. Indeed, the MIC 
of cultures from the systems exposed to the 3 highest doses had changed from 2 mg/l to >32 
mg/l by day 21.
Figure 4 shows the result of Monte Carlo simulations of 10,000 simulated subjects, based 
on the largest published moxifloxacin MIC distribution of M. abscessus, which is from 
Korea.25 Overall, the cumulative fraction of response or proportion of patients that achieved 
or exceeded EC80, given the MIC distribution, was poor for all doses. For the standard dose 
of 400 mg daily, only 4.7% of patients would achieve the EC80, for 600 mg a day 9.7%, 
and for 800 mg a day 12.5%. If the penetration ratio of moxifloxacin AUC achieved in the 
lung versus plasma were 2, as suggested by two outlier pharmacokinetic studies,19,20 the 
cumulative fraction of response would become 12.5% for 400 mg a day, 21.5% for 600 mg 
a day, and 26.6% for 800 mg a day. Either way, standard and high doses of moxifloxacin 
performed poorly. 
Figure 1. Moxifloxacin exposure-effect against M. 
abscessus in the HFS. None of the moxifloxacin 
exposures evaluated attained killing below the 
starting inoculum of 6.0 log10 cfu/ml at any point 
during the study. Regrowth was observed after day 
3 in all the systems.
Figure 2. Moxifloxacin exposure versus M. 
abscessus burden. Inhibitory sigmoid Emax 
curves are shown for the first 3 days, prior to 
replacement of microbial population by drug-
resistant subpopulation. The highest Emax was 
encountered on day 3, but not even that produced 
kill below the stasis level.
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Figure 4 also shows the target attainment at different moxifloxacin MICs. The Figure shows 
that at the standard dose, and at 600 mg a day, the target attainment to achieve EC80 fell to 
below 0.9 (i.e., 90%) after the MIC of 0.25 mg/l. This is the PK/PD derived moxifloxacin 
susceptibility breakpoint for M. abscessus, since above this MIC most patients will not achieve 
optimal microbial effect. It should be borne in mind that even this “optimal kill” would still not 
kill below bacterial burden at the start of treatment. If dose were increased to 800 mg a day, 
the susceptibility breakpoint only changes by one tube dilution. In contrast, the epidemiologic 
cut-off point for the Korean MIC distribution would be 16 mg/l. In Figure 5, we show the 
MIC distributions of M. abscessus from our two clinical practice locations in the Netherlands 
and the Dallas-Fort Worth metroplex in Texas. Given the MIC distributions in Figure 5, and 
the proposed susceptibility breakpoint of 0.25 mg/l, then almost all M. abscessus isolates 
in North Texas and the Netherlands as of 2015 were intrinsically resistant to moxifloxacin. 
Accordingly, the cumulative fraction of responses in these two locales would fall to 0% even 
for a dose of 800 mg a day. 
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Figure 3. Changes in total and moxifloxacin-
resistant subpopulations with time. Total 
M. abscessus population (solid line) and 
moxifloxacin-resistant subpopulation (hatched 
line) over the course of 21 days of treatment with 
different moxifloxacin AUC0-24/MIC exposures. 
A: Control and three lower exposures. While 
the drug-resistant subpopulation increased 
with time, especially beyond day 10, it had not 
completely replaced the total population in 
these lower doses, with the highest dose among 
these lower doses associated with the largest 
moxifloxacin-resistant subpopulation. 
B: At the three highest exposures, the total population had been completely replaced by moxifloxacin-
resistant subpopulation by day 14. 
C: The relationship between moxifloxacin AUC/MIC and size of sub-resistant subpopulation is described 
by systems of inverted “U” curves. At day 1 it was a straight line, then it switches to an inverted “U” curve 
that was more pronounced by day 21.
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Discussion
Moxifloxacin, and quinolones in general, are considered ideal antibiotics given that they are 
bactericidal, are active against a broad spectrum of bacteria, are available both in oral and 
parenteral formulations, have a broad distribution in organs and tissues and can achieve 
therapeutic concentrations both in the intra and extracellular environment.21,30 Indeed, these 
agents have now found broad use in treatment of many slow growing and rapidly growing 
mycobacteria. The MBC/MIC ratio calculated in this study would seem to indicate that the drug 
would work well against M. abscessus. However, in our formal PK/PD study we found that 
even at high exposures, moxifloxacin does not reduce bacterial burden below starting inoculum 
and resistance arises fairly quickly during monotherapy. Therefore, the meaning of standard 
MBC/MIC assays used to determine bactericidal effect is questionable.
Moxifloxacin has been used for M. abscessus pulmonary disease at 400 mg/daily, after the 
discontinuation of parenteral antibiotics that are administered during the first 1-2 months. In 
that role, it is used as part of combination therapy. However, we show that its performance 
in the HFS-Mab does not inspire continued confidence even for that role. Inhibitory sigmoid 
Emax based target exposures such as EC80-EC90 have been used as target exposures to identify 
susceptibility breakpoints of several bacteria, including mycobacteria.8,10-12,31-37 We chose the 
EC80 exposure as optimal kill, which we have found to best translate to the clinic for other 
mycobacteria such as M. tuberculosis and M. avium, and indeed to other Gram-negative and 
Gram-positive organisms, even with drugs that do not kill below stasis.31-35 Indeed, indices of 
microbial such as 3.0 log10 cfu/ml kill that are commonly used in work with Gram-positive cocci 
Figure 5. Moxifloxacin MIC distribution in three 
different practice locations. The MIC distribution 
from Korea was used for the Monte Carlo 
simulations, the other two settings are used as 
comparators. Notably, MIC distribution from the 
Netherlands and from Texas, USA, is showing most 
isolates as resistant to moxifloxacin.
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Figure 4. Probability target attainment of three 
different moxifloxacin doses in 10,000 patients.
Target attainment probability at each MIC fell after 
the 0.25 mg/l to 0% for a dose of 400 mg, and just 
above 60% for 600 mg. That for doses of 800 mg a 
day plummeted after 0.5 mg/l. Since the proportion 
of clinical isolates with an MIC >0.25 mg/l is large 
(and 0% of these achieve the EC80), the fraction of 
all patients who will achieve the EC80 is very small.
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and Gram-negative bacilli are rarely achieved in work with mycobacteria with a single agent. 
Nevertheless, a similar approach to ours has been used to identify susceptibility breakpoints 
even at exposures that are merely associated with stasis for several drugs, with tigecyline and 
Enterobacteriaceae.35-37 Work done with M. tuberculosis in the hollow fiber system to identify 
the EC80 in inhibitory sigmoid Emax model for drugs that kill below stasis as well as those that 
do, in tandem with Monte Carlo simulations, has shown to predict optimal clinical exposures, 
doses, and susceptibility breakpoints to within 94% of the value later on identified in the clinic, 
based on FDA and EMA submissions.8,38-42 This hollow fiber work, which identified these 
exposures and breakpoints later confirmed in the clinic, was done with single strains of the 
M. tuberculosis, with the MIC distribution taken into account only at the stage of Monte carlo 
simulations. We report here on moxifloxacin dosing and optimal exposures using the same 
hollow fiber system and the same inhibitory sigmoid Emax models and EC80 exposures in tandem 
with Monte Carlo simulations, demonstrating limited activity at doses up to 800 mg a day, and 
expect the same degree of accuracy as in tuberculosis. 
In the treatment of M. abscessus, moxifloxacin is used as part of combination therapy. Thus, it 
could be that it would show efficacy in combination therapy. Formal combination therapy studies 
with moxifloxacin in the treatment of M. abscessus will need to be performed in the HFS-Mab, 
in order to explore potential synergy with other agents before definitive recommendations can 
be made to remove it from current regimens. So far, we have examined moxifloxacin high dose 
in combination with tigecyline and clarithromycin, and found that it did not add to the effect of 
these drugs (manuscript in preparation). Similarly, we found that amikacin which also failed to 
kill M. abscessus appreciably as monotherapy, did not add to the effect of clarithromycin and 
cefoxitin, which suggest that findings in monotherapy studies reflect well the efficacy of drugs 
in combination regimens used to treat this infection (manuscript in preparation). Thus, findings 
of moxifloxacin monotherapy are likely to be borne out in combination therapy.
Acquired moxifloxacin resistance has been described in mycobacteria, particularly for M. 
tuberculosis.11 In the absence of other companion antibiotics, moxifloxacin monotherapy 
rapidly leads to resistance as was the case here for M. abscessus. Unfortunately, in this study no 
moxifloxacin exposure was associated with resistance suppression. The relationship between 
acquired moxifloxacin resistance and moxifloxacin AUC/MIC was best described by a quadratic 
function, similar to our findings with M. tuberculosis.25 However, the underlying mechanism 
for moxifloxacin resistance in M. abscessus deserves further exploration; DNA gyrase is still an 
interesting bacterial target against which new inhibitors are being developed with evaluation of 
their potential against M. abscessus and other nontuberculous mycobacteria.43
Finally, according to guidelines, the current breakpoint to determine moxifloxacin resistance 
to rapidly growing mycobacteria such as M. abscessus is ≥4 mg/l in cation-adjusted Mueller 
Hinton broth44, which in a wide MIC distribution28 will barely allow the use of moxifloxacin 
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in 50% of the cases. A 1.0 mg/l susceptibility breakpoint has also been used by the CLSI.44 
In this study, although using a different type of broth (Middlebrook 7H9), we found a PK/PD 
derived breakpoint of 0.25 mg/l. Examination of MIC distributions in our clinical practices 
demonstrated that at this proposed breakpoint, most isolates would be a priori resistant to 
moxifloxacin. This comports well with failure of the moxifloxacin-containing regimens 
in clinical practice. Our findings suggest that the poor outcome observed when treating M. 
abscessus is no more than a reflection of the amount of intrinsically resistant isolates that are 
circulating and infecting patients. The approach that utilizes the hollow fiber system model and 
the EC80 or EC90, followed by Monte Carlo simulations, has been found to be highly accurate in 
predicting MICs above which combination therapy fails in clinical studies, even for drugs that 
do not kill below the stasis line, in the case of tuberculosis and other more mundane bacteria 
such as Gram-negative rods.25,45-53 Thus our findings are likely accurate, but this will require 
clinical validation in the future. Such confirmation will require multivariable pharmacometric 
analyses of clinical data, which does not currently exist for moxifloxacin and M. abscessus 
pulmonary disease.54 Indeed, no such data exists as far as we know for any of the drugs used in 
treatment of pulmonary M. abscessus, since there is lack of clinical trials and large prospective 
clinical cohort studies for this disease. Thus, the PK/PD derived breakpoint is a proposed 
breakpoint to be used for clinical decision making until a large enough data set could better 
identify further breakpoints.
There are some limitations in this study. We performed our evaluation with one laboratory 
strain. Although the strain used was the type strain, ideally this work should be extended to 
clinical isolates with different susceptibility profiles. Indeed, the type strain was not from a 
patient with pneumonia, but an abscess after trauma. It is not clear if strains that cause lung 
disease are intrinsically different from those that cause extrapulmonary disease. Nevertheless, 
even when single strains have been used in PK/PD studies in the hollow fiber with other 
bacteria, results have been found to be fairly accurate and to allow generalizations.11,25,38-42,45-53 
Moreover, here we only report the effect of moxifloxacin alone and there still a need to 
evaluate its performance as part of combination therapy. However, studies evaluating different 
moxifloxacin-based combinations to explore the potential of synergistic combinations as well 
to explore the intracellular model for pulmonary disease have been performed, and are being 
prepared for publication.
In summary, we used the recently developed pre-clinical model for M. abscessus disease to 
evaluate and then identify the efficacy of moxifloxacin, which demonstrated rapid appearance 
of resistance. Efficacy was poor, and moxifloxacin even at high doses is not expected to work in 
the clinic. We used the PK/PD studies to identify and propose a new moxifloxacin susceptibility 
breakpoint of 0.25 mg/l.
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Summary
Mycobacterium abscessus causes chronic pulmonary infections that are extremely difficult to 
cure. The currently recommended combination therapy is associated with high failure rates 
and relapse. Tigecycline has been explored in salvage regimens, with a response rate of 43% 
in those who received at least a month of therapy. We performed a dose-response study in a 
hollow-fiber system model of pulmonary M. abscessus infection in which we recapitulated 
tigecycline human pulmonary concentration-time profiles of 8 different doses for 21 days. We 
identified the maximal kill or efficacy in cfu per milliliter and the ratio of the 0- to 24-h area 
under the concentration-time curve to MIC (AUC/MIC) associated with 80% efficacy (EC80). 
The tigecycline efficacy was 5.38 ± 2.35 log10 cfu/ml, and the drug achieved the unprecedented 
feat of a bacterial level of 1.0 log10 cfu/ml below the pretreatment inoculum (1-log kill) of M. 
abscessus in the hollow-fiber system. The EC80 AUC/MIC ratio was 36.65, while that for a 
1-log kill was 44.6. Monte Carlo experiments with 10,000 patients were used to identify the 
clinical dose best able to achieve the EC80 or 1-log kill. The standard dose of 100 mg/day had 
cumulative fractions of response of 51% for the EC80 and 46% for 1-log kill. For both the EC80 
target and 1-log kill, the optimal tigecycline clinical dose was identified as 200 mg/day. The 
susceptibility breakpoint was <0.5 mg/l. Tigecycline is the most active single agent evaluated 
to date, and we propose that 200 mg/day be examined as the backbone of new combination 
therapy regimens to replace current treatment.
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Introduction
Mycobacterium abscessus is, for all the correct reasons, considered an “antibiotic nightmare”.1 
This pathogen primarily causes chronic pulmonary infections that are extremely difficult to 
cure owing to the extensive drug resistance intrinsic to this organism.2 Personalized treatment 
regimens based on in vitro drug susceptibility testing and aggressive surgical resection yielded 
“cure” rates of only 57% in one case series.3 Even then, over the years there is relapse and death 
among those who have been “cured.” Thus, there has been a continued search for new drugs, 
with the hope to craft a new effective regimen. 
Tigecycline, the first developed glycylcycline, was designed to overcome mechanisms of 
resistance that are known for older tetracyclines, such as the active efflux and the ribosome 
protection mechanisms. It is considered a bacteriostatic antibiotic, sometimes bactericidal, 
with demonstrated broad in vitro effects on several Gram-positive and Gram-negative bacteria, 
including some rapidly growing mycobacteria.4-7 This broad antimicrobial spectrum, its large 
volume of distribution (≥7 to 10 l/kg), and the known intracellular accumulation represent a 
sound rationale for the clinical use of tigecycline.4,5
Although tigecycline is FDA approved to be used for the treatment of complicated skin/
soft tissue infections, complicated intra-abdominal infections, and community-acquired 
bacterial pneumonia, in a recent case series, tigecycline salvage regimens in 30 patients were 
associated with improvement in 43% of patients who received >1 month of therapy.8 These 
patients received doses of tigecycline designed for Gram-negative and Gram-positive bacterial 
infections. In patients treated with tigecycline for pneumonia caused by these other bacteria, 
the main determinant of a clinical response has been identified as a ratio of the free-drug area 
under the concentration-time curve from 0 to 24 h (fAUC
0–24
) to the MIC of >12.8 in plasma.9,10 
This suggests a concentration-dependent effect of tigecycline and that doses could be optimized 
based on the free-drug AUC
0–24
/MIC ratios. 
Here, we wanted to identify the efficacy of tigecycline and utilize it to identify optimal doses 
for treatment of pulmonary disease caused by M. abscessus.
Materials and Methods
Materials
The test strain was M. abscessus subsp. abscessus ATCC 19977 (American Type Culture 
Collection, Manassas, VA). Stocks of the mycobacteria were kept at -80 °C in Middlebrook 
7H9 broth (Remel, Thermo Fisher Scientific, Lenexa, KS) supplemented with 10% oleic 
acid-albumin-dextrose-catalase (OADC) and 15% glycerol. Twenty-four hours before each 
experiment, one vial was thawed and incubated at 30 °C to achieve logarithmic growth phase 
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(log phase). Tigecycline powder was purchased from Baylor University Medical Center 
pharmacy. For each experiment, the antibiotic was reconstituted, sterile filtered, and then 
diluted in sterile water to the desired concentrations. Hollow-fiber cartridges were purchased 
from FiberCell Systems (Frederick, MD).
Drug susceptibility testing
The MIC was determined two times by broth macrodilution in Middlebrook 7H9 broth (here 
referred to as “broth”) read at 72 h.11 In addition, cfu per ml were enumerated from each 
concentration evaluated in the broth macrodilution test to determine the lowest concentration 
associated with >99% inhibition of growth, corresponding to the MIC.
Hollow-fiber study
The hollow-fiber system (HFS) model of pulmonary M. abscessus infection was previously 
developed and used to perform pharmacokinetic/pharmacodynamic (PK/PD) evaluation of 
amikacin and moxifloxacin.12,13 The peripheral compartments of 8 HFSs were each inoculated 
with 20 ml of 6 log10 cfu/ml M. abscessus. Treatment was administered daily for 21 days at 
doses that mimicked the non-protein bound or free AUC
0–24
, peak concentrations, and times 
to maximum concentration achieved in the lungs of humans treated with tigecycline doses of 
0, 12.5, 25, 50, 100, 200, 400, and 800 mg, assuming linear increases in AUC
0–24 
with dose 
since clearance is constant over a range of doses.14-16 The doses were administered to the 
central compartment of each HFS once daily via computerized syringe pumps. Tigecycline 
concentrations achieved in all the systems were validated by repetitive sampling from the 
central compartment of each HFS at 0, 1, 6, 9, 12, 18, 23.5, 25, 30, 33, 36, 42, and 47.5 h 
after the first dose. The M. abscessus burden was quantified by taking 1-ml samples from the 
peripheral compartment culture contents of each system on days 0, 1, 2, 3, 5, 7, 10, 14, and 21 
of treatment. After washing by centrifugation with saline to avoid antibiotic carryover, samples 
were serially 10-fold diluted and cultured on Middlebrook 7H10 agar. The tigecycline MIC was 
identified at the end of the experiment in each HFS by broth macrodilution.
Drug assay
Tigecycline concentrations in the samples collected from the central compartment of each 
HFS were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Tigecycline and tigecycline-D9 (internal standard) were purchased from Toronto Research 
Chemicals (Toronto, Canada). A calibrator, controls, and the internal standard were included in 
each analytical run for quantitation. Stock solutions of tigecycline and internal standard were 
prepared in 80:20 methanol-water at a concentration of 1 mg/ml and stored at -20 °C. A seven 
point calibration curve was prepared by diluting tigecycline stock solution in drug-free medium 
(0.1, 0.2, 1, 2, 5, 10, and 20 mg/l). Quality control samples were prepared by spiking the medium 
with stock standards for two levels of controls. Samples were prepared in 96-well microtiter 
plates by the addition of 10 µl of calibrator, quality controls, or sample to 190 µl 0.1% formic 
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acid in water containing 10 mg/l internal standard followed by vortex mixing. Chromatographic 
separation was achieved on an Acquity ultraperformance liquid chromatography (UPLC) HSS 
T3 analytical column (1.8 µm, 50 by 2.1 mm; Waters) maintained at 30 °C at a flow rate of 0.2 
ml/min with a binary gradient and a total run time of 6 min. The observed m/z values of the 
fragment ions were 586.33 to 569.3 for tigecycline and the internal standard and 595.4 to 578.4 
for tigecycline 13CD. Sample injection and separation was performed with an Acquity UPLC 
interfaced with a Xevo TQ mass spectrometer (Waters). All data were collected using Mass 
Lynx version 4.1 SCN810. The limit of quantitation for this assay was 0.1 mg/l. The inter- and 
intraday variations were 12.1% and 11.8%, respectively.
Pharmacokinetic analysis and PK/PD modeling
Tigecycline concentrations from each of the HFS units at all time points were co-modeled 
using the ADAPT 5 software (Biomedical Simulations Resource, University of Southern 
California) following steps for the pharmacokinetic parameter analysis described in detail 
in prior studies.17-19 The observed AUC
0–24 
and AUC
0–24
/MIC ratios were calculated from the 
pharmacokinetic parameter estimates identified. The dose response was modeled using the 
inhibitory sigmoid Emax model with the total bacterial burden used as the response parameter 
and the steady-state AUC
0–24
/MIC ratio as drug exposure, with maximal kill (Emax) or efficacy 
and effect in log10 cfu/ml. This relationship was used to calculate the EC80, which is the exposure 
mediating 80% of Emax, since 100% Emax lies on an asymptote of the inhibitory sigmoid Emax 
model. In addition, we also calculated the AUC
0–24
/MIC ratio at which the bacterial burden is 
similar to that at time zero (“stasis”), as well as that associated with a 1-log10 cfu/ml decrease 
compared to time zero (“1-log kill”).
Monte Carlo simulations
Monte Carlo simulations were performed in order to translate the HFS-derived AUC/MIC 
exposures to an optimal clinical dose. Steps for the Monte Carlo experiments are detailed in 
recommendations and in our prior work19,20 and were followed to identify the clinical dose best 
able to achieve or exceed specific target exposures in lungs of 10,000 patients with pulmonary 
M. abscessus. Three target exposures were examined: (i) EC80, (ii) AUC0–24/MIC ratio associated 
with stasis, and (iii) AUC
0–24
/MIC ratio associated with 1-log kill. The same exercise was also 
used to identify the PK/PD-derived susceptibility breakpoint, which we consider to be the MIC 
below which >10% of patients achieve the EC80 with standard dosing or, alternatively, with the 
optimal dose that can be tolerated by patients, based on prior work.19-23 We examined doses of 
50 mg, 100 mg, 150 mg, and 200 mg per day. The population pharmacokinetic parameters and 
covariance used as prior data were those from Rubino et al.14 In addition, we took into account 
the fact that the tigecycline AUC in epithelial lining fluid (ELF) in 1.32-fold higher than that 
in plasma.15 Drug concentrations in ELF are considered concentration surrogates at the site of 
effect for pneumonias, including those caused by mycobacteria.14,15,17-26 Since the concentration 
of proteins in ELF in patients is low,25-27 we considered ELF protein binding negligible. An 
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alternate view could be that a large portion of M. abscessus in lungs is intracellular (this is by 
no means resolved), in which case it would be the intracellular tigecycline concentration that 
should be simulated. Since tigecycline’s concentration in alveolar macrophages is >58-fold 
than that in ELF, our use of ELF exposures would constitute a worst-case scenario.15 We also 
examined the probability that these doses would be likely to achieve a plasma AUC of >6.87 
mg · h/l, which was identified by Rubino et al. as being associated with greater incidence of 
nausea and vomiting.10 The tigecycline MIC distribution was from isolates of patients treated 
in northern Texas, as reported by Wallace and colleagues.7 The cumulative fraction of response 
(CFR) is a summation calculated as:
where PTA is the probability of target attainment at each MIC and F is the proportion of isolates 
at each MIC.19,28
Results 
MIC and pharmacokinetic analysis
The tigecycline MIC for the M. abscessus strain was 3.12 mg/l. Tigecycline pharmacokinetics in 
the HFS model of pulmonary M. abscessus infection were best described by a two-compartment 
model, based on Akaike information criterion and Bayesian information criterion scores, as 
intended in the study design. The pharmacokinetic parameters achieved in the HFS model were 
a total clearance of 20.6 ± 29.6 l/h, a volume of the central compartment of 459 ± 13.1 l, an 
intercompartmental clearance of 3.41 l/h, and a peripheral volume of 0.80 ± 0.45 l.
Time-kill curve in the HFS model
Figure 1 shows time-kill curves for the HFS model of pulmonary M. abscessus infection, which 
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Figure 1. Tigecycline time-kill 
curves in the hollow-fiber system 
model of M. abscessus infection. 
The two higher exposures lead to 
considerable killing, which was 
maximum at 7 days. Regrowth 
started at day 10 and after day 
14 was observed in all systems.
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show the bacterial burden over time for each tigecycline AUC
0–24
/MIC exposure. The AUC
0–24
/
MIC ratios of 44.60 and 79.85 achieved considerable killing of the M. abscessus population. 
Figure 1 also shows that the maximum microbial kill was on day 7, when tigecycline achieved 
a microbial kill of 1.37 log10 cfu/ml below the pretreatment bacterial burden (stasis). Regrowth 
was observed after 14 days and occurred with all doses. However, there was no change in 
the tigecycline MIC in any of the HFSs treated with tigecycline or in the non treated control 
systems at the end of therapy.
PK/PD modeling
The inhibitory sigmoid Emax model curves for each sampling day before regrowth are shown 
in Figure 2. The day 7 parameters were an Emax of 5.38 ± 2.35 log10 cfu/ml, a Hill´s slope of 
0.96 ± 0.52, and an EC50 that was an AUC0–24/MIC ratio of 20.42 ± 19.75 (r2=0.96). On day 10, 
which we took as the end of the bactericidal effect since all treated systems started regrowth, the 
Hill´s slope was 1.12 ± 0.64, the EC50 was an AUC0–24/MIC ratio of 10.63 ± 6.68 (r2=0.95), and 
the EC80 was 36.65. The AUC0–24/MIC ratio associated with stasis (i.e., no growth in bacterial 
burden compared to day 0) was 21.3, while that associated with a 1-log kill was 44.60.
Translation of laboratory findings to the clinical world
Next we performed Monte Carlo simulations to identify the probability of doses of tigecycline 
between 50 mg and 200 mg per day achieving or exceeding either the AUC
0–24
/MIC ratio 
associated with stasis, the EC80, or the AUC0–24/MIC ratio associated with a 1-log kill, in 10,000 
patients. The 50-mg/day dose had CFRs of 48.41% of the 10,000 patients for stasis, 1.40% for 
the EC80, and <1% for a 1-log kill. Therefore, that dose would be considered unsatisfactory. 
Figure 3 shows the performance of the standard 100-mg/day dose for each of the three target 
exposures. Notably, the EC80 target shows that the 100 mg was associated with >90% target 
attainment up to an MIC of 0.125 mg/l, after which it plummeted (Figure 3B). The dose 
achieved a CFR of 46.7% for the 1-log kill target. 
Figure 2. Inhibitory sigmoid 
Emax relationships between 
tigecycline AUC0–24/MIC ratios 
and Mycobacterium abscessus 
burden. From day 2 on, the kill 
went below the stasis level, but 
the highest efficacy was at day 
7.
0 10 20 30 40 50 60 70 80
0
1
2
3
4
5
6
7
8
9
10
Day 1
Day 2
Day 3
Day 7
Day 10
Stasis
Day 5
AUC0-24/MIC
M
yc
ob
ac
te
ri
um
 a
bs
ce
ss
us
 lo
g 1
0 C
FU
/m
l
118
Chapter 7
The performance of the 150-mg/day dose is shown in Figure 4. More than 90% of patients 
would achieve stasis at this dose (Figure 4A). In regard to the EC80, the MIC above which >10% 
would fail to achieve that exposure was 0.25 mg/l; at 0.5 mg/l, the proportion fell to 0%. Figure 
4C shows that the proportion that achieved an AUC
0–24
/MIC ratio associated with a 1-log kill at 
150 mg/day was approximately 63%. 
The 200-mg/day dose achieved target exposures as shown in Figure 5. Both stasis (Figure 
5A) and EC80 exposures (Figure 5B) were achieved in >90% of patients. Figure 5B shows 
target attainment of >98% at an MIC of 0.25 mg/l, which then fell to 2.80% at an MIC of 0.5 
mg/l. If this dose was adopted for pulmonary M. abscessus infection, the pharmacokinetic/
pharmacodynamic based susceptibility breakpoint would be 0.5 mg/l, as shown in Figure 5B. 
The AUC
0–24
/MIC ratio associated with a 1-log kill was achieved or exceeded in 87.34% of 
patients, which though short of 90% is close, suggesting that this is the optimal dose for rapid 
microbial kill in pulmonary M. abscessus disease. Since the tigecycline AUC
0–24 
threshold 
that predicts nausea and vomiting is a plasma AUC of >6.87 mg·h/l, we also examined the 
probability of achieving that plasma concentration (as opposed to lung concentrations as 
described above) at the different doses. Figure 6 shows a steep increase in the proportion of 
the patients achieving this at above 150 mg/day, achieving a probability of close to 1 at 200 
mg/day. 
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Figure 3. Probability of target attainment in 
patients treated with 100 mg/day.Proportions 
of 10,000 patients achieving the AUC/MIC 
ratio associated withstasis (A) EC80 target 
(B), and the target AUC/MIC ratio associated 
with a1-log kill (C) are shown. The cumulative 
fraction of response (CFR) is low forthe EC80 
and 1-log kill targets. Moreover, in panel A, the 
standard dose will notachieve even stasis if the 
MIC is 0.5 mg/l.
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Discussion
Tigecycline is efficacious against the notoriously resistant M. abscessus in the hollow-fiber 
model system for pulmonary disease. For the first time in the HFS model of pulmonary M. 
abscessus infection, a drug exhibited a considerable microbial kill below the stasis line, 
exceeding what has been previously observed for amikacin or moxifloxacin.12,13 This magnitude 
of the efficacy means that tigecycline could enter a regimen as the first truly bactericidal drug 
for M. abscessus. This alone should qualify this drug to be considered as a first-line agent early 
during therapy and the backbone for new combination regimens. Perhaps aggressive regimens, 
including combination The tigecycline EC80 exposure for M. abscessus microbial kill was 
calculated as an AUC
0–24
/MIC ratio of 36.65. In patients with community-acquired pneumonia 
due to a variety of Gram-positive and Gram-negative pathogens, the ratio associated with 
faster time to fever resolution for tigecycline was an fAUC
0–24
/MIC ratio of ≥12.8.10 Thus, 
the exposure associated with optimal efficacy that we identified is much higher than that for 
other pathogens. Nevertheless, the microbial kill indices (either EC80, stasis, or 1-log kill) that 
translate from the HFS model of pulmonary M. abscessus infection to patients are still unclear. 
However, in our simulations, it is interesting that the CFR of 46.70% based on the 1-log kill 
target was the one closet to clinical response rates of 43% in tigecycline-containing regimens 
in pulmonary M. abscessus disease studies by Wallace et al.8 This is consistent with the notion 
that other antibiotics currently used exert very limited antimicrobial effects, as seen in our HFS 
model and with clinical experience.1-3,8,12,13 The 200-mg/day dose achieved this 1-log kill target 
exposure in close to 90% of patients, suggesting that it is the optimal dose for a bactericidal 
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effect in these patients. Indeed, this dose has been shown to be more efficacious in studies with 
treatment of other bacterial infections.29,30
Administering 200 mg/day will unfortunately also mean that virtually all patients will achieve 
AUCs of >6.87 mg · h/l, predictive of development of adverse events. It may be that this 
large dose will be administered together with an antiemetic agent, which is in fact common 
practice already, during the first few months of therapy in a multidrug regimen to rapidly 
drive down bacterial the burden and then will be dropped from the regimen.8 This strategy, 
however, sacrifices tolerability of the treatment for efficacy, a difficult trade-off. It could be that 
in combination therapy, lower tigecycline exposures, and hence doses, are needed for optimal 
microbial kill. The lessons from tuberculosis, however, have been that most of the time, the 
optimal exposures identified in monotherapy tend to be the same in combination therapy, likely 
because most combinations exhibit additivity as opposed to synergy.19,20,31
Finally, no susceptibility breakpoint has been established yet for tigecycline against rapidly 
growing mycobacteria, including M. abscessus. Based on our findings here, the PK/PD-derived 
susceptibility breakpoint is ≤0.5 mg/l with the proposed dose, as well as with the current 
standard dose. Indeed, at MICs higher than this, even the dose of 200 mg/day achieves stasis 
in 0% of patients. These breakpoints that we propose differ from the epidemiologic cutoff 
values used by EUCAST. The proposed breakpoints are, rather, designed to identify which 
patients would fail therapy even at the 200-mg dose and are therefore designed for clinical 
decision-making. This gives clinicians a tool to decide whether to use tigecycline, given 
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Figure 5. Probability of target attainment in 
patients treated with 200 mg/day. The dose of 
200 mg/day achieved CFRs of >90% for stasis 
(A) and EC80 (B) and >87% for a 1-log kill (C). 
Panel A also shows that even at this dose, if the 
MIC is >0.5 mg/l, 0% of patients would achieve 
the concentration associated with stasis. Thus, 
susceptibility breakpoints should be below an 
MIC of 1 mg/l.
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higher probabilities of failure even to achieve stasis, with an agent that would be associated 
with high rates of adverse events.
This study has some limitations. First, the assay to monitor and detect the size of the resistant 
subpopulation was not optimized. Thus, we could determine neither the mutation frequency nor 
the proportion of the resistant subpopulation throughout the study. Second, only the M. abscessus 
type strain was examined. Ideally several clinical isolates should be evaluated. Nevertheless, 
taking into account a wider MIC distribution in our simulations should in part compensate for 
that. Third, these are results from an HFS model for extracellular pulmonary M. abscessus 
infection. It is unknown what proportion of the pathogen is extracellular or intracellular in lungs 
of patients. However, given tigecycline’s high ratios of penetration into alveolar macrophages, 
reflected by an alveolar cell-to-serum AUC ratio of 77.5 times15, even the standard dose may 
achieve either the EC80 or 1-log kill in patients. Thus, our dose recommendations may be too 
conservative. Nevertheless, in other mycobacterial pneumonias, the ELF has been accurate as a 
surrogate in prediction in patient clinical studies.31-33
In summary, tigecycline has the potential to improve treatment outcomes in M. abscessus 
disease. To date, it is one of the most active drugs evaluated in the HFS model of pulmonary 
M. abscessus infection. We recommend 200 mg; however, the caveat is that this is based on 
the assumption of a predominantly extracellular bacterial location. The role of tigecycline in 
regimens to treat pulmonary M. abscessus infection deserves further exploration, including 
development of combination therapy regimens.
Figure 6. Proportion of 
10,000 patients who achieve 
the tigecycline AUC threshold 
predictive of nausea and 
vomiting.
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Failure of the amikacin, cefoxitin and 
clarithromycin combination regimen for 
pulmonary mycobacterium abscessus
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Summary
In a hollow-fiber model, we mimicked the drug exposures achieved in the lungs of humans 
treated with standard amikacin, clarithromycin, and cefoxitin combination therapy for 
Mycobacterium abscessus infection. At optimal dosing, a kill rate of -0.09 (95% confidence 
interval [CI], -0.04 to 0.03) log10 cfu per ml/day was achieved over the first 14 days, after which 
there was regrowth due to acquired drug resistance. Thus, the standard regimen quickly failed. 
A new regimen is needed.
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Failure of standard regimen to treat M. abscessus
Clinicians treat Mycobacterium abscessus pulmonary disease with a combination of amikacin, 
clarithromycin, and cefoxitin for 1 to 2 months, followed by an oral maintenance regimen, 
usually with a fluoroquinolone, based on the recommendations of experts.1 However, the use 
of this approach “cures” only 50% even with adjunctive surgery, most of whom relapse or die.2 
We have developed a hollow-fiber model of M. abscessus (HFS-M. abscessus) and evaluated 
the effect of monotherapy of amikacin and moxifloxacin in the system. Each drug failed 
dramatically, and acquired drug resistance (ADR) developed.3,4 Since these drugs are given as 
combination therapy in patients, they could still work in combination. Here, we evaluated the 
performance of the standard combination regimen of amikacin, cefoxitin, and clarithromycin in 
the HFS-M. abscessus to determine potential synergy, and even more importantly, whether the 
combination therapy could prevent ADR.
Antibiotics were purchased from the Baylor University Medical Center Pharmacy (Dallas, 
TX) and from Sigma-Aldrich (St. Louis, MO). Antibiotics were dissolved in water-methanol 
(clarithromycin), sterile filtered, and diluted to the desired concentrations in Middlebrook 7H9 
broth (here broth; Remel, Lenexa, KS). Stock solutions of M. abscessus ATCC 19977 (ATCC, 
Manassas, VA) were grown to logarithmic-growth phase in the broth. MICs were measured 
using broth microdilution.5 The amikacin, cefoxitin, and clarithromycin MICs were 32, 16, and 
8 mg/l, respectively.
The peripheral compartments of six HFS-M. abscessus systems were inoculated with 20 ml of 
6.0 log10 cfu/ml M. abscessus, as previously described.3 Three systems were immediately treated 
with a combination of amikacin, cefoxitin, and clarithromycin, while three replicate systems 
were non-treated controls. Amikacin, cefoxitin, and clarithromycin were administered via 
syringe pumps for 28 days, as in patients. We mimicked free-drug area under the concentration-
time curve from 0 to 24 h (fAUC
0–24
), peak concentration (fCmax), and time to maximum 
concentration achieved in the lungs of humans treated with amikacin and clarithromycin 
administered once daily, at 1,000 mg, and cefoxitin administered at 2 g four times a day.6,7 
Different half-lives in each HFS-M. abscessus system were achieved, as described by us in the 
past.8 Antibiotic concentrations achieved in all the systems were validated by sampling from 
the central compartment of each system at seven time points over 24 h post dose, after which 
concentrations were assayed in a validated multiplexed assay using liquid chromatography-
tandem mass spectrometry in our laboratory at the Baylor University Medical Center. We 
achieved an AUC
0–24
/MIC of 5.3 mg·h/l for clarithromycin, a percentage of time above the MIC 
of 100% for cefoxitin, and an fCmax/MIC of 4.0 of amikacin, so that each drug was at optimal 
free-drug exposure.3 These exposures are actually better than those achieved in most patients 
with standard dosing, based on prior work.3,4,7,9
We sampled each system’s peripheral compartment on days 0, 1, 2, 3, 5, 7, 10, 14, 21, and 28 
of treatment, washed the cultures in saline to avoid antibiotic carryover, serially diluted the 
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cultures, and cultured them on antibiotic-free Middlebrook 7H10 agar. The size of the resistant 
subpopulation was quantified by culturing on Middlebrook agar plates containing 3 times the 
MIC of each antibiotic. The day-to-day bacterial burdens with standard therapy and in the 
controls are shown in Figure 1A. The combination therapy killed at the low rate of -0.09 (95% 
confidence interval [CI], -0.04 to 0.03) log10 cfu/ml/day, to achieve 1.22 log10 cfu/ml kill on 
day 14 compared to the day 0 bacterial burden. After day 14, regrowth was observed. Thus, the 
combination regimen failed quickly, despite optimal exposures. The proportions of amikacin- 
and cefoxitin-resistant subpopulations to total population remained at a low level in the 
untreated control throughout the experiment, as shown in Figure 1B. However, in the systems 
exposed to combination therapy, the cefoxitin-resistant subpopulation increased considerably 
after day 14, while the amikacin resistant subpopulation proportion did not change (Figure 
1C). Clarithromycin resistance could not be reliably assessed because of inducible macrolide 
resistance in M. abscessus.10
The standard regimen tested failed to effectively kill M. abscessus in the 28-day evaluation in 
the HFS-M. abscessus model that mimicked lung disease. Cefoxitin seemed to be the driving 
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c.Figure 1. Efficacy of standard combination 
regimen against M. abscessus and resistance 
emergence during 1 month of treatment .
(A) The initial very slow decline, slower than the 
doubling time of the bacteria, was reversed after 
14 days and all treated systems started to grow.
(B) Changes in bacterial burden and the 
emergence of acquired drug resistance with time 
during repetitive sampling in non-treated controls. 
Total M. abscessus population in untreated 
control (solid line) and amikacin- or cefoxitin-
resistant subpopulation (dashed lines) over the 
course of 28 days. The amikacin- and cefoxitin-
resistant proportion was stable in the untreated 
control. (C) Changes in bacterial burden and the emergence of acquired drug resistance with time during 
repetitive sampling in systems treated with standard therapy. Starting with no cfu per milliliter resistant to 
3 times the cefoxitin MIC, there developed a higher cefoxitin-resistant subpopulation of M. abscessus in the 
systems exposed to standard therapy, coincident with cessation of effect of the triple regimen.
A B
M
. a
bs
ce
ssu
s l
og
10
 C
FU
/m
l
M
. a
bs
ce
ssu
s l
og
10
 C
FU
/m
l
M
. a
bs
ce
ssu
s l
og
10
 C
FU
/m
l
C
 129
C
ha
pt
er
 8
Failure of standard regimen to treat M. abscessus
force of the regimen, as the HFS-M. abscessus shows that while there was initial kill, this was 
abrogated by ADR to cefoxitin. In the nude mouse M. abscessus disseminated disease model, 
cefoxitin has played a key role as well, as the activity of the triple regimen was equal to that of 
cefoxitin alone.11 Mouse studies, while useful, however, do not allow for repetitive sampling 
that would allow for an assessment of the evolution of ADR with time in the same mouse. Even 
though the proportion of bacteria resistant to 3 times the MIC of amikacin did not change, the 
biphasic nature of response on the current amikacin-containing regimen suggests resistance 
as well, albeit with <3-fold increases in MIC. This type of low-level resistance, which rapidly 
emerges within days, has been shown to be due to evolutionarily conserved efflux pumps in 
mycobacteria that are part of the “antibiotic resistance arrow of time”.12,13
Even at above-optimal amikacin and cefoxitin exposures, the regimen still failed. The situation 
observed here resembles the poor outcome often faced when patients are treated with the 
standard combined regimen; if they tolerate it, they may initially respond, but in the end, many 
simply fail to respond at all, and some respond and then relapse. In other words, it is going 
nowhere fast. The propensity to develop multiple drug resistances quickly is in part why M. 
abscessus has been termed the “antibiotic resistance nightmare”.14 Since dosing to achieve 
greater-than-optimal exposure would not result in any greater effectiveness, the solution is a de 
novo building of new regimens that are more bactericidal and can suppress the emergence of 
ADR. One of the alternatives could be to use tigecycline as an anchor drug in such a regimen, 
which has been shown to be effective.15,16 However, tigecycline will need to be combined with 
other effective antibiotics, and the search for such antibiotics is ongoing.
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„the drugs don’t work, they just make you worse…“
(The Verve / Richard Ashcroft; Urban Hymns, 1997)
This thesis summarizes the results of studies performed in a preclinical development track, to 
understand the current treatment and to find new and more efficacious treatment regimens for 
nontuberculous mycobacterial pulmonary disease (NTM-PD), with focus on Mycobacterium 
abscessus. The outcome of NTM-PD treatment, particularly when caused by M. abscessus, is 
often poor.1-3 Many factors determine this outcome, including the immune status of the patient, 
age, co-morbidities, extent of disease, tolerance of the antibiotics and, of course, the efficacy 
of the antibiotics administered. The latter aspect is the focus of the research described in this 
thesis.
Four main issues can be inferred from our experimental work. First, the efficacy of most 
currently recommended antibiotics to treat NTM-PD is low. Second, clofazimine has a potential 
role as part of combination therapy against M. avium and M. abscessus. Third, tigecycline is 
bactericidal against M. abscessus and should be part of a new combination regimen to be tested. 
Fourth, β-lactam antibiotics are likely to be the driving force in the currently recommended 
treatment regimen for M. abscessus disease. With this new knowledge we hope to contribute to 
the understanding and improvement of NTM disease treatment, including the design of more 
effective treatment regimens for NTM-PD.
-New insights in antimicrobial susceptibilities of slowly growing NTM (SGM)
We standardized and performed static time-kill assays for several antibiotics, where we 
observed that all the key antibiotics tested had low activity (Chapter 3). Despite the low 
activity observed, the individual evaluation of antibiotics demonstrated that amikacin had 
the strongest killing effect against M. avium in the time-kill assays (Chapter 3), although 
regrowth was observed soon after the initial killing. 
Previous in vitro experiments showed complete sterilization when amikacin was used against 
M. avium.4 In vivo evaluations in the mouse model also showed remarkable activity, particularly 
when amikacin was combined with either rifabutin or clofazimine.5 The role of adjunctive 
streptomycin was the topic of one of the few randomized clinical trials in NTM-PD. The 
addition of streptomycin to a regimen of rifampicin, ethambutol, and clarithromycin for M. 
avium complex pulmonary disease (MAC-PD) led to a faster conversion to negative cultures, 
but little to no long-term benefits.6 Based hereupon, current guidelines only advocate the use of 
amikacin or streptomycin, early during therapy in patients with severe, mostly fibro-cavitary, 
MAC-PD.7 Our findings support this limited role and use.
Clarithromycin was also tested in our time-kill experiments against M. avium and M. xenopi; its 
effect was also low, particularly for M. avium. Killing took place even at relatively low multiples 
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of the MIC (0.125× MIC) and was hardly concentration dependent. When clarithromycin 
was previously evaluated against M. avium strain 101, in time-kill assays, both concentration 
and time dependent effect were described, and the effect observed was maximal at relatively 
high concentrations (256 mg/l).8 In vivo evidence from the Balb/c and nude mice model, also 
infected with M. avium 101 and treated with clarithromycin-containing regimens, led to the 
conclusion that clarithromycin was the most active antibiotic.9 Macrolides, i.e. clarithromycin 
and azithromycin, are considered the cornerstone for M. avium complex treatment, due to the 
activity observed in the early case series.10,11 However, much more remains to be deciphered 
about macrolides. We clearly observed regrowth after the initial killing by clarithromycin in 
time-kill assays, as well as for amikacin, and that occurred with both M. avium and M. xenopi. 
Therefore, we underline the important concept that macrolides should never be used alone 
in any treatment regimen for NTM; combination therapy should be the rule (Chapter 4).7
Fluoroquinolones have been suggested to play a role in the treatment of M. xenopi as a 
substitute for one of the core antibiotics, particularly the macrolide;7 a clinical trial comparing 
clarithromycin and moxifloxacin as adjuncts to rifampicin and ethambutol is currently under 
way (ClinicalTrials.gov Identifier NCT01298336). We also evaluated moxifloxacin in time-kill 
assays against M. xenopi; as with clarithromycin low moxifloxacin activity was observed and 
killing took a lot of time, but no significant difference was found on the effect obtained with the 
two antibiotics. This observation is in line with the in vivo characterization of drugs against M. 
xenopi in the mouse model, where no differences between clarithromycin- and moxifloxacin-
containing regimens were observed.12 Whether there is a benefit in including both macrolides 
and moxifloxacin in M. xenopi treatment regimens remains to be investigated.
The potential role of clofazimine in M. avium treatment
Previous in vitro evaluations by checkerboard titrations detected synergy between clofazimine 
and both amikacin and clarithromycin activity against several NTM,13-15 thus we moved one 
step further in time-kill experiments to evaluate the possible contribution of such combinations 
in the treatment of M. avium disease. Although the effect of clofazimine alone was mainly 
a concentration-dependent inhibition of growth, clofazimine-amikacin and clofazimine-
clarithromycin combinations prevented the regrowth observed when amikacin or 
clarithromycin were used alone against M. avium (Chapter 4). Synergy was found at specific 
concentrations and the regrowth observed in the systems exposed to single antibiotics was 
associated with mutational resistance to amikacin or clarithromycin in M. avium, evidenced by 
a change in the MIC of the corresponding antibiotic as well as by the occurrence of established 
resistance-conferring mutations in rrs and rrl genes.
In a recent study of 107 patients treated for M. avium complex pulmonary disease (MAC-PD) 
that were followed for a long term, a significantly higher proportion of patients treated with 
clofazimine-containing regimens converted to negative cultures compared to patients treated 
with rifampicin-containing regimens; in addition clofazimine was well tolerated by the majority 
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of patients.16 Another series of cases reported that regimens that include clofazimine were easier 
and less demanding to monitor.17 Treatment outcomes in the few available case series proved 
equal for clofazimine-ethambutol-macrolide and rifampicin-ethambutol-macrolide regimens 
(Chapter 1); a randomized controlled clinical trial comparing these two in MAC-PD is currently 
underway in our center (Eudra CT Register 2015-003786-28). However, much more remains 
to be unraveled about SGM disease treatment. Particularly for M. avium, for which a dynamic 
pharmacokinetic/pharmacodynamic hollow-fiber model is already available,18 there is a need 
to move forward into more research on currently recommended combination regimens as well 
as new regimens. 
-New insights in antimicrobial susceptibilities of rapid growing NTM (RGM)
Static models demonstrated the limited activity of most commonly used antibiotics 
against M. abscessus and M. fortuitum (Chapter 2); this fits well with the generally poor 
outcomes of treatment for NTM, particularly for M. abscessus disease. Here too, amikacin 
showed the strongest killing effect when evaluated against M. abscessus and M. fortuitum, 
but for these species, too, regrowth appeared soon. Time-kill assays performed by other groups, 
although only for 24 hours, evidenced lack of amikacin activity for M. abscessus.19 Based on 
in vitro assays with M. abscessus, others have proposed that the role of amikacin is to help to 
limit the spread of the mycobacteria from infected to uninfected macrophages.20 Treatment 
evaluation in a mouse model for M. abscessus disseminated disease, showed little activity of 
amikacin on the reduction of bacterial load in lungs, therefore the long term use of amikacin 
in the treatment of M. abscessus was questioned.21,22 The current treatment guidelines by the 
American Thoracic Society and Infectious Diseases Society of America (ATS/IDSA) state that 
amikacin, in combination with cefoxitin or imipenem, and a third agent like clarithromycin 
or other (according to the susceptibility profile), may help in controlling the symptoms and 
progression of M. abscessus pulmonary disease, but that is still considered a chronic incurable 
disease for the majority of patients.7
Cefoxitin also showed low activity in our experiments against M. abscessus and M. 
fortuitum, and its effect was very different for both RGM species evaluated (Chapter 2). For 
M. fortuitum, the effect was faster and stronger than for M. abscessus and it was concentration-
dependent, while for M. abscessus cefoxitin activity was slow and concordant with the expected 
time-dependent effect for a β-lactam antibiotic. So, genetically related NTM may differ widely 
in their response to antibiotic treatment; this observation is in line with clinical experiences. 
In opposition to the cefoxitin effect that we (Chapter 2) and others19 have observed in time-
kill assays, an in vitro and intra-macrophage activity evaluation of cefoxitin and imipenem 
indicated that both are active against M. abscessus, although imipenem´s activity might be 
superior to cefoxitin.23 In addition, an in vivo study in the nude mice model for M. abscessus 
disease found that cefoxitin was the most active drug in the currently recommended regimen 
to treat M. abscessus. The pivotal role of cefoxitin (or other β- lactams) in the treatment of M. 
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abscessus was also evident from our hollow-fiber model experiments, which will be presented 
later in this chapter.
The effect of clarithromycin was also low against M. abscessus, perhaps because of erm 
gene induction in M. abscessus 24 at lower concentrations; killing was only observed at higher 
concentrations (> 4× MIC), which is different to the clarithromycin-mediated kill observed for 
SGM; this may represent another example that findings from one NTM are not necessarily 
pertinent to all NTM species. Regrowth was also observed. In vitro information on the 
evaluation of M. abscessus treatment is scarce, but in vivo experiments in the nude mice model 
showed clarithromycin´s limited effect on M. abscessus: it prevented the death of the mice, but 
its impact on bacillary loads was limited.21
Despite erm gene associated inducible resistance in M. abscessus subspecies abscessus and 
some strains of M. abscessus subspecies bolletii, macrolides are still used in M. abscessus 
treatment; medical reasons support its use as well as some in vitro findings like those we 
will discuss below about the potentiality to stop the switch on of the erm gene by using other 
companion drugs like clofazimine.
A combination of two or three antibiotics, including a fluoroquinolone is recommended for 
M. fortuitum treatment, based on the in vitro susceptibility evaluation;7 therefore, we choose 
to evaluate moxifloxacin in our time-kill assays, finding moxifloxacin activity against M. 
fortuitum, particularly at concentration 2× MIC or higher. Because of high MICs (8 mg/l), we 
did not perform time-kill analyses of moxifloxacin against M. abscessus. 
The potential role of clofazimine in M. abscessus treatment
We also tested clofazimine-containing combinations to treat M. abscessus; here too, 
clofazimine-amikacin and clofazimine-clarithromycin, prevented the regrowth observed 
when amikacin or clarithromycin were used alone. However, opposite to what we observed 
for M. avium, neither changes in the MIC nor known mutations in rrs and rrl genes were 
found for M. abscessus when regrowth appeared in the systems exposed to either amikacin or 
clarithromycin. Adaptive resistance through modifications in cell wall permeability, inducible 
resistance mechanisms like transcriptional activators or the methylases blocking access to 
ribosomal targets, and the expression of efflux pumps has been associated in other mycobacteria 
with decrease susceptibility to antimicrobials;25,26 this may be also the case for M. abscessus, 
for which an erm gene has been identified, associated with inducible macrolide resistance.24 
Clofazimine seems to prevent the activation of such mechanisms. Here, it was evidenced that 
M. abscessus does not necessarily share the same mechanism associated with resistance to 
amikacin and clarithromycin in other NTM, e.g. M. avium. Information coming from RNA 
and DNA sequencing will help to clarify this theory, at least for amikacin. 
Although more evidence is needed, particularly for M. abscessus, ours and other researchers´ 
findings call for the future inclusion and evaluation of clofazimine in combination regimens 
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to treat both M. avium and M. abscessus disease. Treatment of M. abscessus infected mice 
with a combination of clofazimine and bedaquiline was effective in decreasing the burden of 
mycobacteria in the organs of the animals, including the lung.22 The exact mechanism of action 
of clofazimine is not entirely understood yet, but what is known is that its role in the electron 
transfer chain at the plasma membrane is related to that of bedaquiline, and both antibiotics have 
synergistic in vivo effect.22,27 In the search for better antibiotic alternatives for NTM treatment 
these two drugs may play an important role in the future.
-What does the hollow-fiber system model tell us about treatment of M. abscessus 
The hollow-fiber system model (HFS) is an in vitro dynamic pharmacokinetic/pharmacodynamic 
model used to mimic the in vivo conditions of varied antibiotic concentrations in human 
compartments over time and its effect against an infecting microorganism. The original HFS 
for mycobacteria was developed for M. tuberculosis and has shown high accuracy (94.4%) 
in forecasting optimal drug exposures, doses, and dosing schedules for clinical use when 
compared to clinical studies.28,29 Since M. abscessus is the most notorious causative agent 
of NTM-PD, this species was selected for the evaluation in the HFS. We standardized and 
used the HFS to evaluate single antibiotic exposures, first for amikacin, the key representative 
of M. abscessus treatment, then for moxifloxacin and tigecycline. Finally, we evaluated the 
guideline-recommended combination therapy of amikacin, cefoxitin and clarithromycin against 
M. abscessus.
Individual exposures
Amikacin showed minimal efficacy in the HFS (Chapter 5), which was considerably lower 
than the efficacy observed in static time-kill assays (Chapter 2). Regrowth was also observed, 
associated with the replacement of the total population by an amikacin-resistant subpopulation 
when exposed to higher doses (Chapter 5). These findings highlight a concern on the discrepant 
results from static vs. dynamic models for NTM, particularly for M. abscessus. While models 
of static concentrations suggested amikacin bactericidal activity, although maximal at 
2-4x MIC, they overestimated its efficacy compared to the HFS model.
Despite the toxicity associated with the use of aminoglycosides, amikacin is considered a key 
antibiotic in NTM therapy.7 However, findings from the nude and IFN-γ knockout (GKO) mice 
models for M. abscessus have shown limited activity of amikacin in lungs, consistent with our in 
vitro findings.21,22 We consider that the role of amikacin in M. abscessus pulmonary disease, 
in the current doses and by intravenous administration, needs to be reconsidered. Other 
investigators have proposed to minimize amikacin toxicity by alternating inhaled amikacin 
with parenteral amikacin, but the efficacy of this combination and dosing strategy remains 
to be determined.30 The analysis of the results of a recently completed clinical trial on the 
use of nebulized liposomal amikacin as an alternative for NTM treatment will provide useful 
information on the future use of this drug, although preliminary information have only shown 
promising results for MAC.31,32
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Moxifloxacin´s efficacy against some slowly growing mycobacteria, particularly M. 
tuberculosis and M. kansasii has been established in the past.33-35 Given this and the current role 
of moxifloxacin in the so called ´continuation phase´ of the treatment of M. abscessus, after the 
initial months of parenteral antibiotics, we also tested it in the HFS (Chapter 6). Surprisingly, 
even at high exposures in the HFS, moxifloxacin did not significantly reduce the M. 
abscessus population and resistance was found soon during monotherapy. Therefore, 
moxifloxacin´s performance does not encourage its continued use in the treatment of M. 
abscessus, unless a synergistic role with other agents is found in combination therapy. 
Based on the findings from HFS and Monte Carlo simulations new breakpoints for amikacin 
and moxifloxacin have been proposed (Chapter 5 and 6). The currently used breakpoints 
need to be reformulated to better correlate with antibiotic efficacy in dynamic models 
or with in vivo outcomes; many are now based on wild type MIC distributions only.36 One 
possible explanation for the poor correlation between in vitro tests and treatment outcomes in 
clinical practice 2 might be that most isolates may have been considered susceptible when they 
are actually resistant to the given doses of amikacin and moxifloxacin. 
The search for new therapeutic options against NTM, led us to use our HFS to test more 
options against M. abscessus. Tigecycline has previously demonstrated in vitro effect on RGM 
and its use in vivo was associated with improvement in 43% of patients who were treated for 
more than a month.37,38 When tigecycline was evaluated in the HFS model of pulmonary M. 
abscessus infection, we observed considerable microbial kill below the stasis line for the first 
time. Its killing exceeded what we previously found for amikacin or moxifloxacin. Tigecycline 
was highly efficacious and the magnitude of this efficacy means that it can be the first 
truly bactericidal antibiotic to be included in a regimen against M. abscessus (Chapter 
7). A dose of 200 mg/day achieved 1 log kill in close to 90% of patients in the Monte Carlo 
simulations, therefore we consider this the optimal dose. There is limited information on the 
effectiveness and safety of high doses of tigecycline; 200 mg/ day has been used and found 
to be more efficacious in combination regimens against other bacterial pathogens, although 
mainly in patients intensive care units, who have increased volumes of distribution.39Adverse 
effects associated with the use of tigecycline at such doses should be carefully considered. The 
use of anti-emetics is a common practice when administering tigecycline that can help with the 
adverse effects, 40 but candidates and strategies for treatment with tigecycline particularly at 
high-doses should be defined.
Regrowth was also observed after 10 days of tigecycline monotherapy in the HFS, but in 
the absence of changes in the MIC, we may have faced adaptive changes in M. abscessus. 
Anyhow, this is an area of particular attention for future research, since resistance to tigecycline 
is uncommon and it will be very interesting to decipher how M. abscessus can grow in the 
presence of tigecycline. Thinking on a better future for NTM treatment, aggressive combination 
regimens including tigecycline should be evaluated in M. abscessus pulmonary disease.
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Combination regimen
We used the HFS model to evaluate the performance and benchmark the standard regimen 
composed by amikacin, clarithromycin and cefoxitin (Chapter 8). Initial killing was observed 
and lasted 14 days, after which regrowth appeared. The standard combination regimen fails 
to kill M. abscessus after 28 days, even under optimal exposures for all the antibiotics. 
This situation resembles the poor outcome commonly observed when treating patients with 
the standard combination regimen: patients seem to respond at the beginning, but then fail or 
relapse. Even with customized treatment regimens, based on in vitro drug susceptibility testing, 
and adjunctive surgery, cure rates were only 57% in a well-documented series of 69 patients.2
Interestingly, the regrowth occurred at the same time an increase of cefoxitin-resistant 
subpopulation occurred. Bringing back the previous discussion, we consider that cefoxitin, or 
β-lactam antibiotics in general, are key drivers of the efficacy of M. abscessus treatment. 
This is in agreement with the in vivo evaluation of the standard combination regimen in the 
nude mice model, where cefoxitin was the only active agent.21 Whether cefoxitin or other 
β-lactam antibiotics will feature in new regimens remains to be determined. Different β-lactams 
and combinations with β-lactamase inhibitors should be tested in the HFS and in vivo first. For 
now, we advise to include them. 
-Designing a new regimen against M. abscessus
According to recent reports, bedaquiline may have some potential against M. abscessus and 
other NTM.22,41 In two different mouse models for M. abscessus disease, bedaquiline treatment 
during eight days reached significant reduction of the bacterial load in several organs, including 
lung. More importantly, when clofazimine was added to bedaquiline, the combination achieved 
more significant reduction in bacterial burden and resulted in less inflammation and cellular 
aggregates in major organs. The evaluation against M. avium showed bacteriostatic activity of 
bedaquiline in the mouse model; provided that bedaquiline’s safety profile was acceptable, it 
has been proposed as a good companion drug of clarithromycin in the combination regimen.42 
Bedaquiline-containing treatment regimens showed only a modest and temporary clinical 
response when it was included for at least 6 months as part of salvage therapy to treat 10 
patients with advanced and refractory lung disease by MAC or M. abscessus. Further studies of 
optimal combination regimens are required to determine the place and use of bedaquiline in the 
management of NTM-PD.41 However, the possible complications of this combination, such as 
cardiovascular safety and cross-resistance, will require further studies.
There is a growing interest on different β- lactams to treat mycobacteria23,43-47 and important 
information is being released. The question is: what is the optimal β-lactam antibiotic to treat 
M. abscessus disease and what is the role of β-lactamase inhibitors? The production of a broad 
spectrum β-lactamase (BlaMab) by M. abscessus was recently described, explaining why the in 
vivo activity of certain β-lactams can be limited when they are susceptible to the hydrolysis;44 
luckily that is not the case for cefoxitin, whose hydrolysis is extremely slow.44 β-lactamase 
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inhibitors have been also evaluated with the goal to reduce the effect of BlaMab.44 The new non-
β-lactam β-lactamase inhibitor avibactam proved most promising, in vitro, when combined with 
imipenem as well as the 5th generation cephalosporin ceftaroline.45,46 Nevertheless, the search 
and evaluation of active β-lactams and their combination with β-lactamase inhibitors continues, 
to provide better options for a new regimen. In fact, we have performed preliminary work with 
ceftaroline-avibactam in the HFS (manuscript in preparation), and it showed bactericidal effect 
against M. abscessus, but this needs further evaluation.
Considering all this information, if we would now have to propose a new regimen for M. 
abscessus, it would be the combination of tigecycline, clofazimine, liposomal amikacin, a 
macrolide and any active β-lactam, like ceftaroline with avibactam, cefoxitin, or imipenem; 
perhaps bedaquiline will also have a role in this combination.
-Knowledge gaps in regimen design 
Before we advance into regimen design, critical knowledge gaps need to be filled: completion 
of individual drug assessment, exploration of synergistic combinations, understanding of 
resistance mechanisms, etc. One of the important questions that need an answer is for example, 
is there tigecycline-clofazimine synergy? A preliminary report on the combined activity of 
clofazimine and tigecycline showed synergy in 42% of the 19 strains tested, and indifference 
in 10 strains;48 however, more studies and a better characterization of such potential synergism 
should be performed. On the other hand, other report on the combination of tigecycline 
with amikacin showed antagonism in >18% of each RGM species evaluated, including M. 
abscessus,49 that should be considered if amikacin will continue being part of the treatment as 
it is now (Figure 1). On the contrary, the combination of tigecycline and clarithromycin was 
synergistic in >90% of M. abscessus isolates,49 this also may indicate that macrolides could still 
have a role in the treatment of M. abscessus, even in the presence of a functional erm gene, as 
discussed above. Our in vitro findings with the combination of clofazimine and clarithromycin 
also support this.
-Other observations from the preclinical models
During the various experiments, several observations apart from the primary study endpoints 
were made. Some of these warrant mention as they may be interesting subjects of further study 
and may learn us more about NTM and their stress responses to antibiotic exposure. First, we 
observed morphological changes in colonies, associated with NTM exposure to amikacin in 
M. abscessus and M. fortuitum (Chapter 2). Perhaps the same phenomenon also took place in 
the series of experiments with M. avium, but the varied morphology common to this species 
prevented us to clearly determine it. Interestingly, changes in M. abscessus included the switch 
from smooth to rough phenotype in the colonies exposed to amikacin at concentrations 2× MIC 
or higher in time-kill assays, or to doses greater than the standard daily dose in the HFS (data 
not shown). The switch in morphology type in M. abscessus has been considered a selective 
Discussion, conclusions and future steps
143
Chapter 9
C
ha
pt
er
 9
advantage that is linked in vitro to loss of glycopeptidolipid in the cell wall and increased 
pathogenicity, while in patients it occurs with the change from acute to chronic infection, linked 
to clinical deterioration.50,51 Other studies have detected that sub-inhibitory concentrations of 
amikacin produce changes in M. abscessus colony morphology, associated with increased 
adherence, aggregation and resistance to phagocytosis, besides an increased stimulation of 
macrophages with the accompanying severity of lung inflammation.52 Whether the changes 
in morphology we observed were part of adaptive response of M. abscessus in the presence 
of amikacin, decoded into the expression of this virulence factor, is a question that needs to 
be answered in the future. Regrowth after initial amikacin killing was observed with all the 
NTM species, but known mutations in rrs gene,53 associated with resistance to aminoglycosides 
in mycobacteria were only demonstrated in M. avium (Chapter 4). In the absence of known 
mutations in the rrs gene, we hypothesize that adaptive changes, such as over expression of 
aminoglycoside modifying enzymes,19,54 are behind the regrowth observed in M. abscessus 
experiments. To further understand the phenomenon of amikacin resistance and the mechanism 
responsible for this phenomenon in M. abscessus, RNA and DNA samples from the HFS 
experiments are being sequenced. 
Second, the lowest antibiotic effect was found for M. abscessus within RGM and for M. avium 
within SGM; interestingly those two species reached higher growth levels in the untreated 
controls (up to 1010 - 1011 cfu/ml) than the others. The consistently high growth levels may, 
to a degree, explain why the observed effect of the antibiotics was lower for M. abscessus 
and M. avium. If the number of logs cfu kill over time is fixed per drug and concentration, the 
killing will appear less prominent in species that can grow to high bacterial loads. As additional 
Figure 1. Synergy and antagonism against M. abscessus in vitro. Green arrows correspond to synergy; red 
arrows correspond to antagonism observed; Question marks reflects that interactions are not well studied yet.
CLOFAZIMINE
AMIKACIN
(inhaled liposomal) BEDAQUILINE
Beta-LACTAM/
AVIBACTAM TIGECYCLINE
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evidence, also high growth for M. abscessus (up to 1012 cfu/ml) was observed in the assays 
performed in the HFS (Chapter 5), despite the differences in the culture conditions compared 
to time-kill assays. Other reports on time-kill assays have also shown high growth, like we 
observed, for M. abscessus or M. avium.8,55 Whether the ability of NTM to replicate in vitro 
and reach high loads is related to their ability to replicate in the host lungs,56 translated into 
virulence and antibiotic resistance, is an issue that will require further study.
Third, when standardizing HFS experiments with M. abscessus, a green/blue pigmentation 
and bacterial aggregates were observed in polysulphone hollow-fiber cartridges, permanently 
bathed in cation-adjusted Mueller Hinton broth. Subculture of bacteria taken from the model 
still produced this pigment, visible as a black discoloration of Columbia sheep blood agar. The 
chemical structure of this pigment is currently under investigation. Are both conditions, the 
pigment and the aggregates (associated with biofilms)57 induced in M. abscessus a response 
that resembles the pathogenicity needed to invade and persist in human lungs? This is another 
question that surely deserves future research in the field of host-pathogen interaction, with 
possible effect for M. abscessus treatment.
Finally, we observed that clumping of M. xenopi was related, in our experiments, to the bacterial 
load. When we started the growth curves and time-kill kinetic experiments with a low bacterial 
load, despite incubation under shaking conditions, clumping was observed during the first 
sampling days, also in the plates that were used to enumerate the cfu/ml of bacteria. However, 
when cultures reached higher loads, clumps were less evident and suspensions turned more 
even, as well as the distribution of cfu on plates. Is this due to the activation of quorum sensing 
in M. xenopi? Since quorum sensing is a mode of cell to-cell communication amongst bacteria, 
partly related with virulence factors, some researchers have questioned if it can become an 
important target for controlling the spread of antibiotic resistant bacteria.58 Whether what we 
observed is quorum sensing, possibly related to M. xenopi virulence, will be also be a subject 
for future research.
-Limitations of the preclinical models
We have detected several limitations in the work we conducted within this thesis. First, the 
experiments were performed only with the NTM type strains; mainly because of the costs 
associated with the extensive evaluations performed, we could not include other strains. Ideally 
clinical isolates should be part of further evaluations and validation of findings. Second, our 
experiments only represent an evaluation of the extracellular infection. Although mycobacteria 
are both extracellular and intracellular pathogens, we prioritized the extracellular evaluation, 
with the idea of a posterior validation of the main and most relevant findings in the intracellular 
environment. In addition, for M. abscessus for example, there is scarce information on the 
proportion of bacteria in the extra or intracellular location in lungs, neither on the different 
oxygen conditions or metabolic states. More fundamental studies into these aspects will benefit 
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therapy simulations. Third, none of our models took into account the role of the immune 
system in the treatment of NTM and here too, future experimental conditions considering 
these variables will provide useful information for the treatment. Fourth, a detailed study of 
resistance mechanisms to amikacin, moxifloxacin and tigecycline was out of the reach of our 
work. However, we took samples from the HFS for future analysis. Hopefully, whole genome 
sequencing and RNA sequencing will provide interesting information on this matter. Fifth, 
there is limited information on the pharmacokinetics of some antibiotics used in the treatment 
of NTM infected patients, particularly on pharmacokinetics at the site of infection. Such data 
are needed to improve infection and treatment simulations in dynamic models.
-Bridging this thesis to other worlds...
In The Netherlands and Europe in general, as well as in the USA and other developed countries, 
there is more awareness of the big challenge NTM-PD and their treatment represents. Where I 
come from, Colombia, and in many other developing countries the situation can be different. It 
was previously conceived that NTM were not really a problem in countries where tuberculosis 
(TB) transmission was an issue, and that NTM and TB were in opposite proportions in several 
settings. However, how much of the patients diagnosed with TB actually have NTM-PD? What 
is the incidence of NTM in our countries? Are developing countries prepared to diagnose and 
treat NTM disease? Those are questions with not answered yet.
In a group of 106 patients with pulmonary TB from Cali, Colombia, recruited in 2005-2006 
to participate in a clinical trial, one patient was initially diagnosed as having TB by clinical 
symptoms and direct smear, but the disease was actually NTM-produced.59 M. kansasii was 
detected, but it happened after months of TB treatment, when solid cultures were positive and 
we exhausted the available tools to identify the strain. Later we found in the same city two more 
patients that were part of the local TB programme, and were facing the same fate. After years 
of being treated for TB and recurrent TB, finally a diagnosis of MAC-PD in one patient and M. 
simiae in the other was made.60 Unfortunately, to decipher that the infection and disease is not 
TB but NTM-produced is not necessarily good news for the patients, but somehow changed 
their lives. These are only examples of what can happen when the protocols for pulmonary TB 
diagnosis have only little room and resources for other mycobacteria producing pulmonary 
disease. There is scarce data on NTM-PD in Colombia, the available information comes from 
TB surveillance performed by the Colombian National Institute of Health (INS), and for 
NTM in general is mainly associated to few outbreaks due to RGM after cosmetic surgery.61,62 
As recently suggested the efforts in developing new treatments and diagnostics for TB can 
be harnessed in the fight against NTM-associated diseases.63 We need to face the growing 
significance of NTM infections and the great challenge that their treatment represents. A global 
picture of the epidemiology of this new treat is needed as much as we need to gather work and 
information from different settings in the world. NTM are for sure present in every scenery, if 
we forget of them, they will not forgive us...
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The focus of this thesis was to investigate the pharmacodynamic foundation of current treatment 
regimens for nontuberculous mycobacterial pulmonary disease (NTM-PD); next, we searched 
for new and more efficacious treatment regimens, with focus on Mycobacterium abscessus.
In Chapter 1 we present a general introduction that provides the background for the study. 
We briefly introduce the reader to the NTM-PD, explaining the main clinical presentations 
and radiological findings. Then, we focused on the treatment of NTM-PD, showing the 
evidence that supports the currently recommended treatment regimens for Mycobacterium 
avium complex and Mycobacterium abscessus disease. The second part of the chapter shifts to 
the evidence that has been provided by preclinical studies, both in vitro and in vivo, through 
different assays and models. Finally, we present the aim of the thesis that is to assess the 
pharmacodynamics of commonly used drugs to treat NTM disease by means of the time–kill 
kinetic assays and the development of a pharmacodynamic model on basis of the in vitro 
hollow fiber system.
In Chapter 2, the results of time-kill kinetics of antibiotics against rapidly growing mycobacteria 
(RGM) are presented. We tested amikacin and cefoxitin against M. abscessus and M. fortuitum, 
clarithromycin only against M. abscessus, and moxifloxacin and linezolid only against M. 
fortuitum. Although amikacin was the most active antibiotic, in general, all antibiotics showed 
low activity, reminiscent of the poor outcome observed in patients with RGM-pulmonary 
disease, particularly when produced by M. abscessus. Regrowth of the mycobacteria after 
several days of exposure was prominent for all tested antibiotics, suggestive of the emergence 
of resistance or tolerance.
In Chapter 3, the outcome of the evaluation of antibiotics against slowly growing mycobacteria 
(SGM) common in pulmonary disease is exposed. As we had observed for RGM, the key 
antibiotics tested against M. avium and M. xenopi also had low activity in time-kill assays. 
Amikacin had the strongest killing capacity against M. avium, supporting its role in a combined 
therapy. For M. xenopi, clarithromycin and moxifloxacin proved equally efficacious, indicating 
that both antibiotics may have identical activity within treatment regimens and that perhaps 
both should be part of treatment regimens.
Both chapter 2 and 3 pointed out that -given the low activity of single drugs- the evaluation of 
antibiotic combinations or combined regimens should be the next step in our study, therefore 
within Chapter 4, we assessed the activity of clofazimine and the activity of the combinations 
of clofazimine-amikacin and clofazimine-clarithromycin against M. abscessus and M. avium, 
by time-kill assays. For both species, clofazimine alone was inactive, but it prevented the 
regrowth observed when amikacin or clarithromycin were used alone, suggesting a potential 
adjunctive role for clofazimine in treatment regimens.
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Moving forward into the direction of performing dynamic pharmacokinetic/pharmacodynamic 
(PK/PD) evaluations, which are more representative of the in vivo situation, Chapter 5 
details on the standardization and development of the hollow-fiber system model (HFS) 
for M. abscessus pulmonary disease. Amikacin, the most active antibiotic in static models 
(Chapter 2 and 3), was chosen for this initial PK/PD evaluation; however, minimal efficacy 
was demonstrated in the HFS. Both microbial kill and the acquisition of drug resistance were 
linked to the peak concentration-to-MIC ratio (Cmax/MIC). The peak/MIC ratio associated with 
80% of the maximal kill (EC80) was 3.20; EC80 is considered the optimal exposure. In Monte 
Carlo simulations, the highest of the standard amikacin dose, 1,500 mg a day, achieved the 
EC80 in less than 21% of the patients, therefore the use of intravenous amikacin in the current 
dose needs to be revisited.
Given the urgent need to find better treatment options for M. abscessus disease, further 
experiments were performed in the HFS. In Chapter 6, the evaluation of moxifloxacin is 
presented. The EC80 was an area under the concentration-time curve (AUC) AUC0–24/MIC ratio 
of 102.11, however, no moxifloxacin concentration killed M. abscessus to bacterial loads below 
the starting inoculum; besides, regrowth was observed after day 3 with all doses. Monte Carlo 
simulations revealed that doses of 400 to 800 mg/day would achieve or exceed the EC80 in 
<12.5% of patients. A moxifloxacin PK/PD susceptibility breakpoint of 0.25 mg/l is proposed, 
which means that almost all M. abscessus clinical isolates should be considered resistant. 
Despite moxifloxacin´s poor efficacy as monotherapy, formal combination therapy studies 
with moxifloxacin still need to be performed in the HFS-M. abscessus to explore potential 
synergy with other agents, before definite recommendations can be made to remove it from 
current regimens. In Chapter 7, we aimed to perform a dose-response study with tigecycline to 
identify its efficacy and determine optimal doses for the treatment of M. abscessus pulmonary 
disease. For the first time in the HFS-M. abscessus model, a drug exhibited a considerable 
microbial kill below the stasis line, exceeding what has been previously observed for amikacin 
or moxifloxacin. The AUC/MIC ratio required to attain the EC80 was 36.65; Monte Carlo 
simulation experiments with 10,000 patients identified that the optimal tigecycline clinical dose 
for adults is 200 mg/day. Since tigecycline proved bactericidal against M. abscessus, it should 
be considered as a first-line agent early during therapy and as a backbone for new combination 
regimens. However, tigecycline is known to cause severe adverse events and its clinical use 
should be cautious, until its safety and efficacy have been established in clinical trials.
Clinicians treat M. abscessus pulmonary disease with a combination of amikacin, clarithromycin 
and either cefoxitin or imipenem, that is the guideline-recommended combination regimen for 
the initial phase of treatment. In Chapter 8 we evaluate the performance of this combination 
regimen in the HFS-M. abscessus, to determine whether there is synergy or prevention of the 
drug resistance observed with single drug exposures. At optimal doses, there was initial kill 
during the first 14 days, but then there was regrowth due to acquired resistance; the standard 
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combination regimen failed after 28 days of evaluation. Cefoxitin seemed to be the driving 
force of this regimen since acquired resistance to cefoxitin abrogated the initial kill. The 
situation observed here resembles the poor long-term outcomes often faced when patients are 
treated with the standard combination regimen.
Finally, Chapter 9 presents the discussion of the main findings, conclusions and future steps. 
Four main issues can be inferred from our experimental work. First, the efficacy of most 
currently recommended antibiotics to treat NTM-PD is low. Second, clofazimine has a potential 
role as part of combination therapy against M. avium and M. abscessus. Third, tigecycline is 
bactericidal against M. abscessus and should be part of a new combination regimen to be tested. 
Fourth, β-lactam antibiotics are likely to be the driving force in the currently recommended 
treatment regimen for M. abscessus disease. Based on our and others’ in vitro findings as well 
as recent clinical information, we propose a combination of tigecycline, clofazimine, liposomal 
amikacin, a macrolide and an active β-lactam antibiotic, like ceftaroline with avibactam, 
cefoxitin, or imipenem as a new regimen to treat M. abscessus disease.
With this new knowledge we hope to contribute to the understanding and improvement of NTM 
disease treatment, including the design of more effective treatment regimens for NTM-PD. 
Critical gaps still need to be filled and these include completion of individual drug assessment, 
exploration of synergistic combinations and understanding of -and influencing- resistance 
mechanisms for all drugs with established or supposed potential in NTM treatment.
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Het doel van dit proefschrift was om de farmacodynamiek van belangrijke antibiotica in 
de huidige behandeling van niet-tuberculeuze mycobacteriële longinfecties (NTM-PD) te 
onderzoeken. Tegelijkertijd evalueerden we nieuwe en mogelijk effectievere behandelingen, 
met name voor Mycobacterium abscessus infecties.
In hoofdstuk 1 geven we een algemene inleiding die de achtergrond voor onze studies 
beschrijft. We introduceren eerst de klinische en radiologische manifestaties van NTM-PD. 
Daarna worden de huidige behandelingen voor NTM-PD en de gegevens waarop deze zijn 
gebaseerd besproken, met de focus op ziekte die veroorzaakt wordt door Mycobacterium avium 
complex en Mycobacterium abscessus. In het tweede deel van het hoofdstuk beschrijven we de 
resultaten van preklinische studies, zowel in vitro als in vivo uitgevoerd, met de verschillende 
testplatforms en modellen. Ten slotte stellen we het doel van deze thesis vast: het evalueren 
van de farmacodynamiek van belangrijke antibiotica die gebruikt worden in de behandeling 
van NTM-PD, door het uitvoeren van time-kill kinetiek testen en het opzetten van een Hollow 
Fiber farmacodynamisch model (hollow fiber model; HFM) om therapie van M. abscessus 
longinfecties te simuleren.
In hoofdstuk 2 presenteren wij de resultaten van de time-kill kinetiek testen van de 
belangrijkste antibiotica gebruikt voor infecties door snel groeiende mycobacteriën (rapid 
growing mycobacteria; RGM). We testten de werkzaamheid van amikacine en cefoxitine tegen 
M. abscessus en M. fortuitum, claritromycine tegen M. abscessus en moxifloxacine en linezolid 
tegen M. fortuitum. Amikacine was het meest effectieve antibioticum, maar alle geteste 
antibiotica vertoonden lage activiteit, passend bij de slechte uitkomst van therapie bij patiënten 
met RGM-longziekte, met name veroorzaakt door M. abscessus. Na enkele dagen blootstelling 
groeiden de mycobacteriën doorgaans weer uit, passend bij het opkomen van resistentie of 
tolerantie.
In hoofdstuk 3 evalueerden we de effectiviteit van de meest gebruikte antibiotica tegen langzaam 
groeiende mycobacteriën (slow growing mycobacteria; SGM). Zoals wij al hadden vastgesteld 
voor RGM, hadden de belangrijkste antibiotica waarvan de werkzaamheid getest werd tegen M. 
avium en M. xenopi, wederom een lage activiteit in time-kill testen. Amikacine had het sterkste 
effect tegen M. avium en dit middel heeft dus mogelijk een plaats in combinatietherapieën voor 
M. avium infecties. Claritromycine en moxifloxacine waren even effectief tegen M. xenopi; 
beide antibiotica kunnen een rol spelen in behandelregimes, eventueel in combinatie.
Hoofdstuk 2 en 3 toonden -met de beperkte activiteit van individuele antibiotica- het belang 
van therapie met meerdere antibiotica aan en dus ook de noodzakelijkheid van in vitro 
evaluatie van combinaties van antibiotica. De volgende stap in ons onderzoek was derhalve 
het onderzoeken, in hoofdstuk 4, van de individuele activiteit van clofazimine, maar ook van 
de combinaties clofazimine-amikacine en clofazimine-claritromycine tegen M. abscessus en 
M. avium, wederom middels time-kill testen. Clofazimine was niet erg actief tegen deze beide 
species, maar het verhinderde wel de uitgroei die werd waargenomen wanneer amikacine of Sa
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claritromycine afzonderlijk werden getest. Dit suggereert een mogelijke potentiërende rol voor 
clofazimine in de antibiotische behandeling van M. avium en M. abscessus infecties.
De volgende stap was het uitvoeren van farmacokinetiek/farmacodynamiek (PK/PD) evaluaties, 
die representatiever zijn voor de in vivo situatie. Hoofdstuk 5 beschrijft de ontwikkeling en 
standaardisatie van een Hollow Fiber model (HFM) voor M. abscessus longziekte. Amikacine, 
dat als het effectiefste antibioticum uit de statische modellen naar voren kwam, (Hoofdstuk 2 
en 3) werd gekozen voor deze eerste PK/PD evaluatie. In het HFM met M. abscessus werd 
echter een minimale werkzaamheid aangetoond in klinisch haalbare doseringen. Zowel 
het bacteriedodend effect als het verwerven van resistentie bleken gerelateerd te zijn aan de 
verhouding van de piekconcentratie en minimaal remmende concentratie (MIC)(Cmax/MIC). De 
verhouding die 80% van het maximale bacteriedodend effect (EC80) opleverde was een Cmax/
MIC ratio van 3,20. Met Monte Carlo simulaties toonden wij aan dat de standaard amikacine 
doses van 750 tot 1500 mg eenmaal daags de EC80 werd bereikt in minder dan 21% van de 
patiënten. Gezien dit beperkte effect dient de plaats en het gebruik van intraveneuze amikacine 
in behandelregimes voor M. abscessus infecties te worden herzien.
De resultaten van antibiotische behandeling van M. abscessus longinfecties zijn bedroevend 
te noemen. Om dit falen te begrijpen en om nieuwe behandelopties te verkennen, voerden 
wij verdere experimenten in het HFM met M. abscessus uit. In hoofdstuk 6 beschrijven 
wij de evaluatie van moxifloxacine, een middel dat veel wordt gebruikt in de M. abscessus 
behandeling. De EC80 was een oppervlak onder de tijd-concentratie curve: MIC (AUC0-24/
MIC) verhouding van 102,11. Geen enkele van de geteste moxifloxacine doseringen kon het 
aantal M. abscessus bacteriën terugbrengen tot onder het initiële inoculum. Bovendien werd 
bij alle doseringen uitgroei waargenomen na dag 3, passend bij het opkomen van resistentie 
of tolerantie. Monte Carlo simulaties lieten zien dat doses van 400-800 mg/dag bij minder 
dan 12,5% van de patiënten zou leiden tot het halen of overstijgen van de EC80. De rol van 
moxifloxacine lijkt dus zeer beperkt. Op basis van deze PK/PD analyse stelden wij een MIC 
breekpunt voor resistentie voor moxifloxacine vast van 0,25 mg/l. Gezien de normale MIC 
verdeling moeten vrijwel alle klinische M. abscessus stammen als resistent beschouwd 
worden. Om eventueel synergistisch potentieel van moxifloxacine te onderzoeken dient nog 
wel de combinatietherapie onderzocht te worden, uitgevoerd in het HFM met M. abscessus. 
In hoofdstuk 7 hebben we de werkzaamheid en optimale dosering van tigecycline voor de 
behandeling van M. abscessus longinfecties onderzocht. Tigecycline bleek het eerste middel 
dat in het HFM met M. abscessus bactericide was en het aantal M. abscessus bacteriën kon 
reduceren tot onder het initiële inoculum, de zogenaamde stasis lijn. De EC80 werd bereikt 
bij een AUC/MIC ratio van 36,65; Monte Carlo experimenten met 10.000 patiënten toonden 
aan dat de optimale tigecycline dosis 200 mg/dag is; het dubbele van de huidige dosis. 
Aangezien tigecycline bactericide bleek tegen M. abscessus, lijkt het een plek te verdienen 
in behandelregimes, zeker in de initiële fase van behandeling. Gezien de aanzienlijke 
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bijwerkingen van tigecycline dient dit echter met voorzichtigheid te gebeuren en bij voorkeur 
pas na bevestiging van veiligheid en effectiviteit in klinische studies.
Richtlijnen voor de behandeling van M. abscessus longinfecties adviseren momenteel een 
combinatieregime van amikacine, claritromycine en cefoxitine of imipenem. In Hoofdstuk 
8 evalueren wij van de effectiviteit van die standaard combinatiebehandeling van amikacine, 
claritromycine en cefoxitine, om te bepalen of deze combinatie synergistisch is en of deze 
resistentievorming, zoals steeds geobserveerd in de monotherapie experimenten, voorkomt. Bij 
optimale dosering, was er een duidelijke bactericide werking tijdens de eerste 14 dagen, maar 
in de daaropvolgende 14 dagen trad weer uitgroei op, als gevolg van verworven resistentie. 
Cefoxitine leek de drijvende kracht achter dit combinatieregime, aangezien de uitgroei pas 
optrad bij het opkomen van verworven resistentie tegen cefoxitine. Deze observatie is goed te 
rijmen met klinische observaties; als patiënten de intensieve therapie tolereren, laten zij vaak 
initieel een microbiologische respons zien. Helaas wordt in latere stadia van behandeling toch 
vaak terugkeer van ziekte gezien. Een nieuw regime is dus hard nodig.
Hoofdstuk 9 is de afsluitende bespreking van de belangrijkste bevindingen, conclusies en 
toekomstige stappen. Vier belangrijke bevindingen kunnen worden afgeleid uit ons experimentele 
werk. Ten eerste, de effectiviteitvan de meeste antibiotica die gebruikt worden in de behandeling 
van NTM-PD is laag. Ten tweede, clofazimine heeft een mogelijke potentiërende rol binnen 
combinatieregimes tegen M. avium en M. abscessus. Ten derde, tigecycline is bactericide tegen 
M. abscessus en zou deel uit kunnen maken van nieuw te ontwerpen combinatieregimes. Ten 
vierde, β-lactam antibiotica (cefoxitine, imipenem) zijn waarschijnlijk de drijvende kracht 
achter het momenteel aanbevolen behandelregime voor M. abscessus infecties. Op basis van 
onze in vitro bevindingen en die van anderen, maar ook van recente klinische studies, stellen 
wij een nieuw regime voor van tigecycline, clofazimine, liposomale amikacine, een macrolide 
en een β-lactam antibioticum, zoals ceftaroline met avibactam, cefoxitine of imipenem, voor 
behandeling van M. abscessus infecties. 
Met deze nieuwe kennis hopen we bij te dragen aan het begrip en het verbeteren van de 
behandeling van NTM infecties, met name het ontwerpen van effectievere behandelingen voor 
NTM longinfecties. Er zijn echter nog vele hiaten in onze kennis op te vullen, te beginnen bij 
de voltooiing van de evaluatie van alle individuele antibiotica die een bijdrage kunnen leveren 
in de behandeling van NTM infecties, het verder verkennen van synergistische combinaties, 
en het vergroten van onze kennis van resistentie mechanismen in NTM en de beïnvloeding 
hiervan.
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El enfoque de esta tesis fue el de investigar los fundamentos farmacodinámicos del tratamiento 
actual de la enfermedad pulmonar por micobacterias no tuberculosas (NTM-PD); posteriormente 
también buscamos y evaluamos nuevos y más eficaces regímenes de tratamiento, con particular 
interés en el tratamiento de Mycobacterium abscessus.
En el capítulo 1 se presenta una introducción general que proporciona las bases del estudio. 
Se hace una breve introducción al lector sobre NTM-PD, en la cual se incluye información 
sobre las principales presentaciones clínicas y los hallazgos radiológicos. Posteriormente, el 
capítulo se centra en el tratamiento de la NTM-PD, y se presenta la evidencia que soporta 
los actuales regímenes de tratamiento para la enfermedad producida por Mycobacterium 
avium y Mycobacterium abscessus. En la segunda parte, se vira hacia la evidencia que los 
estudios pre-clínicos, tanto in vitro como in vivo, han proporcionado a través de diferentes 
ensayos y modelos. Por último, se presenta el objetivo general de la tesis, que es evaluar la 
farmacodinámica de los antibióticos comúnmente utilizados para tratar la NTM-PD, por medio 
de ensayos cinéticos de tiempo-muerte, y el desarrollo de un modelo farmacodinámico in vitro, 
basado en el sistema de fibra hueca.
En el capítulo 2, se exponen los resultados de los ensayos de cinética de tiempo-muerte de 
los antibióticos contra las micobacterias de crecimiento rápido (RGM). Se evaluó amikacina y 
cefoxitina contra dos especies: M. abscessus y M. fortuitum, también se evaluó claritromicina 
contra M. abscessus, y moxifloxacina y linezolid contra M. fortuitum. Aunque amikacina fue 
el antibiótico más activo, en general los antibióticos mostraron una baja actividad, lo que 
concuerda con la mala respuesta clínica observada en los pacientes con enfermedad pulmonar 
producida por RGM, especialmente por M. abscessus. Con todos los antibióticos evaluados se 
observó re-crecimiento de las micobacterias, luego de varios días de exposición, lo cual sugiere 
la aparición de resistencia o tolerancia.
En el capítulo 3, se presenta el resultado de la evaluación de los antibióticos contra 
micobacterias de crecimiento lento (SGM) comunes en la enfermedad pulmonar. Como se 
mencionó anteriormente para RGM, los antibióticos clave evaluados contra M. avium y M. 
xenopi también mostraron una baja actividad en ensayos cinéticos de tiempo-muerte. Amikacina 
mostró actividad bactericida contra M. avium, lo cual soporta su rol en una terapia combinada. 
Para M. xenopi, claritromicina y moxifloxacina no mostraron diferencia en el efecto, lo que 
indica que ambos antibióticos podrían tener una actividad equivalente dentro de los regímenes 
de tratamiento; tal vez ambos antibióticos deben ser parte del régimen de tratamiento.
En los capítulos 2 y 3 se señala que la evaluación de las combinaciones de antibióticos o 
regímenes combinados debería ser el siguiente paso en nuestro estudio, dada la baja actividad 
observada en la evaluación individual de los antibióticos; por lo tanto, en el capítulo 4, se 
evaluó la actividad de la clofazimina y la actividad de las combinaciones de clofazimina- R
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amikacina y clofazimina-claritromicina frente a M. avium y M. abscessus, mediante ensayos 
cinéticos de tiempo-muerte. Para ambas especies, clofazimina no fue muy activo, pero evitó el 
re-crecimiento observado cuando amikacina o claritromicina se utilizaron solos, lo que sugiere 
un posible papel de clofazimina como coadyuvante en los regímenes de tratamiento.
Avanzando en la dirección de realizar evaluaciones más representativas de la situación in vivo, 
el capítulo 5 muestra la estandarización y el desarrollo de un modelo dinámico farmacocinético/
farmacodinámico (PK/PD): el sistema de fibra hueca (HFS) para la enfermedad pulmonar 
producida por M. abscessus. Amikacina, el antibiótico más activo en los modelos estáticos 
(capítulo 2 y 3), fue elegido para esta evaluación inicial de PK/PD; sin embargo, demostró 
mínima eficacia en el HFS. Tanto la muerte microbiana como la adquisición de resistencia a 
los medicamentos se asociaron con la relación entre el pico o concentración máxima (Cmax) y 
el MIC: Cmax/MIC. La relación Cmax/MIC asociada con el 80% del efecto máximo (EC80) fue 
3.20; Se considera que el EC80 es la exposición ideal. En simulaciones de Monte Carlo, la dosis 
estándar más alta de amikacina, 1500 mg/día, logró el EC80 en menos del 21% de los pacientes, 
por lo tanto, el uso intravenoso de amikacin a la dosis utilizada actualmente, debe ser revisado.
Dada la urgente necesidad de probar diferentes antibióticos y encontrar mejores opciones contra 
M. abscessus, más experimentos se llevaron a cabo en el HFS. En el capítulo 6 se presenta 
la evaluación de moxifloxacina. El EC80 fue una relación del área bajo la curva (AUC0-24)
con MIC: AUC0-24/MIC de 102.11; sin embargo, moxifloxacina a ninguna concentración logró 
matar a M. abscessus a niveles por debajo del inoculo de partida; adicionalmente, se observó 
re-crecimiento después del tercer día. Las simulaciones de Monte Carlo revelaron que dosis 
de moxifloxacina de 400 a 800 mg/día lograrían superar el EC80 solo en menos del 12.5% de 
los pacientes. Se propuso un punto de corte de susceptibilidad para moxifloxacina de 0.25 
mg/l, lo que se traduce en que casi la totalidad de las cepas clínicas de M. abscessus deberían 
ser consideradas resistentes. A pesar de que en nuestros experimentos se observó poca eficacia 
de moxifloxacina, antes de hacer recomendaciones definitivas acerca de la exclusión de este 
antibiótico de los regímenes actuales, su potencial de sinergia con otros agentes debe ser 
evaluada en estudios de terapia combinada contra M. abscessus. El capítulo 7 tuvo como 
objetivo identificar la eficacia de tigeciclina y evaluar en un estudio de dosis-respuesta las 
dosis óptimas para el tratamiento de la enfermedad pulmonar producida por M. abscessus. 
Por primera vez en el modelo HFS, un antibiótico mostró producir una considerable muerte 
microbiana, por debajo de la línea de estasis, lo cual es superior a lo observado previamente 
con amikacina y moxifloxacina. La relación AUC/MIC necesaria para obtener el EC80 fue 
36.65. Las simulaciones de Monte Carlo con 10,000 pacientes identificaron que la dosis 
clínica óptima de tigeciclina es de 200 mg/día. Dado que la tigeciclina mostró ser bactericida 
contra M. abscessus, se debe considerar como un agente de primera línea al comienzo del 
tratamiento, jugando un papel fundamental en los nuevos regímenes combinados. Sin 
embargo, es bien sabido que la tigeciclina puede producir reacciones adversas severas, por lo 
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que su uso clínico debe ser cauteloso, hasta tanto su seguridad y eficacia haya sido establecida 
en ensayos clínicos.
La enfermedad pulmonar producida por M. abscessus se trata generalmente con una combinación 
de amikacina, claritromicina y, cefoxitina o imipenem, lo cual constituye el régimen combinado 
estándar, recomendado para la fase inicial de tratamiento en las guías de expertos. En el capítulo 
8 se muestra la evaluación de dicho régimen, de amikacina, claritromicina y cefoxitina, con el 
fin de determinar si estos antibióticos exhiben potencial de sinergia y previenen la resistencia a 
los medicamentos que se observa con las exposiciones individuales. A dosis óptimas, durante 
los primeros 14 días hubo destrucción inicial de las micobacterias, pero luego se observó re-
crecimiento debido a resistencia adquirida; el régimen de combinación estándar falló después 
de 28 días de evaluación. La cefoxitina parece ser la fuerza impulsadora de este régimen, ya 
que la resistencia adquirida a cefoxitina abrogó la matanza inicial. Esta situación se asemeja a 
la mala evolución que a menudo se observa cuando los pacientes son tratados con el régimen 
combinado estándar: si lo toleran, pueden responder inicialmente, pero al final, muchos 
pacientes simplemente no responden, y algunos responden pero luego recaen.
Por último, el capítulo 9 presenta la discusión de los principales hallazgos de este trabajo, 
las conclusiones y los pasos futuros. Cuatro argumentos principales se pueden inferir de este 
trabajo experimental. En primer lugar, la eficacia de los antibióticos más recomendados en la 
actualidad para el tratamiento de la NTM-PD es pobre. En segundo lugar, la clofazimina tiene 
un papel potencial como parte de una terapia combinada contra M. avium y M. abscessus. En 
tercer lugar, la tigeciclina es bactericida contra M. abscessus y debería ser parte de un nuevo 
régimen combinado a evaluar. En cuarto lugar, los antibióticos β-lactámicos son probablemente 
la fuerza impulsora en el régimen de tratamiento actualmente recomendado para la enfermedad 
pulmonar por M. abscessus.
Con base en estos hallazgos, así como en información clínica reciente, proponemos un 
nuevo régimen para tratar la enfermedad pulmonar producida por M. abscessus, basado en la 
combinación de tigeciclina, clofazimina, amikacina liposomal, un macrólido y un β-lactámico 
activo, tal como ceftarolina con avibactam, cefoxitina o imipenem.
Con el nuevo conocimiento generado con este trabajo esperamos contribuir a la comprensión 
y a la mejora del tratamiento de la enfermedad pulmonar producida por NTM, incluido el 
diseño de regímenes de tratamiento más eficaces. Aún persisten vacíos de conocimiento que son 
críticos y que deben ser llenados; es necesario, por ejemplo, completar la evaluación individual 
de medicamentos, explorar combinaciones sinérgicas y profundizar en el entendimiento de 
los diversos mecanismos de resistencia para todos los medicamentos que tienen potencial, 
conocido o supuesto, para el tratamiento de NTM-PD.
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- Advanced conversation course
- PK/PD full day course International Congress. 54th Interscience 
Conference on Antimicrobial Agents and Chemotherapy, ICAAC 
- Biosafety and spill drill training training
- Scientific Integrity course 
- Basic laboratory and BSL2 laboratory training at Baylor Research 
Institute
- University pedagogy diploma course by e-learning, Universidad 
San Buenaventura, Cali, Colombia
2013
2013-2015
2014
2014
2014
2014
2014
2015
2015
2016
0.5
6
3
1.5
1.5
1.0
0.5
1.0
0.5
5
b) Seminars & lectures
- PK/PD weekly meeting (oral presentation)
- Broodje mycobacterie, monthly meeting
- Broodje mycobacterie lecture (oral presentation)
- Medical Microbiology department lectures
- Baylor Research Institute Lectures
2013-2015
2013-2015
2013-2015
2015
2015
2
2
0.75
0.6
0.4
c) Symposia & congresses
- National symposia . Mini-symposium “The nature of the bug”, 
Amsterdam
- International Congress. 54th Interscience Conference on 
Antimicrobial Agents and Chemotherapy, ICAAC (poster 
presentation)
- National symposia. Mini-symposium “Whole genome 
sequencing for Mycobacterium tuberculosis”, Nijmegen
- International Congress. 25th European Congress of Clinical 
Microbiology and Infectious Diseases, Copenhagen, Denmark 
(oral presentation).
- International Congress. 55th Interscience Conference on 
Antimicrobial Agents and Chemotherapy (3 poster presentation)
- National symposia. Genetic Screening , Amsterdam
- National symposia. M. tuberculosis Beijing strains genome. 
Bogotá, Colombia
- International tuberculosis research working meeting. Cali, 
Colombia
2013
2014
2014
2015
2015
2015
2016
2016
0.25
1.5
0.25
1.5
2.5
0.25
0.5
0.75
TEACHING ACTIVITIES
d) Supervision of internships / other
- Supervision Bachelor student internships
- Review of manuscripts for journals
2013-2015
2013-2016
3
0.5
TOTAL 37.25


